search indicatorNeed Help? Search Tools

Books by Subject

all 403 titles


  • "This book is based upon cutting-edge research conducted in the authors lab (Cellular Bioengineering), which over the past decade has developed a number of sophisticated techniques to facilitate use of 3D cell based assays or biosensors. This book uses data from peer-reviewed publications to conclusively justify use of 3D cell cultures in cell-based biosensors (assays) for (HTS). The majority of assays performed in accelerated drug discovery processes are biochemical in nature, but there is a growing demand for live cell-based assays. Unlike biochemical ones, cellular assays are functional approximations of in vivo biological conditions and can provide more biologically relevant information"--Provided by publisher.
  • Clinical cases selected from the LANGE Case Files series, edited by Eugene C. Toy, MD.
  • Protocol amendment -- Adaptive randomization -- Adaptive hypotheses -- Adaptive dose-escalation trials -- Adaptive group sequential design -- Statistical tests for adaptive seamless designs -- Adaptive sample size adjustment -- Two-stage adaptive design -- Adaptive treatment switching -- Bayesian approach -- Biomarker adaptive trials -- Target clinical trials -- Sample size and power estimation -- Clinical trial simulation -- Regulatory perspectives : a review of FDA draft guidance.
  • Despite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.
  • Despite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.
  • This book describes adverse cutaneous drug reactions as among the most frequent events in patients receiving drug therapy. Cardiovascular drugs are an important group as there are a greater number of indications for the use of new drugs and their prescription continues to increase. The exact incidence of cutaneous side effects from cardiovascular drugs is difficult to estimate due to sporadic reporting. Moreover, a reliable connection between a certain drug and a certain type of reaction can only rarely be made, aside from the well-known angioedema/urticaria from angiotensin-converting enzyme inhibitors, lichen planus/lichenoid reaction from beta adrenergic blockers, and photosensitivity from thiazid diuretics. These reactions can extend to rare but life-threatening conditions such as erythroderma, Stevens-Johnson syndrome, toxic epidermal necrolysis and drug hypersensitivity syndrome. Adverse Cutaneous Drug Reactions To Cardiovascular Drugs reviews the reported types of reactions to cardiovascular drugs. Each is discussed according to drug class and the type of dermatologic reaction with special emphasize on cross-reactions and the role of patch testing in diagnosis. A total of 116 images are included featuring clinical appearance of common adverse cutaneous drug reactions and diagnostic procedures such as patch and photopatch testing with the suspected drugs. Complementary tables may allow to scan the most common cutaneous reactions and the related cardiovascular drugs along with the possible cross reactions at first glance. It will thus be of considerable importance to all dermatologists and medical professionals who manage the skin, while being an important reference resource for cardiologists in terms of identifying potential adverse reactions to the drugs they prescribe.
  • Pt. 1. Target organ toxicity. -- Drug-induced liver injury / Michael Holt, Cynthia Ju.-- Drug herpersensitivity reactions involving skin / Oliver Hausmann, Benno Schnyder, Werner J. Pichler.-- Adverse drug reactions affecting blood cells / Richard H. Aster.-- Molecular mechanisms of adverse drug reactions in cardiac tissue / Reza Tabrizchi.-- Mechanisms of drug-induced nephrotoxicity / Thomas D. Nolin, Jonathan Himmelfarb.-- Receptor- and reactive intermediate-mediated mechanisms of teratogenesis / Peter G. Wells, Crystal J.J. Lee, Gordon P. McCallum, Julia Perstin, Patricia A. Harper.-- Pt. II. Mediators/Biochemical pathways.-- Role of reactive metabolites in drug-induced hepatotoxicity / A.M. Srivastava, J. L. Maggs, D. J. Antoine, D. P. Williams, D. A. Smith, B. K. Park.-- Role of cytokines in the mechanism of adverse drug reactions / Mary Jane Masson, Lindsay A. Collins, Lance R. Poh.-- Keap1-Nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity / Ian M. Copple, Christopher E. Goldring, Neil R. Kitteringham, B. Kevin Park.-- Signal transduction pathways involved in drug-induced liver injury / Derick Han, Mie Shinohara, Maria D. Ybanez, Behnam Saberi, Neil Kaplowitz.-- Mictrochondrial involvement in drug-induced liver injury / Dominique Pessayre, Abdellah Mansouri, Alain Berson, Bernard Fromenty.-- Pt. III. Examples/Models.-- Mechanisms of acetaminophen-induced liver necrosis / Jack A. Hinson, Dean W. Roberts, Laura P. James.-- Drug-induced liver injury in humans: the case of Ximelagtran / M. Keisu, T.B. Andersson.-- Troglitazone / Tsuyoshi Yokoi.-- Neviropine hypersensitivity / M. Popovic, J.M. Shenton, J. Chen, A. Baban, T. Tharmanathan, B. Mannargudi, D. Abdulla, J.P. Uetrecht.-- Mechanisms of adverse drug reactions to biologics / Janet B. Clarke.-- Pt. IV. Risk factors/Screening drug candidates.-- Pharmacogenetics of idiosyncratic adverse drug reactions / Munir Pirmohamed.-- Danger hypothesis applied to idiosyncratic drug reactions / Jinze Li, Jack P. Uetrecht.-- Approaches for minimizing metabolic activation of new drug candidates in drug discovery / Sanjeev Kumar, Kaushik Mitra, Kelem Kassahun, Thomas A. Baillie.
  • "Alcohol is the most widely used drug in the world, yet alcoholism remains a serious addiction affecting nearly 20 million Americans. Our current understanding of alcohol's effect on brain structure and related functional damage is being revolutionized by genetic research, basic neuroscience, brain imaging science, and systematic study of cognitive, sensory, and motor abilities. Volume 125 of the Handbook of Clinical Neurology is a comprehensive, in-depth treatise of studies on alcohol and the brain covering the basic understanding of alcohol's effect on the central nervous system, the diagnosis and treatment of alcoholism, and prospect for recovery. The chapters within will be of interest to clinical neurologists, neuropsychologists, and researchers in all facets and levels of the neuroscience of alcohol and alcoholism"--Publisher's description.
  • The APICE 2013 yearbook examines recent advances in various aspects of critical care medicine and highlights the importance of effective communication among researchers, scientists, and clinicians. Among the many topics addressed are trauma care organization, the management of patients with cardiovascular, kidney, and lung disorders, issues relating to severe infections and sepsis, and the humanization of end of life care. The overriding goal of the book is to provide guidance and stimulate further thought on how professional performance in critical care medicine can be improved. Triple B translational research, from the bench to the bedside and back again (via the translation of clinical observations into new research questions), will play a major role in this context, and is particularly discussed in the chapter about sepsis and organ dysfunction. There is no doubt that the transfer of far-reaching and dynamic developments in molecular and cellular biology into clinical practice will be a key component in delivering the care required by individual patients.
  • pt. I. Continuing medical education -- 1. Can I Think what I Read? / Philip D. Lumb -- pt. II. Clinical pharmacology -- 2. Pharmacological Manipulation in ICU / Daniel De Backer, Katia Donadello and Sabino Scolletta -- pt. III. Kidney -- 3. Renal Injury / Vladimir Gašparović, Ivan Gornik -- pt. IV. Ventilation: adult and paediatric -- 4. Respiratory Mechanics: Principles, Utility and Advances / Alysson R. Carvalho, Walter A. Zin -- 5. Capnometry/capnography in Prehospital Cardiopulmonary Resuscitation / Štefek Grmec, Katia Lah and Štefan Mally -- 6. Weaning from Mechanical Ventilation / Irene Cortés Puch, Andrés Esteban -- 7. Ventilatory Strategies in Acute Lung Injury / Edoardo Calderini, Sara Sher and Eleonora Allegritti -- 8. Mechanical Ventilation Beyond the PICU / Giancarlo Ottonello, Alessia Franceschi -- pt. V. Cardiovascular monitoring 9. The Nexfin Monitor--A Totally Non-Invasive Cardiac Output Monitor / Azriel Perel, Wilbert Wesselink and Jos Settels -- 10. Doppler Echocardiography in ICU Patients: Does It Improve Outcome? / Jan Poelaert -- pt. VI. Management of cardiac arrest -- 11. Mild Therapeutic Hypothermia after Cardiac Arrest / Tommaso Pellis, Vincenzo Mione and Willy P. Mercante -- 12. Nasopharyngeal Cooling During Cardiopulmonary Resuscitation / Francesco Fumagalli, Giuseppe Ristagno -- 13. Amplitude Spectrum Area as a Predictor of Successful Defibrillation / Giuseppe Ristagno, Yongqin Li, Antonino Gullo and Joe Bisera -- pt. VII. Advances in experimental and clinical research -- 14. Physiopathology and Severity of Post-Resuscitation Myocardial Dysfunction: Effects of Sodium-Hydrogen Exchanger Isoform-1 (NHE-1) Inhibitors and Erythropoietin / Raúl J. Gazmuri, Iyad M. Ayoub and Jeejabai Radhakrishnan -- 15. Experimental Treatment for Preservation of Mechanically Competent Cardiac Activity Following Cardiac Arrest / Iyad M. Ayoub, Jeejabai Radhakrishnan and Raúl J. Gazmuri -- 16. Erythropoietin Facilitates Return of Spontaneous Circulation and Survival in Victims of Out-of-Hospital Cardiac Arrest / Štefek Grmec, Matej Strand and Raúl J. Gazmuri -- pt. VIII. Infections, sepsis and organ dysfunctions -- 17. Pathophysiology of Resistance amongst Aerobic Gram-negative Bacilli in Particular Acinetobacter Species / Nia Taylor, Luciano Silvestri and Hendrick K.F. Van Saene -- 18. What Have We Learned from the Surviving Sepsis Campaign? / Jean-Louis Vincent, Katia Donadello and Leonardo Gottin -- 19. Source Control / Gabriele Sganga, Valerio Cozza -- 20. Immunoglobulins in Sepsis / Giorgio Berlot, Claudio M. Vassallo and Nicola Busetto -- pt. IX. Perioperative medicine -- 22. Perioperative Medicine--An Introduction / Antonino Gullo, Chiara M. Celestre, Annalaura Paratore and Fortunato Stimoli -- 23. Neuraxial Analgesia for Caesarean and Vaginal Delivery and Childhood Learning Disabilities / Juraj Sprung, Randall Flick and David Warner -- 24. Off-label Drugs in Perioperative Medicine: Clonidine / Cesare Gregoretti, Paolo Pelosi -- pt. X. Spinal cord stimulation -- 25. Cost Effectiveness of Spinal Cord Stimulation in the Management of Severe Angina / Mats Börjesson, Clas Mannheimer -- pt. XI. Neurotrauma -- 26. Clinical Assessment and Diagnostic Procedures in Neurotrauma / Marco Zanello, Matteo Vincenzi and Marco Bandini -- pt. XII. Disaster medicine -- 27. Disaster Preparedness / Francesco Della Corte, Pier Luigi Ingrassia -- 28. Medical Emergency Response in Toxicological Mass Casualty / Pier Luigi Ingrassia, Luca Ragazzoni and Francesco Della Corte -- pt. XIII. Quality of care -- 29. Telemedicine to Improve Care in the Critically Ill / Gastón Murias, Bernat Sales Lluis Blanch -- 30. Professionalism, Quality of Care and Pay-for-Performance Services / Antonino Gullo, Cristina Santonocito, Paolo Murabito and Marinella Astuto.
  • Introduction to antibiotic resistance/ Richard Bax, David Griffin -- The origins of antibiotic resistance/ Gerard D. Wright -- Surveillance programmes and antibiotic resistance: worldwide and regional monitoring of antibiotic resistance trends/ Stephen Hawser -- Current and future challenges in the development of antimicrobial agents/ Robert P. Rennie -- The role of the outer membrane of gram-negative bacteria in antibiotic resistance: Ajax' shield or Achilles' heel?/ Malcolm G.P. Page -- Prevention of drug resistance by combined drug treatment of tuberculosis/ Denis A. Mitchison -- Nonmultiplying bacteria are profoundly tolerant to antibiotics / Yanmin Hu, Anthony Coates -- Persister cells: molecular mechanisms related to antibiotic tolerance / Kim Lewis -- Antimicrobial textiles / J. Vaun McArthur, R.C. Tuckfield, C. Baker-Austin -- Efflux: how bacteria use pumps to control their microenvironment / E. David G. McIntosh -- Antibiotics in phase II and III clinical trials / Anthony R.M. Coates, Gerry Halls.
  • Antibody-drug conjugates 2013
    Springer Protocols
    Antibody-drug conjugate (ADC) clinical pipeline : a review / Ingrid Sassoon and Veronique Blanc -- Antibody-drug conjugate target selection : critical factors / Neil H. Bander -- Selecting an optimal antibody for antibody-drug conjugate therapy : internalization and intracellular localization / Jay Harper ... [et al.] -- Antibody-drug conjugate payloads / Jan Anderl ... [et al.] -- Linker technologies for antibody-drug conjugates / Birte Nolting -- In vivo testing of drug-linker stability / Pierre-Yves Abecassis and Celine Amara -- Pharmacokinetics and ADME characterizations of antibody-drug conjugates / Kedan Lin, Jay Tibbitts, and Ben-Quan Shen -- Safe handling of cytotoxic compounds in a biopharmaceutical environment / Miriam I. Hensgen and Bernhard Stump -- Micro- and mid-scale maleimide-based conjugation of cytotoxic drugs to antibody hinge region thiols for tumor targeting / James E. Stefano ... [et al.] -- Protocols for lysine conjugation / Marie-Priscille Brun and Laurence Gauzy-Lazo -- Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers / Sunil Bhakta, Helga Raab, and Jagath R. Junutula -- Enzymatic antibody modification by bacterial transglutaminase / Patrick Dennler, Roger Schibli, and Eliane Fischer -- Formulation development of antibody-drug conjugates / William J. Galush and Aditya A. Wakankar -- Conjugation process development and scale-up / Bernhard Stump and Jessica Steinmann -- Methods for conjugating antibodies to nanocarriers / Anil Wagh and Benedict Law -- Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy / Yan Chen -- Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography / Jun Ouyang -- Drug-to-antibody ratio (DAR) and drug load distribution by LC-ESI-MS / Louisette Basa -- Determination of charge heterogeneity and level of unconjugated antibody by imaged cIEF / Joyce Lin and Alexandru C. Lazar -- Risk-based scientific approach for determination of extractables/leachables from biomanufacturing of antibody-drug conjugates (ADCs) / Weibing Ding.
  • The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.
  • This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
  • "This book covers clinically used anticancer agents that are either natural products or are clearly derived from natural product leads. The second edition includes drugs that are currently in development. In addition, the text emphasizes the applications of synthetic and medicinal chemistry to the preparation of analogs with enhanced activities. Contributors also address the potential of novel drug discovery through the use of genome mining as well as the status of advanced development candidates. For each compound of class of compounds, the text provides information on the history, structure, mechanism of action, development, synthesis, medicinal chemistry, and clinical applications"-- Provided by publisher. "The search for new lead compounds is a crucial element of modern pharmaceutical research. Natural products provided the only source of pharmaceuticals for thousands of years, and natural products have made enormous contributions to human health through compounds such as quinine, morphine, aspirin (a natural product analog), digitoxin, and many others. The potential of natural products as anticancer agents was recognized in the 1950's by the U. S. National Cancer Institute (NCI) under the leadership of the late Dr. Jonathan Hartwell, and the NCI has since made major contributions to the discovery of new naturally occurring anticancer agents through its contract and grant support, including an important program of plant and marine collections. Many, although not all, of the compound classes described in the following pages owe their origin in whole or in part to NCI support. In spite of the success of the natural products approach to anticancer drug discovery, as exemplified by the following chapters, in recent years their importance as a source of molecular diversity for drug discovery research and development has been overshadowed by newer chemical approaches currently in favor. These approaches include chemical ones which make heavy use of combinatorial chemistry, and biological ones such as manipulation of biosynthetic pathways of microbial metabolites through combinatorial biosynthetic techniques. It is thus worthwhile to review briefly the major reasons why natural products are so important. First, there is a strong biological and ecological rationale for plants and marine invertebrates to produce novel bioactive secondary metabolites"-- Provided by publisher.
  • Pt. 1. General properties of antimicrobial agents -- Pt. 2. Resistance to antimicrobial agents -- Pt. 3. General principles of usage of antimicrobial agents -- Pt. 4. Therapeutic use of antimicrobial agents.
  • Antiplatelet agents 2012
    Part 1. Pathophysiology. Platelets: Production, Morphology and Ultrastructure / Jonathan N. Thon and Joseph E. Italiano -- Platelet Receptors / Alexandre Kauskot and Marc F. Hoylaerts -- Platelet Signaling / Timothy J. Stalker, Debra K. Newman, Peisong Ma, Kenneth M. Wannemacher and Lawrence F. Brass -- Platelet Interaction with the Vessel Wall / Philip G. de Groot, Rolf T. Urbanus and Mark Roest -- Platelets in Atherosclerosis and Thrombosis / Christian Schulz and Steffen Massberg -- Part 2. Pharmacology. Aspirin and Other COX-1 Inhibitors / Carlo Patrono and Bianca Rocca -- Thienopyridines and Other ADP-Receptor Antagonists / Isabell Bernlochner and Dirk Sibbing -- Glycoprotein IIb/IIIa Antagonists / Karen M. Hook and Joel S. Bennett -- Targeting Phosphodiesterases in Anti-platelet Therapy / Matthew T. Rondina and Andrew S. Weyrich -- PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis / Sergio Leonardi and Richard C. Becker -- Thromboxane Receptors Antagonists and/or Synthase Inhibitors / Giovanni Davì, Francesca Santilli and Natale Vazzana -- Inhibitors of the Interaction Between von Willebrand Factor and Platelet GPIb/IX/V / Paolo Gresele and Stefania Momi -- Inhibitors of the Interactions Between Collagen and Its Receptors on Platelets / Hans Deckmyn, Simon F. De Meyer, Katleen Broos and Karen Vanhoorelbeke -- Intracellular Signaling as a Potential Target for Antiplatelet Therapy / Patrick Andre -- Novel Targets for Platelet Inhibition / Kathleen Freson and Chris Van Geet -- Variability of Platelet Indices and Function: Acquired and Genetic Factors / Giovanni de Gaetano, Iolanda Santimone, Francesco Gianfagna, Licia Iacoviello and Chiara Cerletti -- Small RNAs as Potential Platelet Therapeutics / Leonard C. Edelstein and Paul F. Bray -- Pharmacological Modulation of the Inflammatory Actions of Platelets / Richard Amison, Clive Page and Simon Pitchford -- Part 3. Therapy. The Role of Laboratory Monitoring in Antiplatelet Therapy / Marco Cattaneo -- Antiplatelet Agents in Ischemic Heart Disease / Christopher H. May and A. Michael Lincoff -- Antiplatelet Therapy in Cerebrovascular Disorders / Ralph Weber, Johannes Brenck and Hans-Christoph Diener -- Antiplatelet Therapy in Peripheral Artery Disease / Francesco Violi, Stefania Basili, Jeffrey S. Berger and William R. Hiatt -- Primary Prevention of Ischaemic Cardiovascular Disorders with Antiplatelet Agents / Tom Mead.
  • Mechanisms of antisense drug action, an introduction / Stanley T. Crooke ... [et al.] -- The RNase H mechanism / Walt Lima, Hongjiang Wu, and Stanley T. Crooke -- Small RNA silencing pathways / Alla Sigova and Phillip D. Zamore -- Splice switching oligonucleotides as potential therapeutics / Peter Sazani, Maria A. Graziewicz, and Ryszard Kole -- Basic principles of antisense drug discovery / Susan M. Freier and Andrew T. Watt -- The medicinal chemistry of oligonucleotides / Eric E. Swayze and Balkrishen Bhat -- Basic principles of the pharmacokinetics of antisense oligonucleotide drugs / Arthur A. Levin, Rosie Z. Yu, and Richard S. Geary -- Routes and formulations for delivery of antisense oligonucleotides / Gregory E. Hardee, Lloyd G. Tillman, and Richard S. Geary -- Liposomal formulations for nucleic acid delivery / Ian MacLachlan -- Pharmacological properties of 2'-O-methoxyethyl-modified oligonucleotides / C. Frank Bennett -- Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man / Richard S. Geary ... [et al.] -- Toxicologic properties of 2'-O-methoxyethyl chimeric antisense inhibitors in animals and man / Scott P. Henry ... [et al.] -- An overview of the clinical safety experience of first- and second-generation antisense oligonucleotides / T. Jesse Kwoh -- Manufacturing and analytical processes for 2'-O-(2-methoxyethyl)-modified oligonucleotides / Daniel C. Capaldi and Anthony N. Scozzari -- Utilizing chemistry to harness RNA interference pathways for therapeutics : chemically modified siRNAs and antagomirs / Muthiah Manoharan and Kallanthottathil G. Rajeev. Discovery and development of RNAi therapeutics / Antonin R. deFougerolles and John M. Maraganore -- Optimization of second-generation antisense drugs: going beyond generation 2.0 / Brett P. Monia ... [et al.] -- Modulating gene function with peptide nucleic acids (PNA) / Peter E. Nielsen -- Locked nucleic acid / Troels Koch and Henrik Ørum -- Morpholinos / Patrick L. Iversen -- Potential therapeutic applications of antisense oligonucleotides in ophthalmology / Lisa R. Grillone and Scott P. Henry -- Cardiovascular therapeutic applications / Rosanne M. Crooke, Brenda Baker, and Mark Wedel -- Developing antisense drugs for metabolic diseases: a novel therapeutic approach / Sanjay Bhanot -- Inflammatory diseases / Susan A. Gregory and James G. Karras -- Antisense oligonucleotides for the treatment of cancer / Boris A. Hadaschik and Martin E. Gleave -- Targeting neurological disorders with antisense oligonucleotides / Richard A. Smith and Timothy M. Miller -- Mechanisms and therapeutic applications of immune modulatory oligodeoxynucleotide and oligoribonucleotide ligands for toll-like receptors / Jörg Vollmer and Arthur M. Krieg -- Aptamer opportunities and challenges / Charles Wilson.
  • The modern unhealthy diet and lifestyle in conjunction with pathogens, environmental carcinogens and multiple other risk factors increase humans' susceptibility to different diseases exemplified by elevated levels of cancers, cardiovascular and communicable diseases. Screening of potential drugs from medicinal plants and animals provides a promising strategy for the alleviation of the impact of these diseases. Components with potential medicinal applications include RIPs, RNases, lectins, protease inhibitors and numerous small compounds. These compounds have shown both preventive and therapeutic effects for humans. This book is a compilation of articles written by internationally renowned experts exploring the different uses of medicinal compounds in human therapeutics. Here we provide a comprehensive outlook on both qualitative and quantitative studies focusing on medicinal plants and animals, and establishing a link between laboratory research discovery and clinical applications.
  • Part I Human immunodeficiency virus type 1 (HIV-1) -- Fluorescence-based high-throughput screening assay to identify HIV-1 inhibitors / Peggy Geluykens ... [et al.] -- Homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion / Liesbet Smeulders ... [et al.] -- Identification of HIV-1 reverse transcriptase inhibitors using a scintillation proximity assay / Bertrand Van Schoubroeck ... [et al.] -- Biochemical screening assays to identify HIV-1 integrase inhibitors / Marleen Clynhens ... [et al.] -- HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance / Peter Van den Eede ... [et al.] -- Part II Hepatitis viruses -- In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis / Rumin Zhang and William T. Windsor -- Novel hepatitis C virus NS5B polymerase assay of de novo initiated RNA synthesis directed from a heteropolymeric RNA template / Eric Ferrari and Hsueh-Cheng Huang -- Selecting and characterizing drug-resistant hepatitis C virus replicon / Inge Vliegen, Leen Delang, and Johan Neyts -- Cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors / Leen Vijgen ... [et al.] -- Expression and purification of hepatitis C virus protease from clinical samples / Liesbet van der Helm -- Surface plasmon resonance as a tool to select potent drug candidates for hepatitis C virus NS5B polymerase / Erna Cleiren, Benoit Devogelaere, and Katleen Fierens -- Amplification and sequencing of the hepatitis C virus NS3/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b / Diana Koletzki ... [et al.] -- Southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures / Dawei Cai ... [et al.] -- In vitro phenotyping of recombinant hepatitis B virus containing the polymerase/reverse transcriptase gene from clinical isolates / Yang Liu and Kathryn M. Kitrinos -- Part III Flaviviruses -- Cell-based antiviral assays for screening and profiling inhibitors against dengue virus / Edwin Yunhao Gong ... [et al.] -- Duplex real-time RT-PCR assay for profiling inhibitors of four dengue serotypes / Edwin Yunhao Gong ... [et al.] -- High-throughput screening using dengue virus reporter genomes / Wolfgang Fischl and Ralf Bartenschlager -- Fluorimetric and HPLC-based dengue virus protease assays using a FRET substrate / Christoph Nitsche and Christian D. Klein -- Expression and purification of dengue virus NS5 polymerase and development of a high-throughput enzymatic assay for screening inhibitors of dengue polymerase / Edwin Yunhao Gong ... [et al.] -- Detection and quantification of flavivirus NS5 methyl- transferase activities / Siew Pheng Lim, Christophe Bodenreider, and Pei-Yong Shi -- Testing antiviral compounds in a dengue mouse model / Wouter Schul, Andy Yip, and Pei-Yong Shi -- Construction of self-replicating subgenomic west nile virus replicons for screening antiviral compounds / Sofia L. Alcaraz-Estrada, Erin Donohue Reichert, and Radhakrishnan Padmanabhan -- Part IV Herpes viruses -- Methods for screening and profiling inhibitors of herpes simplex viruses / Edwin Yunhao Gong -- In vivo evaluation of antiviral efficacy against genital herpes using mouse and guinea pig models / Frances Valencia, Ronald L. Veselenak, and Nigel Bourne -- Fluorescence-based high-throughput screening assay for identifying human cytomegalovirus inhibitors / Christel Van den Eynde ... [et al.] -- Part V Respiratory viruses -- Fluorescence-based high-throughput antiviral compound screening assay against respiratory syncytial virus / Leen Kwanten, Ben De Clerck, and Dirk Roymans -- Screening and evaluation of anti-respiratory syncytial virus compounds in cultured cells / Anna Lundin, Tomas Bergström, and Edward Trybala -- Evaluation of antiviral efficacy against human respiratory syncytial virus using cotton rat and mouse models / Joke Van den Berg, Leen Kwanten, and Dirk Roymans -- In vivo evaluation of antiviral compounds on respiratory syncytial virus using a juvenile vervet monkey (Chlorocebus pygerythrus) infection model / Lieselot Houspie ... [et al.] -- Methods to determine mechanism of action of anti-influenza inhibitors / Angela Luttick, Stephanie Hamilton, and Simon P. Tucker -- Methods for evaluation of antiviral efficacy against influenza virus infections in animal models / Donald F. Smee and Dale L. Barnard -- Part VI Alphaviruses -- Development of a high-throughput antiviral assay for screening inhibitors of chikungunya virus and generation of drug-resistant mutations in cultured cell / Edwin Yunhao Gong ... [et al.] -- Mouse model of chikungunya virus with utility in antiviral studies / Ashley Dagley and Justin G. Julander.
  • Appetite control 2012
    The volume Appetite Control provides a comprehensive description of the mechanisms controlling food intake, and thereby energy balance, in the mammalian organism. During the last decade, research in this area has produced a remarkable wealth of information and has characterized the function of numerous peptides, transmitters, and receptors in appetite control. Dysfunction of these circuits leads to obesity, a growing health concern. However, the plethora of mechanistic information is in marked contrasts to an almost complete lack of anti-obesity drugs that meet the safety standards required for the chronic therapy of morbid obesity. Consequently, ongoing research aims to identify additional targets and agents for a pharmacological intervention. Thus, the mechanisms of appetite control as well as all agents interfering with its control are of considerable practical interest.The authors of the volume are distinguished scientists who are leading experts in the field, and who have contributed important, original data to our understanding of the mechanisms of appetite control. They have quite different scientific backgrounds and, together, they represent all relevant disciplines. Thereby, the topics are presented from different points of view, not exclusively from that of pharmacology and neuroendocrinology. Thus, the volume addresses all scientists who are interested in the field of obesity research and the pathophysiology of appetite control.
  • Introduction -- Application of prodrug chemistry to GLP-1 -- Experimental procedures -- Characterization of prodrugs -- Conclusion -- Appendix I. Schematic synthesis of longer acting prodrugs -- Appendix II: Structure of peptides in Table A.1 -- Appendix III: Structure of peptides in table A.2 -- Appendix IV: Structure of peptides in table A.3 -- Appendix V: Structure of peptides in table A.4 Appendix VI: Structure of peptides in table A.5 -- Appendix VII. Structure of peptides in table A.6 -- Appendix VIII: Acylataion of HO-His7, GLP(8-37) -- Appendix IX: A note on nomenclature.
  • This comprehensive volume provides an update on the current state of pharmacometrics in drug development. It consists of nineteen chapters all written by leading scientists from the pharmaceutical industry, regulatory agencies and academia. After an introduction of the basic pharmacokinetic and pharmacodynamic concepts of pharmacometrics in drug development, the book presents numerous examples of specific applications that utilize pharmacometrics with modeling and simulations over a variety of therapeutic areas, including pediatrics, diabetes, obesity, infections, psychiatrics, Alzheimer?s disease, and dermatology, among others. The examples illustrate how results from all phases of drug development can be integrated in a more timely and cost-effective process. Applying pharmacometric decision tools during drug development can allow objective, data-based decision making. At the same time, the process can identify redundant or unnecessary experiments as well as some costly clinical trials that can be avoided. In addition to cost saving by expedited development of successful drug candidates, pharmacometrics has an important economic impact in drug product selection. Unsuccessful drug candidates can be identified early and discontinued without expending efforts required for additional studies and allocating limited resources. Hence, pharmacometric modeling and simulation has become a powerful tool to bring new and better medications to the patient at a faster pace and with greater probability of success.
  • Omics & microarrays revisited -- The commercial microarrays -- Supports & surface chemistries -- The arraying processes -- Gene expression microarray-based applications -- Protein microarray applications -- Multiplex assays.
  • Introduction to biopharmaceutical conformational analysis : issues and methods -- Comparability of biotechnological/biological products and biological generics -- Application of native electrophoresis for the study of protein conformation -- Affinity chromatography including hydrophobic interaction chromatography in the study of biopolymer conformation -- Size-exclusion chromatography and bimolecular conformation -- Use of analytical ultracentrifugation to study biomolecular conformation -- Use of differential scanning calorimetry to measure conformational change in proteins and other biomacromolecules -- Light scattering and biomacromolecular conformation -- Use of luminescence to measure conformational change in biopharmaceuticals with emphasis on protein and protein drug products -- Near-infrared spectroscopy and macromolecular conformation -- Use of mid-infrared and Fourier transform infrared spectroscopy to study conformation of biomacromolecules -- Use of Raman spectroscopy to evaluate biopharmaceutical conformation -- The use of UV-VIS spectrophotometry for the characterization of biopharmaceutical products -- Use of optical rotatory dispersion and circular dichroism to study therapeutic biomacromolecule conformation -- Use of nuclear magnetic resonance for the characterization of biotherapeutic products -- Use of chemical probes for the study of protein conformation -- Use of hydrogen exchange in the study of biopharmaceutical conformation -- Use of chemical modification for the conformational analysis of biopharmaceuticals -- Use of immunology to characterize biopharmaceutical conformation -- Use of limited proteolysis to study the conformation of proteins of biotechnological interest -- Other technologies for the characterization of conformational change in biopharmaceuticals -- Development of an experimental approach for the study of the conformation of a biological therapeutic product.
  • This volume describes our current understanding of the biological role of visual and non-visual arrestins in different cells and tissues, focusing on the mechanisms of arrestin-mediated regulation of GPCRs and non-receptor signaling proteins in health and disease. The book covers wide range of arrestin functions, emphasizing therapeutic potential of targeting arrestin interactions with individual partners.
  • Every three years, the International Society for Arterial Chemoreception (ISAC) arranges a Meeting to bring together all of the major International research groups investigating the general topic of oxygen sensing in health and disease, with a prime focus upon systemic level hypoxia and carotid body function. This volume summarises the proceedings of the XIXth meeting of the Society, held in Leeds, UK during the summer of 2014. As such this volume represents a unique collection of state of the art reviews and original, brief research articles covering all aspects of oxygen sensing, ranging from the molecular mechanisms of chemotransduction in oxygen sensing cells such as the carotid body type I cells, to the adverse, reflex cardiovascular outcomes arising from carotid body dysfunction as seen, for example, in heart failure or obstructive sleep apnoea. This volume will be of tremendous interest to basic scientists with an interest in the cellular and molecular biology of oxygen sensing and integrative, whole organism physiologists as well as physicians studying or treating the clinical cardiovascular consequences of carotid body dysfunction.
  • Ocular toxicity is routinely assessed in toxicology studies conducted for regulatory purposes. Ocular anatomy and physiology and the assessment of ocular toxicity itself can be challenging to scientists involved in the safety assessment of pharmaceuticals, pesticides and other agents. Anatomical and physiological differences between species can impact the nature of ocular effects observed following intended or unintended exposure of ocular tissues to xenobiotics. Ocular Toxicity in Laboratory Animals provides a concise reference addressing ocular anatomy and physiology across species that will enhance the design and interpretation of toxicology studies conducted for regulatory purposes. The book provides an overview of routine and advanced techniques that are used to assess ocular toxicity including slit lamp biomicroscopy, indirect ophthalmoscopy, electrophysiology and imaging methods for the anterior and posterior segments of the eye. Additionally, the book defines the regulatory expectations for pharmaceuticals intended to treat ocular diseases and for other non-pharmaceutical regulated chemicals. With contributions from experts in the field, Ocular Toxicity in Laboratory Animals is an authoritative, accessible guide for toxicologists and other scientists involved in conducting toxicology studies for regulatory purposes and/or reviewing data from such studies.
  • "This atlas contains more than 700 illustrations that the authors have collected over the years as well as references and information pertaining to recently developed drug classes, including biologics. It is a useful bench reference for practicing pathologists and may also be used as a reference text by other experts from related fields. The atlas is organised into different chapters based on systemic pathology. Each chapter has illustrations with legends, and the atlas includes some rare examples of unique lesions found during toxicity studies over many years."--Publisher's website.
  • Microbial drug resistance: a historical perspective / William C. Summers -- Ecology of antibiotic resistance genes / Abigail A. Salyers, Nadja Shoemaker, and David Schlesinger -- Global response systems that confer resistance / Paul F. Miller and Philip N. Rather -- Multidrug efflux pumps: structure, mechanism, and inhibition / Olga Lomovskaya ... [et al.] -- Mechanisms of aminoglycoside antibiotic resistance / Gerard D. Wright -- Resistance to [beta]-lactam antibiotics mediated by [beta]-lactamases : structure, mechanism, and evolution / Jooyoung Cha, Lakshmi P. Kotra, and Shahriar Mobashery -- Target modification as a mechanism of antimicrobial resistance / David C. Hooper -- Antibiotic permeability / Harry Taber -- Genetic methods for detecting bacterial resistance genes / Ad C. Fluit -- Evolution and epidemiology of antibiotic-resistant pneumococci / Christopher Gerard Dowson and Krzysztof Trzcinski -- Antimicrobial resistance in the enterococcus / George M. Eliopoulos -- Methicillin resistance in staphylococcus aureus / Keeta S. Gilmore, Michael S. Gilmore, and Daniel F. Sahm -- Mechanism of drug resistance in mycobacterium tuberculosis / Alex S. Pym and Stewart T. Cole -- Antibiotic resistance in enterobacteria / Nafsika H. Georgopapadakou -- Resistance as a worldwide problem / Paul Shears -- Public health responses to antimicrobial resistance in outpatient and inpatient settings / Cindy R. Friedman and Arjun Srinivasan -- Antibacterial drug discovery in the 21st century / Steven J. Projan.
  • Basic & clinical pharmacology 2015 (13th ed.)
    12th ed., 2012 AccessMedicine
  • This book explains the chemistry of Organophosphorus compounds (OPs), their mechanism of toxicity and the history of OPs from their initial discovery to the development of new compounds such as Novichoks. It details the harmful effects to human health both as a result of acute and chronic OP exposure and the necessary clinical management of affected patients to reduce their toxic side effects. The book also explains the detrimental effect that OPs have had on the environment and the efforts being made to prevent this in the future. Finally, the book looks at the incidents where OPs have been used as chemical warfare agents. Basic and Clinical Toxicology of Organophosphorus Compounds aims to act as a comprehensive guide to all aspects of OPs and is a key resource for clinical toxicologists and related health professionals involved in the prevention, diagnosis and clinical management of OP patients, toxicologists and other scientists involved in research on OPs including regulatory issues and postgraduate students in Toxicology and related fields.
  • "This manual informs about practical procedures in ... assessment based on experience from existing national fluoridation programmes. The assessment tools will primarily be useful in assisting countries in achieving an effective fluoride exposure. It is a hope that the manual will stimulate oral health personnel and public health administrators to use a systematic approach for managing and analysing data obtained from different levels of fluoride exposure. Finally the manual encourages inter-country collaboration on surveillance systems for community programmes using fluoride for prevention of dental caries."--Publisher's description.
  • Prologue -- Preface -- Overview -- Approaches to utilising decision-making framework -- Benefit-risk assessment of medicines by pharmaceutical companies and regulatory authorities -- Development of a universal benefit-risk framework and template -- Implementation of the benefit-risk assessment template by mature agencies -- Implementation of the benefit- risk summary template by a maturing agency: A case study -- Communicating benefit-risk decisions by US FDA, EMA, TGA and Health Canada -- Conclusions and future directions -- References.
  • Bioinformatics and drug discovery 2005
    Springer Protocols
    New strategies in drug discovery / Eliot H. Ohlstein ... [et al.] -- Basic microarray analysis: strategies for successful experiments / Scott A. Ness -- From microarray to biological networks: analysis of gene expression profiles / Xiwei Wu and T. Gregory Dewey -- Microarray analysis in drug discovery and clinical applications / Siqun Wang and Qiong Cheng -- Ontology-driven approaches to analyzing data in functional genomics / Francisco Azuje, Fatima Al-Shahrour, and Joaquin Dopazo -- Gene evolution and drug discovery / James O. McInerney ... [et al.] -- Standardization of microarray and pharmacogenomics data / Cassey S. Husser ... [et al.] -- Clinical applications of bioinformatics, genomics, and pharmacogenomics / Omer Iqbal and Jawed Fareed -- Protein interactions probed with mass spectrometry / Suma Kaveti and John R. Engen -- Discovering new drug targeting sites on flexible multidomain protein kinases -- combining segmental isotopic and site-directed spin labeling for nuclear magnetic resonance dectection of interfacial clefts / Thomas K. Harris -- Nuclear magnetic resonance-based screening methods for drug discovery / Laurel O. Sillerud and Richard S. Larson -- Receptor binding sites: bioinformatic approaches / Darren R. Flower -- In silico protein design: fitting sequence onto structure / Bassil I. Dahiyat -- Chemical database preparation for compound acquisition or virtual screening / Cristian G. Bologa, Marius M. Olah, and Tudor I. Oprea -- Bioinformatics platform development: from gene to lead compound / Alexis S. Ivanov ... [et al.].
  • Biologicals' Characteristics / K. Ho and J.-H. Trouvin -- From the Biosimilar Concept to the Marketing Authorisation / M. Pavlovic and J.-L. Prugnaud -- Immunogenicity / J.-L. Prugnaud -- Substitution and Interchangeability / J.-L. Prugnaud -- G-CSFs: Onco-Hematologist's Point of View / D. Kamioner -- The Oncologist's Point of View / C. Chouaïd -- Biosimilars: Challenges Raised by Biosimilars: Who is Responsible for Cost and Risk Management? / F. Megerlin.
  • "This is the first book entirely devoted to the design and analysis for assessment of biosimilarity and drug interchangeability of biosimilars, and test for comparability in manufacturing processes of biologic products. It covers all of the statistical issues that may occur in biosimilar studies under various study designs at various stages of research and development of biologic products"-- Provided by publisher.
  • "... provides an established, recognized, authoritative and comprehensive source on medicinal chemistry and drug discovery and development. This flagship reference for medicinal chemists and pharmaceutical professions has been thoroughly updated and expanded across 8 volumes to incorporate the entire process of drug development (preclinical testing, clinical trials, etc.) alongside the traditional strengths in medicinal chemistry and drug discovery"--Provided by publisher.
  • Fluorescent measurement of [Ca²+]c: basic practical considerations / Alec W.M. Simpson -- Measurement of [Ca²+]i in whole cell suspensions using fura-2 / Robert A. Hirst ... [et al.] -- Measurement of [Ca²+]i in cell suspensions using indo-1 / Adriaan Nelemans -- Confocal microscopy: theory and applications for cellular signaling / Stephen C. Tovey, Paul J. Brighton, and Gary B. Willars -- Single-cell and subcellular measurement of intracellular Ca²+ concentration / Anthony J. Morgan and Andrew P. Thomas -- Ratiometric Ca²+ measurements using the FlexStation scanning fluorometer / Ian C.B. Marshall, Izzy Boyfield, and Shaun McNulty -- Measuring Ca²+ changes in multiwell format using the fluorometric imaging plate reader / Ian C.B. Marshall, Davina E. Owen, and Shaun McNulty -- Measurement of Ca²+ entry using cells ⁴⁵Ca²+ / Mercedes Villarroya ... [et al.] -- Measurement of [³H]PN200-110 and [¹²⁵I]-conotoxin MVIIA binding / Kazuyoshi Hirota and David G. Lambert -- Whole-cell patch clamp recording of voltage-sensitive Ca²+ channel currents: heterologous expression systems and dissociated brain neurons / Atticus H. Hainsworth, Andrew D. Randall, and Alessandro Stefani -- Measurement of phospholipase C by monitoring inositol phosphates using [³H]inositol-labeling protocols in permeabilized cells / Alison Skippen, Philip Swigart, and Shamshad Cockcroft -- Measurement of inositol(1,4,5)triphosphate using a stereospecific radioreceptor mass assay / Darren Smart -- Measurement of calcium fluxes in permeabilized cells using a ⁴⁵Ca²+ uptake and release assay / Robert A. Wilcox -- Microinjection of myo-inositol(1,4,5)trisphosphate and other calcium-mobilizing agents into intact adherent cells / Robert A. Wilcox, Ian D. Forsythe, and Terence J. McCann -- Measurement of free [Ca²+] changes in agonist-sensitive internal stores using compartmentalized fluorescent indicators / Aldebaran M. Hofer -- Measurement of [Ca²+]i in smooth muscle strips using front-surface fluorimetry / Hideo Kanaide -- Measurement of calcium and movement in heart cells / Leong L. Ng and Paulene A. Quinn -- Simultaneous analysis of intracellular pH and Ca²+ from cell populations / Raul Martinez-Zaguilan ... [et al.] -- Measurement of cytosolic-free Ca²+ in plant tissue / Martin R. McAinsh and Carl K.-Y. Ng -- Assay and purification of calmodulin-dependent protein kinase / Rajendra K. Sharma -- Assay and purification of calmodulin-dependent cyclic nucleotide phosphodiesterase and isozyme separation / Rajendra K. Sharma -- Measurement of Ca²+-ATPase activity (in PMCA and SERCA1) / Danuta Kosk-Kosicka.
  • This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
  • This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies.Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy.Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press.
  • Combining computational and experimental methods for identifying molecular targets of phytochemicals / Ann M. Bode and Zigang Dong -- Common methods used for the discovery of natural anticancer compounds / Min Tang ... [et al.] -- Nrf2-target approaches in cancer chemoprevention mediated by dietary phytochemicals / Francisco Fuentes ... [et al.] -- Methods to analyze chemopreventive effect of silibinin on prostate cancer biomarkers protein expression / Gagan Deep, Swetha Inturi, and Rajesh Agarwal -- Approach to the evaluation of berries for cancer prevention with emphasis on esophageal cancer / Gary D. Stoner ... [et al.] -- Use of mouse models for lung cancer chemoprevention studies / Yian Wang ... [et al.] -- Azoxymethane plus dextran sulfate sodium-induced mouse colon cancer model for the study of dietary chemoprevention of inflammation-associated carcinogenesis / Ha-Na Lee, Hye-Won Yum, and Young-Joon Surh -- Use of seahorse extracellular flux analyzer in mechanistic studies of naturally occurring cancer chemopreventive agents / Michelle B. Moura ... [et al.] -- Utilizing RNA-seq to define phytochemical-induced alterations in insulin and IGF-regulated transcriptomes / Heather Beckwith and Douglas Yee -- Ex vivo use of keratinocytes from adult mice to define stem cell activities in cancer research / Rebecca J. Morris ... [et al.] -- Quantitation of acetaldehyde-DNA adducts : biomarkers of alcohol consumption / Silvia Balbo and Stephen S. Hecht -- Imaging tools in discovery and development of phytochemical chemopreventive agents / Marna Ericson -- Designing the chemoprevention trials of tomorrow : applying lessons learned from past definitive trials / Karen Colbert Maresso and Ernest Hawk.
  • Cannabinoids 2005
  • Overview of Capillary Electrophoresis in Pharmaceutical Analysis -- Theoretical Consideration in Performance of Various Modes of CE -- Equipment Considerations for Capillary Electrophoresis -- Method Development for Pharmaceutical Analysis -- Role of CE in Drug Substance and Drug Product Development -- General Considerations to Improve Performance of CE Methods -- Overview of Current Regulatory Guidance -- Qualification of CE Instrumentation -- Robustness Testing of CE Methods -- Validation of Analytical Methods Using Capillary Electrophoresis-- The Need for CE Methods in Pharmacopeial Monographs -- CE in Impurity Profiling of Drugs -- Ion Analysis Using Capillary Electrophoresis -- Role of CE in Biopharmaceutical Development and Quality Control -- Capillary Electrophoresis and Bioanalysis -- CE as an Orthogonal Technique to Chromatography -- Capillary Electrochromatography of Pharmaceuticals -- Coupling CE and Chip-based Devices and Mass Spectrometry.
  • ch. 1. Synthetic methodologies / Chikako Saotome, Osamu Kanie -- ch. 2. Complex carbohydrate synthesis / Makoto Kiso, Hideharu Ishida, Hiromune Ando -- ch. 3. The chemistry of sialic acid / Geert-Jan Boons, Alexei V. Demchenko -- ch. 4. Solid-phase oligosaccharide synthesis / Peter H. Seeberger -- ch. 5. Solution and polymer-supported synthesis of carbohydrates / Shin-Ichiro Nishimura -- ch. 6. Enzymatic synthesis of oligosaccharides / Jianbo Zhang, Jun Shao, Prezemk Kowal, Peng George Wang -- ch. 7. Glycopeptides and glycoproteins : synthetic chemistry and biology / Oliver Seitz -- ch. 8. Synthesis of complex carbohydrates : Everninomicin 13,384-1 / K. C. Nicolaou, Helen J. Mitchell, Scott A. Snyder -- ch. 9. Chemical synthesis of asparagine-linked glycoprotein oligosaccharides : recent examples / Yukishige Ito, Ichiro Matsuo -- ch. 10. Chemistry and biochemistry of asparagine-linked protein glycosylation / Barbara Imperiali, Vincent W.-F. Tai -- ch. 11. Conformational analysis of C-glycosides and related compounds : programming conformational profiles of C- and O-glycosides / Peter G. Goekjian, Alexander Wei, Yoshito Kishi -- ch. 12. Synthetic lipid A antagonists for sepsis treatment / William J. Christ, Lynn D. Hawkins, Michael D. Lewis, Yoshito Kishi -- ch. 13. Polysialic acid vaccines / Harold J. Jennings -- ch. 14. Synthetic carbohydrate-based vaccines / Stacy J. Keding, Samuel J. Danishefsky -- ch. 15. Chemistry, biochemistry, and pharmaceutical potentials of glycosaminoglycans and related saccharides / Tasneem Islam, Robert J. Linhardt -- ch. 16. A new generation of antithrombotics based on synthetic oligosaccharides / Maurice Petitou, Jean-Marc Herbert -- ch. 17. Sequencing of oligosaccharides and glycoproteins / Stuart M. Haslam, Kay-Hooi Khoo, Anne Dell -- ch. 18. Preparation of heterocyclic 2-deoxystreptamine aminoglycoside analogues and characterization of their interaction with RNAs by use of electrospray ionization mass spectrometry / Richard H. Griffey, Steven A. Hofstadler, Eric E. Swayze -- ch. 19. Glycosylation analysis of a recombinant P-selectin antagonist by high-pH anion-exchange chromatography with pulsed electrochemical detection (HPAEC/PED) / Mark R. Hardy, Richard J. Cornell -- ch. 20. Analytical techniques for the characterization and sequencing of glycosaminoglycans / Ram Sasisekharan, Zachary Shriver, Mallik Sundaram, Ganesh Venkataraman -- ch. 21. Thermodynamic models of the multivalency effect / Pavel I. Kitov, David R. Bundle -- ch. 22. Synthetic multivalent carbohydrate ligands as effectors or inhibitors of biological processes / Laura L. Kiessling, Jason K. Pontrello, Michael C. Schuster -- ch. 23. Glycosyltransferase inhibitors / Karl-Heinz Jung, Richard R. Schmidt -- ch. 24. RNA-aminoglycoside interactions / Haim Weizman, Yitzhak Tor -- ch. 25. Glycosylated natural products / Jon S. Thorson, Thomas Vogt -- ch. 26. Novel enzymatic mechanisms in the biosynthesis of unusual sugars / Alexander Wong, Xuemei He, Hung-Wen Liu -- ch. 27. Neoglycolipids : identification of functional carbohydrate epitopes / Ten Feizi, Alexander M. Lawson, Wengang Chai -- ch. 28. A preamble to aglycone reconstruction for membrane-presented glycolipid mimics / Murugesapillai Mylvaganam, Clifford A. Lingwood -- ch. 29. Small molecule inhibitors of the sulfotransferases / Dawn E. Verdugo, Lars C. Pedersen, Carolyn R. Bertozzi -- ch. 30. Carbohydrate-based treatment of cancer metastasis / Reiji Kannagi -- ch. 31. N-acetylneuraminic acid derivatives and mimetics as anti-influenza agents / Robin Thomson, Mark Von Itzstein -- ch. 32. Modified and modifying sugars as a new tool for the development of therapeutic agents : the biochemically engineered N-acyl side chain of sialic acid : biological implications and possible uses in medicine / Rüdiger Horstkorte, Oliver T. Keppler, Werner Reutter -- ch.33 . Modified and modifying sugars as a new tool for the development of therapeutic agents : glycosidated phospholipids as a new type of antiproliferative agents / Kerstin Danker, Annette Fischer, Werner Reutter -- ch. 34. Glycoside primers and inhibitors of glycosylation / Jillian R. Brown, Mark M. Fuster, Jeffrey D. Esko -- ch. 35. Carbohydrate-based drug discovery in the battle against bacterial infections : new opportunities arising from programmable one-pot oligosaccharide synthesis / Thomas K. Ritter, Prof. Dr. Chi-Huey Wong.
  • 1. Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression / T.C. Thompson, S.A. Tahir, L. Li, M. Watanabe, K. Naruishi, G. Yang, Ken-ichi Tabata, S. Kurosaka, K. Edamura, R. Tanimoto, P. Corn, D. Kadmon, C.J. Logothetis, P. Troncoso, C. Ren, A. Goltsov, and S. Park -- 2. Caveolin-1 in Colon Cancer: The Flexible Connection to Wnt Signaling / Andrew F.G. Quest, Vicente A. Torres, Diego A. Rodriguez, Jorge Gutierrez-Pajares, and Julio C. Tapia -- 3. Caveolin-1 and Pancreatic Ductal Adenocarcinoma / David W. Rittenhouse, Oeendree Mukherjee, Nathan G. Richards, Charles J. Yeo, Agnieszka K. Witkiewicz, and Jonathan R. Brody -- 4. Caveolin-1 in Brain Tumors / Rebecca Senetta and Paola Cassoni -- 5. The Role of Caveolin-1 in Skin Cancer -- / Alessandra Carè, Isabella Parolini, Federica Felicetti, and Massimo Sargiacomo -- 6. Caveolins in Tumor Angiogenesis / Grzegorz Sowa -- 7. Caveolin-1 and Breast Cancer / Gloria Bonuccelli and Michael P. Lisanti -- 8. Caveolin-1 and Cancer-Associated Stromal Fibroblasts / Isabelle Mercier and Michael P. Lisanti.
  • 1. GRB2 Signaling as a Molecular Target for Cancer / Alessio Giubellino -- 2. Human Arylamine N-acetyltransferase 1: From Drug Metabolism to Drug Target / Fernando Rodrigues-Lima, Julien Dairou, Florent Busi, and Jean-Marie Dupret -- 3. Targeting Argininosuccinate Synthetase in Cancer Therapy / Niramol Savaraj, Min You, Chunjing Wu, Macus Tien Kuo, Vy Dinh, Medhi Wangpaichitr, and Lynn Feun -- 4. Parathyroid Hormone-Related Peptide Signaling in Cancer / Franco Oreste Ranelletti and Giovanni Monego -- 5. Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma / Francesco Piazza and Gianpietro Semenzato -- 6. Role of Bile Acids in Carcinogenesis of Gastrointestinal Tract / Hiroshi Yasuda and Fumio Itoh -- 7. AIB1: A Transcriptional Coactivator Which Integrates Signaling Cross Talk in Cancer Cells / Macarena Ferrero and Jaime Font de Mora -- 8. Rational Design of DNA Anticancer Agent That Targets Signal Transducer and Activator of Transcription 3 (Stat3) for Cancer Therapy / Naijie Jing -- 9. Estrogen Receptor Signaling in Lung Cancer / P.A. Hershberger and J.M. Siegfried -- 10. Microparticle Dissemination of Biological Activities: Implications for Cancer Biology / Pauline P. Goh -- 11. Protein Kinase D Signaling in Cancer / Peter Storz -- 12. Cell Signaling and Cancer: Integrated, Fundamental Approach Involving Electron Transfer, Reactive Oxygen Species, and Antioxidants / Peter Kovacic and Ratnasamy Somanathan -- 13. Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy / Fabio P.S. Santos, Inbal Hazan-Halevy, and Zeev Estrov.
  • An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities - the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in the last several years. So much has changed since the 1st edition of this book was published in 2004. There are now additional manufacturing processes for producing commercial biopharmaceuticals - transgenic plant cell cultures and transgenic animals. In addition to commercial recombinant proteins and monoclonal antibodies, there are now commercial cell-based medicines (cellular therapy) and DNA-based medicines (gene therapy). Biosimilars are now on the marketplace in Europe, and under review for commercial approval in the USA. Vaccine manufacturing has resurged due to the concerns of potentially pandemic mutated animal influenzas (e.g., swine flu, bird flu). Strategic international regulatory guidances have been adopted that are driving the entire pharmaceutical industry, including biopharmaceuticals, to a higher standard of performance, including Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality Systems (PQS). The vast majority of the over 600 regulatory references listed in this book were either issued or updated since the release of the 1st edition. All of these changes are the reason this updated edition includes not only biopharmaceuticals but also other biologics (e.g., live virus vaccines, human plasma-derived proteins, cell-based medicines, natural-sourced proteins) that have CMC regulatory compliance concerns and challenges in common with the genetically-engineered biologics (i.e., the biopharmaceuticals).
  • Part I. Virology, pathogenesis, and clinical and epidemiological features of disease -- Part II. Host response to infection and genetics of disease -- Part III. Vaccine platforms and treatment options -- Part IV. Animal and tissue culture models of infection -- Part V. Conclusions -- Index.
  • Introduction to cancer -- Antimetabolites -- DNA-interactive agents -- Antitubulin agents -- Cell signaling inhibitors -- Hormonal therapies -- Tumour targeting strategies -- Biologicals -- The future -- Personalized medicine (oncogenomics) -- Adjunct therapies.
  • "Natural products play crucial roles in modern drug development and constitute a prolific source of novel lead compounds or pharmacophores for ongoing drug discovery programs. Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds presents cutting-edge research in the chemistry of bioactive natural products and demonstrates how natural product research continues to make significant contributions in the discovery and development of new medicinal entities."--Page [4] of cover.
  • This book puts hydrogen sulfide in context with other gaseous mediators such as nitric oxide and carbon monoxide, reviews the available mechanisms for its biosynthesis and describes its physiological and pathophysiological roles in a wide variety of disease states. Hydrogen sulfide has recently been discovered to be a naturally occurring gaseous mediator in the body. Over a relatively short period of time this evanescent gas has been revealed to play key roles in a range of physiological processes including control of blood vessel caliber and hence blood pressure and in the regulation of nerve function both in the brain and the periphery. Disorders concerning the biosynthesis or activity of hydrogen sulfide may also predispose the body to disease states such as inflammation, cardiovascular and neurological disorders. Interest in this novel gas has been high in recent years and many research groups worldwide have described its individual biological effects. Moreover, medicinal chemists are beginning to synthesize novel organic molecules that release this gas at defined rates with a view to exploiting these new compounds for therapeutic benefit.
  • Chemokine receptors 2007
  • With the addition of 130 herbs and 100 new references, the second edition provides a basic understanding of the science behind Chinese herbal preparations. Using the same format that made the first edition so popular, author Thomas Li provides a seamless integration of topics drawn from a diverse array of sources. The first table presents major constituents and therapeutic values of more than 1800 species. The data are arranged alphabetically by the Latin name followed by common Chinese and English names. Tables 2 and 3 present data on a total of 700 North American herbs belonging to the same species or genus as Chinese herbs, and a comparison of active ingredients and claimed therapeutic values. Appendices 1, 2, and 3 cross-reference Chinese and scientific names, and major active ingredients and their sources in the Chinese and North American herbs cited in the tables.
  • Part 1. Synthesis and characterization of chitin and chitosan derivatives -- part 2. Biological activities of chitin and chitosan derivatives -- part 3. Biomedical applications of chitin and chitosan derivatives.
  • Circadian clocks 2013
    Molecular and cellular basis of circadian clocks -- Molecular components of the mammalian circadian clock / Ethan D. Buhr and Joseph S. Takahashi -- The epigenetic language of circadian clocks / Saurabh Sahar and Paolo Sassone-Corsi -- Peripheral circadian oscillators in mammals / Steven A. Brown and Abdelhalim Azzi -- Cellular mechanisms of circadian pacemaking: beyond transcriptional loops / John S. O'Neill, Elizabeth S. Maywood, and Michael H. Hastings -- The clock in the brain: neurons, glia, and networks in daily rhythms / Emily Slat, G. Mark Freeman Jr., and Erik D. Herzog -- Circadian control of physiology and behavior -- Circadian clocks and metabolism / Biliana Marcheva, Kathryn M. Ramsey, Clara B. Peek, Alison Affinati, Eleonore Maury, and Joseph Bass -- The circadian control of sleep / Simon P. Fisher, Russell G. Foster, and Stuart N. Peirson -- Daily regulation of hormone profiles / Andries Kalsbeek and Eric Fliers -- Circadian clocks and mood-related behaviors / Urs Albrecht -- Chronopharmacology and chronotherapy -- Molecular clocks in pharmacology / Erik S. Musiek and Garret A. FitzGerald -- Cancer chronotherapeutics: experimental, theoretical,and clinical aspects / E. Ortiz-Tudela, A. Mteyrek, A. Ballesta, P.F. Innominato, and F. Lévi -- Pharmacological modulators of the circadian clock as potential therapeutic drugs: focus on genotoxic/anticancer therapy / Marina P. Antoch and Roman V. Kondratov -- Light and the human circadian clock / Till Roenneberg, Thomas Kantermann, Myriam Juda, Ceéline Vetter, and Karla V. Allebrandt -- Systems biology of circadian clocks -- Mathematical modeling in chronobiology / G. Bordyugov, P.O. Westermark, A. Korenčič, S. Bernard, and H. Herzel -- Mammalian circadian clock: the roles of transcriptional repression and delay / Yoichi Minami, Koji L. Ode, and Hiroki R. Ueda -- Genome-wide analyses of circadian systems / Akhilesh B. Reddy -- Proteomic approaches in circadian biology / Maria S. Robles and Matthias Mann.
  • "The successful utilization of biomarkers in clinical development and, indeed, realization of personalized medicine require a close collaboration among different stakeholders: clinicians, biostatisticians, regulators, commercial colleagues, and so on. For this reason, we invited experts from different fields of expertise to address the opportunities and challenges, and discuss recent advancements related to biomarkers and their translation into clinical development. The first four chapters discuss biomarker development from a clinical perspective ranging from introduction to biomarkers to recent advances in RNAi screens, epigenetics, and rare disease as targets for personalized medicine approaches. Chapters 5 through 10 are devoted to considerations from a statistical perspective, and the last chapter addresses the regulatory issues in biomarker utilization. A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as pathological process or response to a therapeutic intervention. Although there is nothing new about biomarkers such as glucose for diabetes and blood pressure for hypertension, the current focus on molecular biomarkers has taken the center stage in the development of molecular medicine. Molecular diagnostic technologies have enabled the discovery of molecular biomarkers and are assisting in the definition of the pathogenic mechanism of diseases. Biomarkers represent the basis of the development of diagnostic assays as well as the target for drug discovery. Biomarkers can help monitoring drugs effect in clinical trials as well as in clinical practice"-- Provided by publisher.
  • Currently, there are tremendous advances being made in understanding the basic science of both the structure and function of botulinum neurotoxins. This knowledge is opening up opportunities in regard to both therapeutic uses and treatment and protection options for civil and bio-defense applications. This volume fully evaluates the status of neurotoxin research and exploitation, with a focus on clinical application. The book is a multi-authored collection of chapters written by the leading authorities responsible for the current scientific and clinical research that is advancing the understanding and exploitation of the neurotoxins, and is both up to date and authoritative.
  • This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.
  • A thorough knowledge of pharmacological and therapeutic principles is vital if drugs are to be used safely and effectively for increasingly informed patients. Those who clearly understand how drugs get into the body, how they produce their effects, what happens to them in the body, and how evidence of their therapeutic effect is assessed, will choose drugs more skilfully, and use them more safely and successfully than those who do not. Now in a fully revised 11th edition, Clinical Pharmacology is essential reading for undergraduate medical students, junior doctors and anyone concerned with ev.
  • "This book highlights the behavioral and neurobiological issues relevant for drug development, reviews evidence for an innovative approach for drug discovery and presents perspectives on multiple special topics ranging from therapeutic drug use in children, emerging technologies and non-pharmacological approaches to cognitive enhancement."--Publisher's website.
  • Medical and Psychosocial Aspects of Cognitive Enhancement -- Pharmacological Neuroenhancement: Substances and Epidemiology / Andreas G. Franke, Klaus Lieb -- Psychopharmacological Neuroenhancement: Evidence on Safety and Efficacy / Dimitris Repantis -- A Bubble of Enthusiasm: How Prevalent Is the Use of Prescription Stimulants for Cognitive Enhancement? / Bradley Partridge -- Modeling the Effects of Modafinil on Selective Attention Electroencephalographic Neural Correlates / Carlos Trenado -- Behavioral Neuroenhancement / Martin Dresler -- The Influence of Sports on Cognitive Task Performance - A Critical Overview / Pavel Dietz -- The Human Experiment: How We Won't Win the Rat Race. What Can We Learn from Brain Stimulation in Humans and Rats About Enhancing the Functional Neurobiology of Higher Cognitive Functions? / Colleen A. Dockery -- Philosophical and Ethical Aspects of Cognitive Enhancement -- Better Brains or Bitter Brains? The Ethics of Neuroenhancement / Kirsten Brukamp -- Cognitive Enhancement - To What End? / Michael Hauskeller -- Nano-bionic Devices for the Purpose of Cognitive Enhancement: Toward a Preliminary Ethical Framework / Frédéric Gilbert -- Cognitive-Enhancing Drugs, Behavioral Training and the Mechanism of Cognitive Enhancement / Emma Peng Chien -- What Is Cognitive Enhancement and Is It Justified to Point Out This Kind of Enhancement Within the Ethical Discussion? / Roland Kipke -- No Pain, No Gain? Objections to the Use of Cognitive Enhancement on the Basis of Its Potential Effects on the Value of Achievement / Lisa Forsberg -- Does the Cognitive Enhancement Debate Call for a Renewal of the Deliberative Role of Bioethics? / Cynthia Forlini, Eric Racine -- Sociological, Political and Legal Aspects of Cognitive Enhancement -- The Biopolitics of Cognitive Enhancement / Peter B. Reiner -- Are We Heading Towards an 'Enhancement Society'? / Armin Grunwald -- Leveling the Playing Field: Fairness in the Cognitive Enhancement Debate / Greta Wagner -- My Mind Is Mine!? Cognitive Liberty as a Legal Concept / Jan-Christoph Bublitz -- Cognitive Enhancement and Criminal Behavior / Elizabeth Shaw -- Enhanced Control and Criminal Responsibility / John Danaher.
  • Surfactants and block copolymers in drug delivery / Ambikanandan Misra ... [et al.] -- Application of colloidal properties in drug delivery / Swarnlata Saraf -- Polymeric nanocapsules for drug delivery : an overview / Sílvia S. Guterres ... [et al.] -- Poly(alkyl cyanoacrylate) nanoparticles for drug delivery and vaccine development / Anja Graf, Karen Krauel-Göllner, Thomas Rades -- Stimuli-sensitive polymer gels for dermal and transdermal drug delivery and their application in the development of smart textile materials / Witold Musial and Vanja Kokol -- Micelles : the multifunctional nanocarrier for colloidal drug delivery / Chandana Mohanty, Sarbari Acharya, and Sanjeeb K. Sahoo -- Multiple emulsions : an overview and pharmaceutical applications / Jatin Khurana, Somnath Singh, and Alekha K. Dash -- Pharmaceutical and biotechnological applications of multiple emulsions / Rita Cortesi and Elisabetta Esposito -- Nanoemulsions as drug delivery systems / Figen Tirnaksiz, Seyda Akkus, and Nevin Celebi -- Microemulsion systems : application in delivery of poorly soluble drugs / Ljiljana Djekic and Marija Primorac -- Diclofenac solubilization in mixed nonionic surfactants microemulsions / Monzer Fanun -- Self-emulsifying drug delivery systems / D. P. Maurya, Yasmin Sultana, and M. Abul Kalam -- Liquid crystals and their application in the field of drug delivery / Rakesh Patel and Tanmay N. Patel -- Liquid crystalline nanoparticles as drug nanocarriers / Anan Yaghmur and Michael Rappolt -- Niosomal delivery system for macromolecular drugs / Yongzhuo Huang, Faquan Yu, and Wenquan Liang -- A new class of mesoscopic aggregates as a novel drug delivery system / Federico Bordi, Cesare Cametti, and Simona Sennato -- Liposomes and biomacromolecules : effects of preparation protocol on in vitro activity / Paola Luciani, Debora Berti, and Piero Baglioni -- Colloidal nanocarrier systems as a tool for improving antimycobacterial and antitumor activities and reducing the toxicity of usnic acid / N. S. Santos-Magalhães ... [et al.] -- Dendrimers in drug delivery / Hu Yang -- Microsphere : a novel drug delivery system / Abdus Samad ... [et al.] -- Colloids in aerosol drug delivery system / Nazrul Islam -- Respiratory aerosol dynamics with applications to pharmaceutical drug delivery / Jinxiang Xi, P. Worth Longest, and Paula J. Anderson -- Colloidal carriers for drug delivery in dental tissue engineering / Nader Kalaji, Nida Sheibat-Othman, and Hatem Fessi -- Classification and application of colloidal drug delivery systems : passive or active tumor targeting / H. Yesim Karasulu, Burcak Karaca, and Ercüment Karasulu -- Nanocarriers for imaging applications / Vandana Patravale and Medha Joshi.
  • "Presents recent research developments to aid fighting fungal infections The currently available means of combating fungal infections are still weak and clumsy. The application of fungal genomics offers an unparalleled opportunity to develop novel antifungal drugs. Interestingly, several novel antifungal drug targets have already been identified and validated. However, it is too early to expect any novel antifungal drug as drug discovery programs are still in their infancy. In addition to classical and genomic approaches to drug discovery, traditional knowledge derived from natural products and phytomedicine can provide a multitude of alternative modes of combating fungal infection. This book comprises 20 chapters on various aspects pertaining to fungal diseases in human and animals, their reservoir, fungal pathogenesis, their management and recent advances in their treatment. Issues of antifungal drug toxicity, especially nephrotoxicity, are also discussed. The development of resistance in fungal pathogens, including multidrug resistance and its mechanism, is dealt with in two chapters. Diverse diagnostic approaches to fungal infections are also reviewed. The combinational drug strategies used in combating invasive fungal infections are addressed in detail. The management of pulmonary mycoses in stem cell transplantation is also given special focus. Novel antifungal drugs (synthetic and herbal), fungal vaccines, and metabolic pathways as drug targets are discussed in detail in three different chapters. Subsequently the roles of innate immunity, cytokine therapy and immunomodulators in the treatment of fungal infections are elaborated upon. As novel drug delivery systems have a great potential for modifying the pharmacokinetics of medications, the last chapter takes this fact into consideration in its examination of state-of-the-art delivery systems in controlling fungal infections."--Publisher's website.
  • Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
  • This volume addresses not only a series of key topics in the discipline of veterinary pharmacology and therapeutics that will be of interest to those researching and treating animal disease, but also emphasising the comparative aspects of the subject and the interface with human health and disease.
  • v. 1. Global perspective / volume editor, Peter D. Kennewell -- v. 2. Strategy and drug research / volume editor, Walter H. Moos -- v. 3. Drug discovery technologies / volume editor, Hugo Kubinyi -- v. 4. Computer-assisted drug design / volume editor, Jonathan S. Mason -- v. 5. ADME-Tox approaches / volume editors, Bernard Testa and Han van de Waterbeemd -- v. 6. Therapeutics areas I: central nervous system, pain, metabolic syndrome, urology, gastrointestinal and cardiovascular / volume editor, Michael Williams -- v. 7. Therapeutic areas II: cancer, infectious diseases, inflammation & immunology and dermatology / volume editors, Jacob J. Plattner & Manoj C. Desai -- v. 8. Case histories and cumulative subject index / volume editors, John B. Taylor & David J. Triggle.
  • This book focuses on applications of compound library design and virtual screening to expand the bioactive chemical space, to target hopping of chemotypes to identify synergies within related drug discovery projects or to repurpose known drugs, to propose mechanism of action of compounds, or to identify off-target effects by cross-reactivity analysis. Both ligand-based and structure-based in silico approaches, as reviewed in this book, play important roles for all these applications. Computational chemogenomics is expected to increase the quality and productivity of drug discovery and lead.
  • Empirical pharmacokinetics -- Numerical methods for PK parameter estimation -- Physiological aspects on pharmacokinetics -- Modelling the distribution process -- PK/PD modelling.
  • Part I. In vitro protocols for studying expression and activity of cyclooxygenase enzymes and characterisation of their inhibition patterns -- 1. In vitro cyclo-oxygenase expression and activity protocols : introduction to Part I / Roderick J. Flower -- 2. Techniques used to study regulation of cyclooxygenase-2 promoter sites / Hiroyasu Inoue and Rieko Nakata -- 3. Purification of recombinant human COX-1 and COX-2 / James K. Gierse -- 4. Cloning and expression of cyclooxygenase-1 and cyclooxygenase-2 / Nicholas R. Staten and Beverly A. Reitz -- 5. Expression of cyclooxygenase isoforms in the baculovirus expression system / John C. Hunter, Natalie M. Myres, and Daniel L. Simmons -- 6. Peroxidase active site activity assay / Kelsey C. Duggan, Joel Musee, and Lawrence J. Marnett -- 7. Study of inhibitors of the PGH synthases for which potency Is regulated by the redox state of the enzymes / Olivier Boutaud and John A. Oates -- 8. Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors / Stefan Laufer and Sabine Luik -- 9. In vitro cyclooxygenase activity assay in tissue homogenates / Samir S. Ayoub -- 10. Techniques used to characterize the binding of cyclooxygenase Inhibitors to the cyclooxygenase active site / William F. Hood -- 11. In vitro Assays for cyclooxygenase activity and inhibitor characterization / Mark C. Walker and James K. Gierse -- -- Part II. Extraction and measurement of prostanoids and isoprostanes -- 12. Extraction and measurement of prostanoids and isoprostanes : introduction to Part II / Paola Patrignani -- 13. Prostanoid extraction and measurement / Lorenzo Polenzani and Samir S. Ayoub -- 14. Measurement of 8-iso-prostaglandin F2a in biological fluids as a measure of lipid peroxidation / Stefania Tacconelli, Marta L. Capone, and Paola Patrignani -- -- Part III. In vivo models to study involvement of cyclooxygenase products in health and disease -- 15. In vivo models to study cyclooxygenase products in health and disease: introduction to Part III / Derek W. Gilroy, Melanie Stables, and Justine Newson -- 16. Protocols to assess the gastrointestinal side effects resulting from inhibition of Cyclo-Oxygenase isoforms / Brendan J.R. Whittle -- 17. Cyclooxygenase enzymes and their products in the carrageenan-induced pleurisy in rats / Adrian R. Moore, Samir S. Ayoub, and Michael P. Seed -- 18. Iloprost-induced nociception : determination of the site of anti-nociceptive action of cyclooxygenase inhibitors and the Involvement of cyclooxygenase products in central mechanisms of nociception / Samir S. Ayoub and Regina M. Botting.
  • The pharmacokinetic basis of therapeutics -- The pharmacodynamic basis of therapeutics -- Adverse reactions and drug-drug interactions -- Herb-drug interactions -- Food-drug interactions.
  • 1. Translational Strategies for Development of Antibody-Based Therapeutics: An Overview / Mohammad Tabrizi, Gadi Gazit Bornstein and Scott L. Klakamp -- 2. Discovery Process for Antibody-Based Therapeutics / Heather H. Shih -- 3. Technologies for the Generation of Human Antibodies / Ramesh R. Bhatt, John S. Haurum and C. Geoffrey Davis -- 4. Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics / Randall J. Brezski and Juan Carlos Almagro -- 5. Biophysical Considerations for Development of Antibody-Based Therapeutics / Andrew W. Drake and Giuseppe A. Papalia -- 6. Considerations in Establishing Affinity Design Goals for Development of Antibody-Based Therapeutics / Mohammad Tabrizi -- 7. Bioanalytical Considerations for Development of Antibody-Based Therapeutics: Pharmacokinetics and Immunogenicity / Cherryl B. Funelas and Scott L. Klakamp -- 8. Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology / Gregory Landes and Kathleen Elias -- 9. Factors Impacting the Tumor Localization and Distribution of Antibody-Based Therapeutics in Oncology / David C. Blakey -- 10. Preclinical Safety Considerations for the Development of Antibody-Based Therapeutics / Lolke de Haan -- 11. Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics / Donald E. Mager -- 12. Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational Strategies for Development of Antibody-Based Therapeutics / Feng Jin -- 13. Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics / Mohammad A. Tabrizi and Cherryl B. Funelas -- 14. Translational Research in Alzheimer's Disease for Development of Antibody-Based Therapeutics / Eric C. Yuen, Enchi Liu and Gene G. Kinney -- 15. Considerations in Manufacturing Process Development for Antibody-Based Therapeutics / Paula C. Miller and Peiling Xu -- 16. Strategies for Development of Next Generation Antibody-Based Therapeutics / Mohammad Tabrizi and Gadi Gazit Bornstein -- 17. Immune Complex Therapies for Treatment of Immune Thrombocytopenia / Rong Deng and Joseph P. Balthasar -- 18. Application of Bioinformatics Principles for Target Evaluation / Anthony Carvalloza, Mohammad Fallahi and Sahba Tabrizifard -- 19. Concluding Remarks / Mohammad Tabrizi, Gadi Gazit Bornstein and Scott L. Klakamp.
  • The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens?
  • Development of novel vaccines gives an overview of the tasks in basic research leading to the final product â" the vaccine and its applications, belonging to the most complex biologics in the pharmaceutical field. Distinct from most textbooks in the vaccine arena, the current issue focuses on the translational aspect, namely, how research results can be transformed into life-saving medical interventions. Each chapter of the book deals with one important paradigm for the development of novel vaccines, along the value chain towards the final vaccine, and furthermore, with the inevitable tools required for this process. Contributions are prepared by teams of scientists, all of whom are experts in the field, most of them anchored in biomedical organizations devoted to translational culture, thereby lighting the certain topics from different views. This volume is a must read for researchers engaged in vaccine development and who really want to see their research results to become a product.
  • Targeting type 2 diabetes -- Dual acting and pan-PPAR activators as potential anti-diabetic therapies -- GLP-1 agonists and dipeptidyl-peptidase IV inhibitors -- Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes -- SGLT inhibitors as new therapeutic tools in the treatment of diabetes -- Inhibitors of 11[beta]-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy -- Nampt and its potential role in inflammation and type 2 diabetes -- Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance -- Overcoming insulin resistance with ciliary neurotrophic factor -- Thermogenesis and related metabolic targets in anti-diabetic therapy -- Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes -- Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes -- AMP-activated protein kinase and metabolic control -- Mitochondria as potential targets in antidiabetic therapy -- Research and development of glucokinase activators for diabetes therapy : theoretical and practical aspects.
  • "Discussion Framework for Clinical Trial Data Sharing: Guiding Principles, Elements, and Activities is part of a study of how data from clinical trials might best be shared. This document is designed as a framework for discussion and public comment. This framework is being released to stimulate reactions and comments from stakeholders and the public. The framework summarizes the committee's initial thoughts on guiding principles that underpin responsible sharing of clinical trial data, defines key elements of clinical trial data and data sharing, and describes a selected set of clinical trial data sharing activities."--Publisher's website.
  • Introduction and historical perspective / Patrick Forterre -- Human DNA topoisomerase I : structure, enzymology and biology / James J. Champoux -- Mitochondrial topoisomerases / Ilaria Dalla Rosa, Yves Pommier, and Hongliang Zhang -- Structure and mechanism of eukaryotic type IIA topoisomerases / James M. Berger and Neil Osheroff -- Essential functions of topoisomerase III-alpha in the nucleus and mitochondria / Stefanie Hartman Chen, Jianhong Wu, and Tao-shih Hsieh -- DNA topoisomerase I and illegitimate recombination / Céline Auzanneau and Philippe Pourquier -- Topoisomerase-induced DNA damage / Yves Pommier and Neil Osheroff -- Topoisomerases and carcinogenesis : topoisomerases III-alpha and BLM / Mounira Amor-Guéret and Jean-François Riou -- Topoisomerases inhibitors : a paradigm for interfacial inhibition / Christophe Marchand and Yves Pommier -- Topoisomerases I inhibitors : chemical biology / Beverly A. Teicher -- Topoisomerases II inhibitors : chemical biology / Anna Rogojina ... [et al.] -- Topoisomerases I inhibitors : current use and prospects / Yan Makeyev ... [et al.] -- Topoisomerases II inhibitors : current use and prospects / Olivier Mir ... [et al.] -- Transcriptional stress by camptothecin : mechanisms and implications for the drug antitumor activity / Giovanni Capranico ... [et al.] -- Mechanisms regulating cellular responses to DNA topoisomerases I-targeted agents / Piero Benedetti and Mary-Ann Bjornsti -- Tyrosyl-DNA-phosphodiesterase / Thomas S. Dexheimer ... [et al.] -- Ubiquitin and ubiquitin-like proteins in repair of topoisomerases-mediated DNA damage / Shyamal D. Desai -- Repair of topoisomerases II-mediated DNA damage : fixing DNA damage arising from a protein covalently trapped on DNA / John L. Nitiss ... [et al.] -- Topoisomerases and apoptosis / Olivier Sordet and Stéphanie Solier.
  • Dopamine 2005
  • Part I. Fundamentals -- Chapter 1. Introduction -- Chapter 2. Dose Finding in Clinical Trials -- Chapter 3. The Continual Reassessment Method -- Chapter 4. One-Parameter Dose-Toxicity Models -- Chapter 5. Theoretical Properties -- Chapter 6. Empirical Properties -- Part II. Design Calibration -- Chapter 7. Specifications of a CRM Design -- Chapter 8. Initial Guesses of Toxicity Probabilities -- Chapter 9. Least Informative Normal Prior -- Chapter 10. Initial Design -- Part III. CRM and Beyond -- Chapter 11. The Time-to-Event CRM -- Chapter 12. CRM with Multiparameter Models -- Chapter 13. When the CRM Fails -- Chapter 14. Stochastic Approximation.
  • Drug delivery 2010
    This volume gives a topical overview of various modern approaches to drug targeting covering today's options for specific carrier systems allowing successful drug treatment at various sites of the body difficult to address and increasing the benefit-risk-ratio.
  • Drug delivery systems 2008
    Springer Protocols
    Drug delivery systems--an overview / Kewal K. Jain -- The role of the adeno-associated virus capsid in gene transfer / Kim M. Van Vliet ... [et al.] -- Delivering small interfering RNA for novel therapeutics / Patrick Y. Lu and Martin C. Woodle -- Catheters for chronic administration of drugs into brain tissue / Michael Guarnieri, Benjamin S. Carson, Sr., and George I. Jallo -- Transdermal drug delivery systems : skin perturbation devices / Marc B. Brown ... [et al.] -- Controlling the release of proteins/peptides via the pulmonary route / Sunday A. Shoyele -- Engineering protein particles for pulmonary drug delivery / Sunday A. Shoyele -- 2B-Trans technology : targeted drug delivery across the blood-brain barrier / Pieter J. Gaillard and Albertus G. de Boer -- Drug delivery in cancer using liposomes / Crispin R. Dass -- pH-responsive nanoparticles for cancer drug deliery / Youqing Shen ... [et al.] -- Extended-release oral drug delivery technologies : monolithic matrix systems / Sandip B. Tiwari and Ali R. Rajabi-Siahboomi.
  • Polymers in Drug Delivery: Concepts, Developments and Potential / Rongjun Chen -- Amphiphilic Molecules in Drug Delivery Systems / Salomé dos Santos, Bruno Medronho -- Sizing Nanoparticles in Liquids: An Overview of Methods / Margarida Figueiredo -- Nanoparticles for Oral Delivery of Insulin / Antonio J. Ribeiro, Raquel Seiça -- Bioartificial Pancreas: In the Road to Clinical Application / Joana Crisóstomo, Jorge F. J. Coelho -- Cationic Liposome-Based Systems for Nucleic Acid Delivery: From the Formulation Development to Therapeutic Applications / Henrique Faneca, Ana Luísa Cardoso -- Biomaterial-Based Vectors for Targeted Delivery of Nucleic Acids to the Nervous System / Ana Paula Pêgo, Hugo Oliveira -- Biofabrication of Hydrogel Constructs / Rúben F. Pereira, Henrique A. Almeida -- The Warburg Effect Is a Guide to Multipurpose Cancer Therapy Including Trace Element Delivery / Anatoliy V. Popov, Leonid G. Menchikov -- In Silico Research in Drug Delivery Systems / André Filipe Ferreira, Rodrigo José Lopes -- The Importance of Controlled/Living Radical Polymerization Techniques in the Design of Tailor Made Nanoparticles for Drug Delivery Systems / Nuno Rocha, Patrícia Mendonça, Joana R. Góis.
  • Virtual screening for lead discovery / Yat T. Tang and Garland R. Marshall -- Computer-aided drug discovery and development / Shuxing Zhang -- Using active site mapping and receptor-based pharmacophore tools : prelude to docking and de novo/fragment-based ligand design / Ashutosh Tripathi, J. Andrew Surface, and Glen E. Kellogg -- Methods for evaluation of structural and biological properties of antiinvasive natural products / Mudit Mudit [and others] -- Solid-phase peptide synthesis using microwave irradiation / Justin K. Murray, Jennifer Aral, and Les P. Miranda -- Fluorescent and lanthanide labeling for ligand screens, assays, and imaging / Jatinder S. Josan [and others] -- DNA-directed assembly microarray for protein and small molecule inhibitor screening / Ng Jin Kiat [and others] -- Selection of peptide ligands for human placental transcytosis systems using in vitro phage display / Saleem Basha, Shruthi Vaidhyanathan, and GIovanni M. Pauletti -- Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability / Paul W. Sylvester -- Imaging NF-KB signaling in mice for screening anticancer drugs / Delira Robbins and Yunfeng Zhao -- Evaluation of anticancer agents using flow cytometry analysis of cancer stem cells / Vineet Gupta, Qian-Jin Zhang, and Yong-Yu Liu -- Chemical screening with zebrafish embryos / Hanbing Zhong and Shuo Lin -- iTRAQ labeling coupled with LC-MALDI mass spectrometry for monitoring temporal response of colorectal cancer cells to butyrate treatment / Hwee Tong Tan [and others] -- Heterotypic cell adhesion assay for the study of cell adhesion inhibition / Seetharama D. Satyanarayanajois, Sharon Ronald, and Jining Liu -- Evaluation of antibacterial activity of proteins and peptides using a specific animal model for wound healing / Ramar Perumal Samy [and others] -- In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting / Punett Gaitonde and Sathy V. Balu-Iyer.
  • Section A. Introduction -- section B. Clinical pharmacokinetics -- section C. Human studies in clinical pharmacology -- section D. Regulations.
  • Section I, Safety pharmacology: -- Introduction to safety pharmacology -- Status of safety pharmacology and present guidelines -- Central nervous system (CNS) safety pharmacology studies -- Methods in cardiovascular safety pharmacology -- Safety pharmacology of drugs for the urinary tract -- Respiratory function assays in safety pharmacology -- Metabolism pharmacology -- Peripheral nervous system -- Safety of intravenous and inhalation anesthetics -- Side effects of central analgesic drugs -- Safety pharmacology of antiinflammatory drugs -- Safety pharmacology of drugs with osteoarthritis-related activity -- Safety pharmacology of blood constituents -- Ocular toxicity tests -- Assays in endocrine safety pharmacology -- Safety assays in skin pharmacology -- Magnetic resonance imaging in pharmaceutical safety assessment -- Section II, Safety pharmacokinetics: -- Introduction -- Physicochemical properties -- In-silico ADME modeling -- Absorption-in vitro tests-cell based -- Absorption-in vitro tests-non cell based -- Distribution-in vitro tests-protein binding -- Perfused organs -- Metabolism studies in vitro and in vivo -- Distribution-across barriers -- Drug-drug interaction-enzyme induction -- Drug-drug interaction-enzyme inhibition -- Absorption -- In vivo distribution -- Distribution-in vivo-other methods -- Bioanalytical assays-Toxicokinetics -- Bioanalytical assays-liquid chromatography coupled to tandem spectrometry -- Bioanalytical assays-gas chromatography -- Bioanalytical assays-RIA/EIA -- Clinical studies-typical designs -- Pharmacogenomics in DME -- Typical PK/PD approaches -- Population kinetics in drug development -- Section III, Safety toxicology: -- Introduction -- International guidelines for the development of pharmaceutical compounds -- General toxicity -- In silico methods -- Alternative methods for carcinogenicity testing -- Genotoxicity -- Reproductive toxicology -- Application of toxicoproteomics in profiling drug effects.
  • Introduction to Drug-Drug Interactions -- Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion -- Mechanisms of Drug Interactions II: Transport Proteins -- Drug-Food Interactions -- Interactions Between Herbs and Antiinfective Medications -- Drug-Cytokine Interactions -- Beta-Lactam Antibiotics -- Macrolides, Azalides, and Ketolides -- Quinolones -- Glycopeptides, Lipopeptides, and Lipoglycopeptides -- Miscellaneous Antibiotics -- Drugs for Tuberculosis -- Drug Interactions with Antiretrovirals for HIV Infection -- Non-HIV Antiviral Agents -- Antifungal Agents -- Antimalarial Agents -- Antiprotozoal and Anthelmintic Agents -- Drug Interaction Considerations Throughout Drug Development -- Probe Cocktail Studies -- Design and Data Analysis in Drug Interaction Studies.
  • 1. Pharmacokinetics -- 2. Drug Metabolizing Enzymes -- 3. Oral Absorption -- 4. Transporters -- 5. Metabolism-Based Drug Interactions -- 6. Biotransformation and Bioactivation -- 7. Prediction of Human Pharmacokinetics -- 8. Advances in Bioanalysis as It Relates to ADME -- 9. ADME Properties and Their Dependence on Physicochemical Properties -- 10. In Silico ADME Tools -- 11. Approved Drugs -- 12. Chemical Nomenclature.
  • Renal cytochrome P450s and flavin-containing monooxygenases : potential roles in metabolism and toxicity of 1,3-butadiene, trichloroethylene, and tetrachloroethylene / Adnan A. Elfarra -- Experimental approaches for the study of cytochrome P450 gene regulation / Hollie I. Swanson ... [et al.] -- Insulin and growth factor signaling : effects on drug metabolizing enzymes / Sang K. Kim, Kimberly J. Woodcroft, and Raymond F. Novak -- Catalytic function and expression of glutathione transferase zeta / Philip G. Board, M.W. Anders, and Anneke C. Blackburn -- Glucuronidation of fatty acids and prostaglandins by human udp glucuronosyltransferases / Anna Radominska-Pandya, Joanne M. Little and Arthur Bull -- Transcriptional regulation of UDP-glucuronosyltransferases / Anna Radominska-Pandya, Peter I. Mackenzie, and Wen Xie -- Phenotypic and genotypic characterization of n-acetylation / Craig K. Svensson and David W. Hein -- Methods and approaches to study metabolism and toxicity of acetaminophen / Sam A. Bruschi -- Modulation of drug metabolism and antiviral therapies / Bernhard H. Lauterburg -- Modulation of thiols and other low-molecular-weight cofactors : effects on drug metabolism and disease susceptibility / Charles V. Smith -- Multidrug resistance proteins and hepatic transport of endo- and xenobiotics / Phillip M. Gerk and Mary Vore -- Structural determinants of folate and antifolate membrane transport by the reduced folate carrier / Wei Cao and Larry H. Matherly -- Glutathione transport in the kidneys : experimental models, mechanisms, and methods / Lawrence H. Lash -- Human cytosolic sulfotransferases : properties, physiological functions, and toxicology / Charles N. Falany.
  • This comprehensive volume discusses approaches for a systematic selection of delivery systems for various classes of therapeutic agents including small molecule, protein, and nucleic acid drugs. Specific topics covered in this book include: Solution, suspension, gel, nanoparticle, microparticle, and implant dosage forms; Refillable and microneedle devices; Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery; Physical methods including iontophoresis for drug delivery; Rational selection of routes of administration and delivery systems; Noninvasive and continuous drug monitoring; Clinical endpoints and regulatory path to drug product development; Emerging and existing drugs and drug targets.
  • Multidrug Resistance Mediated by MDR-ABC Transporters / Gergely Szakács ... [et al.] -- Metastasis and Drug Resistance / Dominic Fan ... [et al.] -- The Role of Autophagy and Apoptosis in the Drug Resistance of Cancer / Tomohisa Yokoyama ... [et al.] -- Mechanisms of Resistance to targeted Tyrosine Kinase Inhibitors / Stacey J.Baker, E. Premkumar Reddy -- Targeting Transglutaminase-2 to overcome Chemoresistance in Cancer Cells / Kapil Mehta, Jansina Y. Fok -- Extracellular Matrix-Mediated Drug Resistance / P.S. Hodkinson, Tariq Sethi -- Oxidative Stress and Drug Resistance in Cancer / Dunyaporn Trachootham, Wan Zhang, Peng Huang -- Nuclear Factor-kB and Chemoresistance / Ajaikumar B.Kunnumakkara, Preetha Anand, Bharat B. Aggarwal -- Drug Resistance and the Tumor Suppressor p53 : The Paradox of Wild-Type Genotype in Chemorefractory Cancers / Zahid H. Siddik -- Resistance to Differentiation Therapy / Bulent Ozpolat -- MicroRNAs and Drug Resistance / Elisa Barbarotto, George A. Calin -- Molecular Signatures of Drug Resistance / Melissa A. Troester, Jason I. Herschkowitz, Katherine A. Hoadley -- Assessment of Drug Resistance in Anticancer Therapy by Nuclear Imaging / Natalie Charnley, Catharine West, Pat Price -- Overcoming Drug Resistance by Phytochemicals / Marion M. Chan, Dunne Fong.
  • Developing Combination Drugs in Preclinical Studies / Alberto Lodola -- Preclinical Evaluation of Juvenile Toxicity / Paul C. Barrow, Stéphane Barbellion, Jeanne Stadler -- Necropsy and Sampling Procedures in Rodents / Laurence Fiette, Mohamed Slaoui -- Histopathology Procedures: From Tissue Sampling to Histopathological Evaluation / Mohamed Slaoui, Laurence Fiette -- Principles and Methods of Immunohistochemistry / José A. Ramos-Vara -- Tissue Microarrays and Digital Image Analysis / Denise Ryan, Laoighse Mulrane, Elton Rexhepaj, William M. Gallagher -- Micronucleus Assay and Labeling of Centromeres with FISH Technique / Ilse Decordier, Raluca Mateuca, Micheline Kirsch-Volders -- The Use of Bacterial Repair Endonucleases in the Comet Assay / Andrew R. Collins -- Manual Whole-Cell Patch-Clamping of the HERG Cardiac K+ Channel / Xiao-Liang Chen, Jiesheng Kang, David Rampe -- Generation and Analysis of Transcriptomics Data / Philip D. Glaves, Jonathan D. Tugwood -- Protocols of Two-Dimensional Difference Gel Electrophoresis to Investigate Mechanisms of Toxicity / Emmanuelle Com, Albrecht Gruhler, Martine Courcol, Jean-Charles Gautier -- Protocols and Applications of Cellular Metabolomics in Safety Studies Using Precision-Cut Tissue Slices and Carbon 13 NMR / Gabriel Baverel, Sophie Renault, Hassan Faiz, Maha Hage, Catherine Gauthier, Agnès Duplany, Bernard Ferrier, Guy Martin -- Statistical Analysis of Quantitative RT-PCR Results / Richard Khan-Malek, Ying Wang -- Evaluation of Mitochondrial Respiration in Cultured Rat Hepatocytes / Jean-Pierre Marchandeau, Gilles Labbe -- FETAX Assay for Evaluation of Developmental Toxicity / Isabelle Mouche, Laure Malesic, Olivier Gillardeaux -- Evaluation of Embryotoxicity Using the Zebrafish Model / Lisa Truong, Stacey L. Harper, Robert L. Tanguay -- Protocols of In Vitro Protein Covalent Binding Studies in Liver / Jean-François Lévesque, Stephen H. Day, Allen N. Jones -- Utilization of MALDI-TOF to Determine Chemical-Protein Adduct Formation In Vitro / Ashley A. Fisher, Matthew T. Labenski, Terrence J. Monks, Serrine S. Lau -- Utilization of LC-MS/MS Analyses to Identify Site-Specific Chemical Protein Adducts In Vitro / Ashley A. Fisher, Matthew T. Labenski, Terrence J. Monks, Serrine S. Lau / One-Dimensional Western Blotting Coupled to LC-MS/MS Analysis to Identify Chemical-Adducted Proteins in Rat Urine / Matthew T. Labenski, Ashley A. Fisher, Terrence J. Monks, Serrine S. Lau -- Identification of Chemical-Adducted Proteins in Urine by Multi-dimensional Protein Identification Technology (LC/LC-MS/MS) / Matthew T. Labenski, Ashley A. Fisher, Terrence J. Monks, Serrine S. Lau -- Optimization of SELDI for Biomarker Detection in Plasma / Jean-Francois Léonard, Martine Courcol, Jean-Charles Gautier -- Differential Proteomics Incorporating iTRAQ Labeling and Multi-dimensional Separations / Ben C. Collins, Thomas Y. Lau, Stephen R. Pennington, William M. Gallagher -- NMR and MS Methods for Metabonomics / Frank Dieterle, Björn Riefke, Götz Schlotterbeck, Alfred Ross, Hans Senn, Alexander Amberg -- Absolute Quantification of Toxicological Biomarkers by Multiple Reaction Monitoring / Thomas Y. Lau, Ben C. Collins, Peter Stone, Ning Tang, William M. Gallagher, Stephen R. Pennington.
  • Drug transporters 2011
    Uptake transporters of the human OATP family / Jörg König -- In vitro and in vivo evidence of the importance of organic anion -- transporters (OATs) in drug therapy / Gerhard Burckhardt and Birgitta Christina Burckhardt -- Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy / Anne T. Nies et al. -- Role of the intestinal bile acid transporters in bile acid and drug disposition / Paul A. Dawson -- The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation / Bruno Stieger -- P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations / Ingolf Cascorbi -- Importance of P-glycoprotein for drug-drug interactions / Hartmut Gläser -- Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy / Dietrich Keppler -- In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters(BCRP/MXR/ABCP/ABCG2) / Henriette E. Meyer zu Schwabedissen and Heyo K. Kroemer -- Molecular mechanisms of drug transporter regulation / Rommel G. Tirona -- In vivo probes of drug transport: commonly used probe drugs -- to assess function of intestinal P-glycoprotein (ABCB1) in humans / Stefan Oswald, Bernd Terhaag, and Werner Siegmund.
  • Print Material
    This book provides vital information about drug-DNA interactions. Understand the types of structural and bonding information that can be obtained using specific physico-chemical methods and discover how to design new drugs that are more effective than current treatments and have fewer side effects. Find detailed information about X-ray crystallography, NMR spectroscopy, molecular modeling, and optical spectroscopy such as UV-Visible absorption, fluorescence, circular dichroism (CD), flow linear dichroism (FLD), infrared (IR) and Raman spectroscopy.
  • I. Mechanisms of liver injury. Drug-induced liver injury / Neil Kaplowitz -- Cytochrome P450 activation of toxins and hepatotoxicity / F. Peter Guengerich -- Mechanistic role of acyl glucuronides / Howard Horng, Hilde Spahn-Langguth, and Leslie Z. Benet -- Oxidant stress, antioxidant defense, and liver injury / Mitchell R. McGill and Hartmut Jaeschke -- Hepatotoxicity due to mitochondrial injury / John J. Lemasters -- Mechanisms of cell death and relevance to drug toxicity / Lily Dara, Derick Han, and Neil Kaplowitz -- Role of membrane transport in hepatotoxicity and pathogenesis of drug-induced cholestasis / Bruno Stieger and Gerd A. Kullak-Ublick -- Liver sinusoidal endothelial cells and liver injury / Laurie D. Deleve -- Macrophages and kupffer cells in drug-induced liver injury / Mark Barnes ... [et al.] -- Role of inflammation in drug-induced liver injury / Robert A. Roth and Patricia E. Ganey -- Role of the adaptive immmune system in idiosyncratic drug-induced liver injury / Jack Uetrecht -- Role of tissue repair and death proteins in liver injury / Harihara M. Mehendale -- Genetic factors in the pathogenesis of drug-induced liver injury / Ann K. Daly and Christopher P. Day -- II. Diagnosis and management. Clinical manifestations and management of drug-induced liver diseases / Willis C. Maddrey -- Histopathological evaluationof drug-induced liver disease / David E. Kleiner -- Risk factors for drug-induced liver disease / Raj Vuppalanchi and Maga Chalasani -- Biomarkers for drug-induced liver injury / Paul B. Watkins -- Causality assessment / M. Isabel Lucena ... [et al.] -- III. Hepatotoxicity of specifid drugs. Mechanisms of acetaminophen-induced liver disease / Jack A. Hinson -- Acetaminophen / Laura P. James -- Mechanisms underlying the hepatotoxicity of nonsteroidal antiinflammatory drugs / Urs A. Boelsterli -- Nonsteroidal antiinflammatory drugs and leukotriene receptor antagonists / James H. Kewis and Jonathan G. Stine -- Mechanism, pathology, and clinical presentation of hepatotoxicity of anesthetic agents / J. Gerald Kenna -- Anticonvulsant agents / Munir Pirmohamed and J. Steven Leeder -- Hepatotoxicity of psychotropic drugs and drugs of abuse / Dominique Larrey and Marie-Pierre Ripault -- Hepatotoxicity of antimicrobials and antifungal agents / Richard H. Moseley -- Hepatotoxicity of antitubercular drugs / Sumita Verma and Neil Kaplowitz -- Hepatotoxicity of antiviral agents / Marina Núñez -- Hepatotoxicity of cardiovascular and antidiabetic drugs / Dina Halegoua-De Marzio and Victor J. Navarro -- Cancer chemotherpay / Laurie D. Deleve -- Hepatotoxicity of immunosuppressive drugs / Adrian Reuben -- Hepatotoxicity related to methotrexate / Guruprasad P. Aithal -- Adverse effects of hormones and hormone antagonists on the liver / Shivakumar Chitturi and Geoffrey C. Farrell -- Mushroom poisoning / François Durand and Dominique Valla -- Hepatotoxicity of herbals and dietary supplements / Leonard Seeff, Felix Stickel, and Victor J. Navarro -- Occupational and environmental hepatotoxicity / Keith G. Tolman and Anthony S. Dalpiaz -- Chronic liver disease from drugs / Einar S. Björnsson -- IV. Future directions. Regulatory perspectives / Mark I. Avigan -- Drug-induced liver injury research networks / Robert J. Fontana -- LiverTox / Jay H. Hoofnagle.
  • Male sexual health -- Structure and physiology of the testis -- Introduction -- The spermatozoa -- Sperm motility -- Capacitation and acrosome reaction -- Fertilization of the oocyte -- Testing substances that compromise spermatogenesis and fertility (adapted from Creasy 1997) -- Testosterone production and testosterone effects -- Physiology of erection -- Introduction -- Role of androgens in erection -- Priapism -- Physiology of ejaculation -- Drugs which compromise male sexual health -- Adverse drug effects -- Male sexual health and drugs -- Drugs which compromise testicular function -- Drugs which compromise erectile function -- Drugs which compromise ejaculation -- Database of drugs.
  • "Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting."
  • Pharmakokinetics -- Pharmacodynamics and signal transduction -- Toxicology -- Treatment of infectious diseases -- Cancer and immunopharmacology -- Autonomic nervous system -- Hematology -- Cardiovascular system -- Renal system -- Inflammatory disorders -- Gastrointestinal pharmacology -- Endocrine pharmacology -- Central nervous system.
  • 1. Introduction -- 2. Investigative Toxicology: The State of the Art -- 3. Screening Technologies I: Human Cell-Based Approaches -- 4. Screening Technologies II: Toxicogenomics -- 5. Screening Technologies III: Metabolomics -- 6. Screening Technologies IV: Pharmacogenetics -- 7. Qualifying Biomarkers -- 8. Pharmacovigilance -- 9. Integration -- 10. The Future of Safety Science.
  • Part 1. Overview of Non-Cannabinoid Receptors -- Overview of Nonclassical Cannabinoid Receptors / Grzegorz Godlewski and George Kunos -- Overview of Non-CB1/CB2 Cannabinoid Receptors: Chemistry and Modeling / Evangelia Kotsikorou and Patricia Reggio -- Part 2. G-Protein Coupled Receptors -- GPR55 in the CNS / Hui-Chen Lu, Jane E. Lauckner, John W. Huffman and Ken Mackie -- The Role of GPR55 in Bone Biology / Lauren S. Whyte and Ruth A. Ross -- The Role of GPR55 in Cancer / Clara Andradas, María M. Caffarel, Eduardo Pérez-Gómez, Manuel Guzmán and Cristina Sánchez -- GPR18 and NAGly Signaling: New Members of the Endocannabinoid Family or Distant Cousins? / Douglas McHugh and Heather B. Bradshaw -- Cannabinoid Signaling Through Non-CB1R/Non-CB2R Targets in Microglia / Neta Rimmerman, Ewa Kozela, Rivka Levy, Zvi Vogel and Ana Juknat -- Part 3. Ion Channels -- Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors / Vincenzo Di Marzo and Luciano De Petrocellis -- Nonpsychoactive Cannabinoid Action on 5-HT3 and Glycine Receptors / Li Zhang and Wei Xiong -- Part 4. Transcription Factors -- Peroxisome Proliferator-Activated Receptors and Inflammation / James Burston and David Kendall -- Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction / Paola Mascia, Gianluigi Tanda, Sevil Yasar, Stephen J. Heishman and Steven R. Goldberg -- Part 5. Conclusions/Therapeutic Potential -- Conclusions: Therapeutic Potential of Novel Cannabinoid Receptors / Mary E. Abood, Roger G. Sorensen and Nephi Stella.
  • DNA Methylation and Cancer -- Genome-Wide Epigenetic Modifications in Cancer -- DNA Repair and the Control of DNA Methylation -- Errors in Erasure: Links Between Histone Lysine Methylation Removal and Disease -- Histone Modifications in Cancer Biology and Prognosis -- Dynamics of Histone Lysine Methylation: Structures of Methyl Writers and Erasers -- Epigenetic Mechanisms of Mental Retardation -- Histone and DNA Modifications in Mental Retardation -- HDAC Inhibitors and Cancer Therapy -- Epigenetic Mechanisms in Acute Myeloid Leukemia -- The Liver-Specific MicroRNA miR-122: Biology and Therapeutic Potential -- Transcriptional Regulatory Networks in Embryonic Stem Cells -- Small Molecules in Cellular Reprogramming and Differentiation -- Index.
  • Anti-Inflammatory Plants -- Plants Affecting the Central Nervous System -- Plants for Chemotherapy of Neoplastic Diseases.
  • "There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher.
  • Print Material
    "This publication provides readers with a thorough understanding of enzyme-inhibitor evaluation to assist them in their efforts to discover and optimize novel drug therapies. Key topics such as competitive, noncompetitive, and uncompetitive inhibition, slow binding, tight binding, and the use of Hill coefficients to study reaction stoichiometry are all presented. Examples of key concepts are presented with an emphasis on clinical relevance and practical applications."--Jacket.
  • This volume presents recent developments in the novel drug development and potential of extremophilic cyanobacteria. It discusses how these tiny organism originated, produce oxygen that leads to evolution of life on the earth, how their survival strategies in extreme climatic conditions lead to diverse metabolic pathways, and the opportunity to use them to develop novel drugs. The book is comprised of five chapters, starting with the origin of cyanobacteria, their survival strategies under extreme conditions, and their capabilities to change metabolic activities.The second chapter explores the different metabolic pathways found in cyanobacteria and examines advances in this field and recent techniques like MALDI-TOF imaging and metagenomics tools as well as in silico techniques for rapid screening of secondary metabolites. Further chapters cover the glycomics of cyanobacteria, anticancer drug development, and some issues and challenges of using cyanobacteria to develop drugs. Extremophilic Cyanobacteria For Novel Drug Development provides insight into future perspectives in drug development and is a key resource for students, researchers and professionals in pharmacy, medicinal chemistry, pharmacognosy biotechnology, biology, and academics.
  • This comprehensive reference provides an in-depth discussion on state-of-the-art regulatory science in bioequivalence. In sixteen chapters, the volume explores a broad range of topics pertaining to bioequivalence, including its origin and principles, statistical considerations, food effect studies, conditions for waivers of bioequivalence studies, Biopharmaceutics Classification Systems, Biopharmaceutics Drug Disposition Classification System, bioequivalence modeling/simulation, and best practices in bioanalysis. It also discusses bioequivalence studies with pharmacodynamic and clinical endpoints as well as bioequivalence approaches for highly variable drugs, narrow therapeutic index drugs, liposomes, locally acting gastrointestinal drug products, topical products, and nasal and inhalation products. FDA Bioequivalence Standards is written by FDA regulatory scientists who develop regulatory policies and conduct regulatory assessment of bioequivalence. As such, both practical case studies and fundamental science are highlighted in these chapters. The book is a valuable resource for scientists who work in the pharmaceutical industry, regulatory agencies, and academia as well as undergraduate and graduate students looking to expand their knowledge about bioequivalence standards.
  • Fertility control 2010
    Part 1. Female Reproduction -- New Insights into Ovarian Function / JoAnne S. Richards and Stephanie A. Pangas -- Estrogen Signaling in the Regulation of Female Reproductive Functions / J. K. Findlay, S. H. Liew, E. R. Simpson and K. S. Korach -- Progesterone Receptors and Ovulation / Orla M. Conneely -- Contraception Targets in Mammalian Ovarian Development / Eileen A. McLaughlin and Alexander P. Sobinoff -- Proteomics of Embryonic Implantation / T. Garrido-Gómez, F. Dominguez and C. Simón -- Evaluation of Plasma Membrane Calcium/Calmodulin-Dependent ATPase Isoform 4 as a Potential Target for Fertility Contro / Elizabeth J. Cartwright and Ludwig Neyses -- Part 2. Male Reproduction -- New Insights into Sperm Physiology and Pathology / R. John Aitken, Mark A. Baker, Geoffry N. De Iuliis and Brett Nixon -- The Epididymis as a Target for Male Contraceptive Development / B. T. Hinton and T. G. Cooper -- Sperm-Zona Pellucida Interaction: Molecular Mechanisms and the Potential for Contraceptive Intervention / Matthew D. Dun, Lisa A. Mitchell, R. John Aitken and Brett Nixon -- Mouse Models as Tools in Fertility Research and Male-Based Contraceptive Development / Duangporn Jamsai and Moira K. O'Bryan -- Part 3. New options: From target to product -- Male Hormonal Contraception / E. Nieschlag -- Family Planning: Today and in the Future / Michael J. K. Harper.
  • Fighting Multidrug Resistance with Herbal Extracts, Essential Oils and their Components offers scientists a single source aimed at fighting specific multidrug-resistant (MDR) microorganisms such as bacteria, protozoans, viruses and fungi using natural products. This essential reference discusses herbal extracts and essential oils used or under investigation to treat MDR infections, as well as those containing antimicrobial activity that could be of potential interest in future studies against MDR microorganisms. The need to combat multidrug-resistant microorganisms is an urgent one and this book provides important coverage of mechanism of action, the advantages and disadvantages of using herbal extracts, essential oils and their components and more to aid researchers in effective antimicrobial drug discovery . Addresses the need to develop safe and effective approaches to coping with resistance to all classes of antimicrobial drugs . Provides readers with current evidence-based content aimed at using herbal extracts and essential oils in antimicrobial drug development . Includes chapters devoted to the activity of herbal products against herpes, AIDS, tuberculosis, drug-resistant cancer cells and more.
  • There are numerous excellent reviews on Fragment Based Drug Discovery (FBDD), but there are to date no hand-holding guides or protocols with which one can embark on this orthogonal approach to complement traditional high throughput screening methodologies. This Methods in Enzymology volume offers the tools, practical approaches, and hit-to-lead examples on how to conduct FBDD screens. The chapters in this volume cover methods that have proven to be successful in generating leads from fragments, including chapters on how to apply computational techniques, nuclear magnetic resonance, surface plasma resonance, thermal shift and binding assays, protein crystallography, and medicinal chemistry in FBDD. Also elaborated by experienced researchers in FBDD are sample preparations of fragments, proteins, and GPCR as well as examples of how to generate leads from hits. Offers the tools, practical approaches, and hit-to-lead examples on how to conduct FBDD screens. The chapters in this volume cover methods that have proven to be successful in generating leads from fragments, including chapters on how to apply computational techniques, nuclear magnetic resonance, surface plasma resonance, thermal shift and binding assays, protein crystallography, and medicinal chemistry in FBDD.
  • Over the past decade, significant progress has been made in the theory and applications of pharmacodynamics of antimicrobial agents. On the basis of pharmacokinetic-pharmacodynamic modeling concepts it has become possible to describe and predict the time course of antimicrobial effects under normal and pathophysiological conditions. The study of pharmacokinetic-pharmacodynamic relationships can be of considerable value in understanding drug action, defining optimal dosing regimens, and in making predictions under new or changing pre-clinical and clinical circumstances. Not surprisingly, pharmacokinetic-pharmacodynamic modeling concepts are increasingly applied in both basic and clinical research as well as in drug development. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics is designed as a reference on the application of pharmacokinetic-pharmacodynamic principles for the optimization of antimicrobial therapy, namely pharmacotherapy, and infectious diseases. The reader is introduced to various aspects of the fundamentals of antimicrobial pharmacodynamics, the integration of pharmacokinetics with pharmacodynamics for all major classes of antibiotics, from basic research to clinical situations.
  • Nanoscience and nanotechnology overview -- Liposome preparation and characterization -- Solid polymeric nanoparticles -- Lipid nanoparticles -- Polymeric vesicles -- Low molecular weight amphiphile micelles -- Polymeric micelles -- Niosomes -- Quantum dots -- Magnetic particles -- Drug nanoparticles -- Polymeric pro-drugs -- Therapeutic Applications of pharmaceutical nanosystems -- Drug solubilisation -- Gene therapy -- Chemotherapy -- Tissue engineering -- Anti-infectives -- Vaccination -- Anti-arthritic drugs -- Imaging agents -- Commercial exploitation of pharmaceutical nanosystems -- Future perspectives -- Multiple Choice -- Problem Sets -- Case Studies -- Suggested Reading.
  • "This book collects in-depth discussions from more than 30 noted specialists on topics such as quality control, experimental formulations, pharmaceutical ingredients, conventional and modified-release products, and bioequivalence. It considers key elements in the formulation of generic drug products including the availability of raw materials and chemical purity. It contains new chapters on experimental formulation development, and the relationship between the FDA and the United States Pharmacopeia"--Provided by publisher.
  • Print Material
    Generic drugs are now familiar objects in clinics, drugstores, and households around the world. We like to think of these tablets, capsules, patches, and ointments as interchangeable with their brand-name counterparts: why pay more for the same? And yet they are not quite the same. They differ in price, in place of origin, in color, shape, and size, in the dyes, binders, fillers, and coatings used, and in a host of other ways. Claims of generic equivalence, as physician-historian Jeremy Greene reveals, are never based on being identical to the original drug in all respects, but in being the same in all ways that matter. How do we know what parts of a pill really matter? Decisions about which differences are significant and which are trivial in the world of therapeutics are not resolved by simple chemical or biological assays alone. Questions of therapeutic similarity and difference are also always questions of pharmacology and physiology, of economics and politics, of morality and belief. Greene chronicles the social, political, and cultural history of generic drugs, narrating the evolution of the generic drug industry from a set of mid-twentieth-century "schlock houses" and "counterfeiters" into an agile and surprisingly powerful set of multinational corporations in the early twenty-first century. The substitution of bioequivalent generic drugs for more expensive brand-name products is a rare success story in a field of failed attempts to deliver equivalent value in health care for a lower price. Greene's history sheds light on the controversies shadowing the success of generics: problems with the generalizability of medical knowledge, the fragile role of science in public policy, and the increasing role of industry, marketing, and consumer logics in late-twentieth-century and early twenty-first century health care.
  • Genomic Biomarkers for Pharmaceutical Development: Advancing Personalized Health Care provides an in-depth review of the state of translational science across all stages of pharmaceutical development with a special focus on personalized health care. This book provides a complete picture of biomarker development and validation in a pharmaceutical setting while addressing the inherent challenges of targeting the appropriate indications, biomarker robustness, regulatory hurdles, commercialization and much more. It features case studies devoted to the applications of pharmacogenomics, toxicogenomics, and other genetic technologies as they support drug discovery and development. With chapters written by international authorities in industry and academia, this work is a truly unique presentation of the thoughts and approaches that lead to the development of personalized medicine. Intended for all those involved in clinical translational research, this book is the ideal resource for scientists searching for the applications, strategies and successful approaches of translational science in pharmaceutical development. Provides case studies in applications of pharmacodynamic and predictive markers in drug development in oncology, autoimmunity, respiratory diseases and infectious diseases. Shows how to identify potential new therapeutic targets in different diseases and provides examples of potential new disease indications for life cycle management of drugs. Authored by leading international experts from industry and academia.
  • The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a unique project that brings together the regulatory authorities of Europe, Japan and the US and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of product registration. In Japan, the members are the Ministry of Health, Labour and Welfare (MHLW), and the Japan Pharmaceutical Manufacturers Association (JPMA). In Europe, the members are the EU (Representatives of the European Commission and the European Medicines Agency [EMA]), and the European Federation of Pharmaceutical Industries and Associations (EFPIA). In the United States, the members are the Food and Drug Administration (FDA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) is the secretariat of the ICH. Additional members include Observers from WHO, European Free Trade Association (EFTA), and Canada. The Observers represent non-ICH countries and regions. This volume considers one of ICH's major categories, Safety, covering topics relating to in vitro and in vivo pre-clinical studies (Carcinogenicity Testing, Genotoxicity Testing, etc.). Since the start of the ICH process, many guidelines have been written, but in most cases there is a lack of awareness of the many issues that were addressed during the development of the consensus guidances. Further, just as it is important to understand what the guidances state, it is also important to understand the thoughts, debates, and intent of the experts involved, which are not included in the guidance documents. Why has the guideline been written as it is written, why are some topics ignored, and why have some initial guidance proposals have been deleted. These and other related questions and answers are the contents of this book, written by experts who were directly involved in writing the ICH guidances that drive drug development today.
  • Introduction / Terrence P. Tougas, Jolyon P. Mitchell -- Current Approaches to APSD Measurements of OIPs Based on Inertial Impaction / Jolyon P. Mitchell, Daryl L. Roberts -- Physical Causes of APSD Changes in Aerosols from OIPs and Their Impact on CI Measurements / Helen Strickland, Beth Morgan -- Good Cascade Impactor Practices / Jolyon P. Mitchell -- The AIM and EDA Concepts: Why They Are Needed and How They Fit Together / Jolyon P. Mitchell, Terrence P. Tougas -- Product Life Cycle Approach to Cascade Impaction Measurements / Richard Bauer, J. David Christopher -- Theoretical Basis for the EDA Concept / Terrence P. Tougas, Jolyon P. Mitchell -- Performance Characterization of EDA and Its Potential to Improve Decision Making in Product Batch Release / J. David Christopher, Helen Strickland -- Verification of the EDA Concept Through an Assessment of Theoretical Failure Modes, Failure Mode Analysis, and Case Studies with Real Data / Helen Strickland, Beth Morgan -- Validating AIM-Based Instrumentation and Associated Measurement Techniques / Mark Copley, Jolyon P. Mitchell -- The Regulatory and Compendial Pathways to Acceptance for AIM and EDA Concepts / Steven C. Nichols, Jolyon P. Mitchell -- Applying the AIM Concept in Support of Developing Improved In Vitro-In Vivo Relationships for OIPs / Jolyon P. Mitchell, Mark Copley -- Future Directions for the AIM and EDA Concepts / Terrence P. Tougas, Jolyon P. Mitchell -- Conclusions / Terrence P. Tougas, Svetlana A. Lyapustina.
  • Print Material
  • Drug invention and the pharmaceutical industry -- Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination -- Pharmacodynamics: molecular mechanisms of drug action -- Drug toxicity and poisoning -- Membrane transporters and drug response -- Drug metabolism -- Pharmacogenetics -- Neurotransmission: the autonomic and somatic motor nervous systems -- Muscarinic receptor agonists and antagonists -- Anticholinesterase agents -- Agents acting at the neuromuscular junction and autonomic ganglia -- Adrenergic agonists and antagonists -- 5-Hydroxytryptamine (serotonin) and dopamine -- Neurotransmission and the central nervous system -- Drug therapy of depression and anxiety disorders -- Pharmacotherapy of psychosis and mania -- Hyponotics and sedatives -- -- Opioids, analgesia, and pain management -- General anesthetics and therapeutic gases -- Local anesthetics -- Pharmacotherapy of the epilepsies -- Treatment of central nervous system degenerative disorders -- Ethanol and methanol -- Drug addiction -- Regulation of renal function and vascular volume -- Renin and angiotensin -- Treatment of myocardial ischemia and hypertension -- Pharmacotherapy of congestive heart failure -- Anti-arrhythmic drugs -- Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs -- Drug therapy for hypercholesterolemia and dyslipidemia -- Histamine, bradykinin, and their antagonists -- Lipid-derived autacoids: eicosanoids and platelet-activating factor -- Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout -- Immunosuppressants, tolerogens, and immunostimulants -- Pulmonary pharmacology -- Hematopoietic agents: growth factors, minerals, and vitamins -- Introduction to endocrinology: the hypothalamic-pituitary axis -- Thyroid and anti-thyroid drugs -- Estrogens and progestins -- Androgens -- ACTH, adrenal steroids, and pharmacology of the adrenal cortex -- Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia -- Agents affecting mineral ion homeostasis and bone turnover -- Pharmacotherapy of gastric acidity, peptic ulcers, and gastroesophageal reflux disease -- Treatment of disorders of bowel motility and water flux; anti-emetics; agents used in biliary and pancreatic disease -- Pharmacotherapy of inflammatory bowel disease -- General principles of antimicrobial therapy -- Chemotherapy of malaria -- Chemotherapy of protozoal infections: amebiasis, giardiasis, trichomoniasis, trypanosomiasis, leishmaniasis, and other protozoal infections -- Chemotherapy of helminth infections -- Sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections -- Penicillins, cephalosporins, and other β-lactam antibiotics -- Aminoglycosides -- Protein synthesis inhibitors and miscellaneous antibacterial agents -- Chemotherapy of tuberculosis, mycobacterium avium complex disease, and leprosy -- Antifungal agents -- Antiviral agents (nonretroviral) -- Antiretroviral agents and treatment of HIV infection -- General principles of cancer chemotherapy -- Cytotoxic agents -- Targeted therapies: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines -- Natural products in cancer chemotherapy: hormones and related agents -- Ocular pharmacology -- Dermatological pharmacology -- Contraception and pharmacotherapy of obstetrical and gynecological disorders -- Environmental toxicology; carcinogens and heavy metals -- Appendix I: Principles of prescription order writing and patient compliance -- Appendix II: Design and optimization of dosage regimens: pharmacokinetic data.
  • ER-bound steps in the biosynthesis of G protein-coupled receptors / Christian Nanoff and Michael Freissmuth -- Role of chaperones in G Protein coupled receptor signaling complex assembly / Denis J. Dupré, Maha M. Hammad, Patrick Holland and Jaime Wertman -- GPCR oligomerization: contribution to receptor biogenesis / Kathleen Van Craenenbroeck -- The functional size of GPCRs: monomers, dimers or tetramers? / Darlaine Pétrin and Terence E. Hébert -- Regulation of post-Golgi traffic of G protein-coupled receptors / Guangyu Wu -- Regulated GPCR trafficking to the plasma membrane: general issues and the CCR5 chemokine receptor example / Hamasseh Shirvani, Gabriel Gätà and Stefano Marullo -- Regulatory processes governing the cell surface expression of LH and FSH receptors / Deborah L. Segaloff -- Chaperone-mediated assembly of G protein complexes / Barry M. Willardson and Christopher M. Tracy -- Synthesis and assembly of G protein [beta][gamma] dimers: comparison of in vitro and in vivo studies / Jane Dingus and John D. Hildebrandt -- Preferential assembly of G-[alpha][beta][gamma] complexes directed by the [gamma] subunits / Janet D. Robishaw -- G Protein trafficking / Philip B. Wedegaertner -- Differential assembly of GPCR signaling complexes determines signaling specificity / Pascal Maurice, Abla Benleulmi-Chaachoua and Ralf Jockers -- GPCR and voltage-gated calcium channels (VGCC) signaling complexes / Christophe Altier -- Pharmacological chaperones correct misfolded GPCRs and rescue function: protein trafficking as a therapeutic target / Guadalupe Maya-Núñez, Alfredo Ulloa-Aguirre, Jo Ann Janovick and P. Michael Conn.
  • Introduction to therapeutic drug monitoring. -- Monitoring free drug concentration. -- Analytical techniques for measuring concentrations of therapeutic drugs in biological fluids. -- The pre-analytical phase of drug testing: from specimen collection to analysis. -- Effect of hemolysis, high bilirubin, lipemia, paraproteins, and system factors on therapeutic drug monitoring. -- Digoxin: so many interferences and how to eliminate them. -- Interferences with measurement of anticonvulsants. -- Pitfalls in measuring antidepressant drugs. -- Immunosuppressive drugs: pharmacokinetics, preanalytic variables, and analytical considerations. -- Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. -- Pharmacogenetics and personalized medicine: issues and methodology. -- Interference of heterophilic and other antibodies in measurement of therapeutic drugs by immunoassays. -- Drug-herb and drug-food interactions: impact on therapeutic drug monitoring. -- Toxic element testing with clinical specimens. -- Alcohol testing. -- Introduction to drugs of abuse testing. -- Urinary adulterants and drugs of abuse testing. -- Hair, oral fluid, sweat, and meconium testing for drugs of abuse: advantages and pitfalls. -- Abused and designer drugs and how they escape detection. -- Interpretation of amphetamines screening and confirmation testing. -- Clinical false-positive drug test results. -- Providing expert witness for alcohol and positive drugs of abuse test results.
  • Modern pharmaceutical analysis : an overview / S. Ahuja -- Combinatorial chemistry and high-throughput screening in drug discovery and development / Ken Appell, John J. Baldwin and William J. Egan -- Solid-state analysis / Harry G. Brittain -- Degradation and impurity analysis for pharmaceutical drug candidates / Karen M. Alsante, Robert C. Friedmann, Todd D. Hatajik, Linda L. Lohr, Thomas R. Sharp, Kimberly D. Snyder and Edward J. Szczesny -- Preformulation studies / Edward Lau -- Solid dosage-form analysis / Philip J. Palermo -- Parenteral dosage forms / Gregory A. Birrer, Satya S. Murthy, Jie Liu and Judy Estrada -- New drug delivery systems / David C. Pang -- Compendial testing / Christine F. Richardson -- Method development / Henrik T. Rasmussen -- Setting up specifications / Ian E. Davidson -- Validation of pharmaceutical test methods / Jonathan B. Crowther -- Stability studies / Jessica Cha, Joseph S. Ranweiler and Philip A. Lane -- Analytical methodology transfer / Stephen Scypinski -- Pharmaceutical analysis documentation / Hitesh Chokshi and Kathleen Schostack -- An innovative separation platform : electrophoretic microchip technology / Lian Ji Jin, Jerome Ferrance, Zhili Huang and James P. Landers.
  • Fulltext ScienceDirect
    Acute ischemic stroke / Christopher Bladin and Stephen Davis -- Subarachnoid hemorrhage / Nader Pouratian, Aaron S. Dumont, and Neal F. Kassell -- Spontaneous intracerebral hemorrhage / Michael D. Hill -- Traumatic brain injury / Wayne M. Alves and Lawrence F. Marshall -- Acute seizures and status epilepticus / Susan Herman -- Clinical trials in neuro-ophthalmology / Madhura Tamhankar and Laura Balcer -- Brain resuscitation / Edwin Nemoto and Charles C. King -- Clinical trials in brain injury after cardiac arrest / Romergryko G. Geocadin and Daniel F. Hanley -- Efficient dose-response finding strategies for acute neuroemergency treatments / Tom Parke ... [et al.] -- Biostatistical issues in neuroemergency clinical trials / Wayne M. Alves -- Data safety and monitoring board: role in acute neurological trials / Brett E. Skolnick -- Role of a project medical officer in acute neuroemergency clinical trials / Joseph A. Kwentus -- Ethical considerations in neuroemergency clinical trials / Wayne M. Alves -- Industry perspective on drug development / Thomas C. Wessel and Christopher Gallen -- Regulatory perspective / Lisa L. Travis.
  • Contributors -- Introduction for Clinicians to the Fourth Edition -- Selected Additional Reading for Health and Mental Health Professionals -- Published Resources for Parents and Teachers -- Information on the Internet -- Copyright, Citation, and Disclaimer -- Appendix 1: Medicines With FDA Indication for Attention-Deficit/Hyperactivity Disorder (ADHD) -- Appendix 2: Medicines Typically Used for Anxiety and Depression -- Appendix 3: Medicines Typically Used for Psychosis -- Appendix 4: Medicines Typically Used for Mood Stabilization or Reducing Aggression Drugs by Generic and Brand Names: Alprazolam (Xanax) -- Amitriptyline -- Amphetamine (Dexedrine, ProCentra, Zenzedi, Adderall, Vyvanse) -- Aripiprazole (Abilify) --Asenapine (Saphris) -- Atenolol (Tenormin) -- Atomoxetine (Strattera) -- Benzodiazepines Used for Sleep: Estazolam (ProSom), Flurazepam, Temazepam (Restoril), Triazolam (Halcion) -- Benztropine (Cogentin) -- Bupropion (Wellbutrin, Aplenzin, Forfivo) -- Buspirone -- Carbamazepine (Tegretol, Carbatrol, Epitol, Equetro, Tegretol XR) -- Chlorpromazine -- Citalopram (Celexa) -- Clomipramine (Anafranil) -- Clonazepam (Klonopin) -- Clonidine (Catapres, Catapres-TTS, Kapvay) -- Clozapine (Clozaril, FazaClo, Versacloz) -- Cyproheptadine -- Desipramine (Norpramin) -- Desmopressin Acetate (DDAVP, Stimate) -- Diazepam (Valium) -- Diphenhydramine (Benadryl) -- Duloxetine (Cymbalta) -- Escitalopram (Lexapro) -- Fluoxetine (Prozac, Symbyax) -- Fluphenazine -- Fluvoxamine (Luvox CR) -- Gabapentin (Neurontin, Gralise, Gralise Starter) -- Guanfacine (Tenex, Intuniv) -- Haloperidol (Haldol) -- Hydroxyzine (Vistaril) -- Hypnotics-Sleep Medications (Nonbenzodiazepines): Eszopiclone (Lunesta), Zaleplon (Sonata), Zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist) -- Iloperidone (Fanapt) -- Imipramine (Tofranil) -- Lamotrigine (Lamictal, Lamictal XR) -- Levomilnacipran (Fetzima) -- Lithium (Lithobid) -- L-methylfolate (Deplin) -- Lorazepam (Ativan) -- Loxapine (Loxitane, Adasuve) -- Lurasidone (Latuda) -- Melatonin -- Metformin (Glucophage, Glucophage XR, Fortamet, Glumetza, Riomet) -- Methylphenidate (Methylin, Ritalin, Metadate, Concerta, Daytrana, Quillivant, Focalin) -- Mirtazapine (Remeron) -- Modafinil (Provigil), Armodafinil (Nuvigil) -- N-acetylcysteine -- Nortriptyline (Pamelor) -- Olanzapine (Zyprexa, Symbyax) -- Omega-3 Fatty Acids (Epanova, Lovaza) -- Oxcarbazepine (Trileptal, Oxtellar XR) -- Paliperidone (Invega) -- Paroxetine (Paxil, Pexeva, Brisdelle, Paxil CR) -- Perphenazine -- Pimozide (Orap) -- Pindolol -- Prazosin (Minipress) -- Propranolol (Inderal) -- Quetiapine (Seroquel) -- Ramelteon (Rozerem) -- Risperidone (Risperdal) -- Sertraline (Zoloft) -- Thiothixene -- Topiramate (Topamax, Topiragen, Trokendi XR, Qudexy SR) -- Trazodone (Oleptro) -- Trifluoperazine -- Valproic Acid (Depakene, Stavzor), Divalproex (Depakote, Depakote ER, Depakote Sprinkles) -- Venlafaxine (Effexor), Desvenlafaxine (Pristiq, Khedezla) -- Vilazodone (Viibryd) -- Vortioxetine (Brintellix) -- Ziprasidone (Geodon).
  • Preface -- Contributors -- ch 1. Ma huang and the ephedra alkaloids / Steven B. Karch -- ch. 2. Kava / Douglas D. Glover -- ch. 3. Ginkgo biloba / Timothy S. Tracy -- ch. 4. Valerian / Brian J. Isetts -- ch. 5. St. John's wort / Dean Filandrinos, Thomas R. Yentsch, and Katie L. Meyers -- ch. 6. Echinacea / Daniel Berkner and Leo Sioris -- ch. 7. Feverfew / Richard L. Kingston -- ch. 8. Garlic / Leslie Helou and Ila M. Harris -- ch. 9. Ginger / Douglas D. Glover -- ch. 10. Saw palmetto / Timothy S. Tracy -- ch. 11. Panax ginseng / Timothy S. Tracy -- ch. 12. Cranberry / Timothy S. Tracy -- ch. 13. Hawthorn / Timothy S. Tracy -- ch. 14. Evening primrose / Margaret B. Artz -- ch. 15. Citrus aurantium / Anders Westanmo -- ch. 16. Vitex agnus-castus / Margaret B. Artz -- ch. 17. Billberry / Timothy S. Tracy -- Index.
  • This site features fact sheets on herbs and medicinal plants outlining where each herb is found, what it is used for, how it is used, and any safety concerns and possible drug interaction issues. Also includes publications, presentations, and educational materials on herbs. Searchable. Also available in Spanish. From the University of Texas (UT) at El Paso and UT Austin Cooperative Pharmacy Program.
  • The Good, the bad, and the ugly : a story of two medications -- An Ethical framework -- The Pharmaceutical industry and the free market -- Patents, generic drugs, and academic science -- Research and profits -- Suppression of research data -- The Quality of pharmaceutical research -- The Drug rep: historical background -- The Drug rep today -- The Influence of drug reps: what the data show -- Continuing medical education -- Professional organizations and journal advertising -- The Industry and the consumer -- The FDA: from patent medicines to AIDS drugs -- The FDA and the industry, 1990-2004 -- Solutions: the management and divestment strategies -- Solutions requiring enhanced professionalism in medicine -- Solutions requiring regulatory reform.
  • The metabolism of sulfur especially by sulfurtransferases had been intensively studied in mid 1900s. Three enzymes, cystathionine synthase (CBS), cystathionine lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3MST) were found to have the capacity to produce H2S in vitro. However, H2S was recognized simply as a by-product of the metabolic pathways or as a marker for evaluating the activity of enzymes rather than as a physiological active molecule. In the late 1980s relatively high concentrations of sulfide were measured in the brain that led to the successive studies of identifying the physiological functions of H2S. Recently, the steady-state concentrations of H2S have been re-evaluated and found to be much less than that initially measured. However, despite these differences, such re-evaluations served to further confirm the existence of H2S in mammalian tissues. H2S is produced in almost every organ and plays various roles such as neuromodulation, vasodilation, insulin release, inflammation, angiogenesis and cytoprotection. The unregulated production of H2S and improper responses of target molecules are involved in the pathogenesis of various diseases. This book focuses on these topics as well as on the recent progress in the biology and the therapeutic development of this molecule.
  • Ibuprofen is one of the most successful drugs used worldwide for the treatment of mild to moderate pain and various inflammatory conditions, even in a low-dose form for over-the-counter (OTC), non-prescription sale. Over the past 40 years, ibuprofen has been proven to be as safe or safer and just as effective as established non-steroidal anti-inflammatory drugs (NSAIDs) or coxibs. This book reviews the pharmacology, clinical uses and adverse effects of ibuprofen. Its disposition and unique modes of action in relation to clinical effects are discussed as well as various formulations and the impact of food and other variables on its actions and gastro-intestinal safety. The use of combinations of ibuprofen with other drugs (e.g. paracetamol, codeine and caffeine) are critically assessed. There are already some indications of potential therapeutic benefits of the drug combinations in treating certain painful conditions, while still retaining the relative safety benefits of ibuprofen (at least at OTC dosages). The impact of natural products and Chinese Medicines on the safety of ibuprofen is also reviewed. The book is written in a more general style, including explanatory diagrams, for anyone interested in the properties, actions and uses of ibuprofen.
  • Immunopharmacology 2008
  • Pattern matching / Scott Markel and Vinodh N. Rajapakse -- Tools for computational protein annotation and function assignment / Jaume M. Canaves -- The impact of genetic variation on drug discovery and development / Michael R. Barnes -- Mining of gene expression data / Aedin Culhane and Alvis Brazma -- Text mining / Bruce Gomes, William Hayes, and Raf Podowski -- Pathways and networks / Eric Minch and Ivayla Vatcheva -- Molecular interactions: learning from protein complexes / Ana Rojas, David de Juan, and Alfonso Valencia -- In silico siRNA design / Darryl León -- Predicting protein subcellular localization using intelligent systems / Rajesh Nair and Burkhard Rost -- Three-dimensional structures in target discovery and validation / Seán I. O'Donoghue, Robert B. Russell, and Andrea Schafferhans -- Comparative genomics / Viviane Siino, Bruce Pascal, and Christopher Sears -- Pharmacogenomics / Bahram Ghaffarzadeh Kermani -- Target identification and validation using human simulation models / Seth Michelson, Didier Scherrer, and Alex L. Bangs -- Using protein targets for in silico structure-based drug discovery / Tad Hurst -- Database management / Arek Kasprzyk and Damian Smedley -- BioIT hardware configuration / Philip Miller -- BioIT architecture: software architecture for bioinformatics research / Michael Dickson -- Workflows and data pipelines / Michael Peeler -- Ontologies / Robin A. McEntire and Robert Stevens.
  • Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled 2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
  • ch. 1. Introduction to Functional Biotechnology, p. 1-72 -- ch. 2. Organizational Structures, p. 73-76 -- ch. 3. Markets and Factors, p. 77-78 -- ch. 4. Biotechnology and Medicine, p. 79-116 -- ch. 5. Drug Discovery, p. 117-144 -- ch. 6. Molecular Pharma-Biotechnology, p. 145-194 -- ch. 7. Research and Development, p. 195-200 -- ch. 8. Pharmaceutical Production, p. 201-238 -- ch. 9. Safety, p. 239-240 -- ch. 10. Environment, p. 241-243 -- ch. 11. Ethics, p. 245-246 -- ch. 12. Companies, Institutes, Networks, and Organizations, p. 247-261.
  • Epidemiology of IGF-1 and cancer / Katharina Nimptsch and Eward Giovannucci -- Aging and cancer : the IGF- I connection / Kalina Biernacka, Claire Perks, and Jeff Holly -- Obesity, type 2 diabetes and cancer / Rosalyn D. Ferguson and Derek LeRoith -- IGF system and breast cancer / Marc A. Becker and Douglas Yee -- The role of insulin-like growth factor signaling in prostate cancer development and progression / Bruce Montgomery, James Dean, and Stephen Plymate -- IGF-1 cellular action and its relationship to cancer : evidence from in vitro and in vivo studies / Rosalyn D. Ferguson ... [et al.] -- Insulin-like growth factor signaling in pediatric sarcomas / Xiaolin Wan, Su Young Kim, and Lee J. Helman -- Cancer genes, tumor suppressors, and regulation of IGF1-R gene expression in cancer / Haim Werner ... [et al.] -- Mouse models of IGF-1R and cancer / Craig I. Campbell, James J. Petrik, and Roger A. Moorehead -- Targeting the insulin-like growth factor-I receptor in cancer therapy / David R. Clemmons -- Targeting insulin-like growth factor receptor 1 (IGF-1R) and insulin receptor signaling by tyrosine kinase inhibitors in cancer / Joan M. Carboni, Mark Wittman, and Fei Huang -- Calories and cancer : the role of insulin-like growth factor-1 / Stephen D. Hursting ... [et al.] -- Cancer cell metabolism / Akash Patnaik, Jason W. Locasale, and Lewis C. Cantley -- Overlaps between the insulin and IGF-I receptor and cancer / Antonino Belfiore and Roberta Malaguarnera.
  • Antifungal agents -- Antifungal susceptibility testing: Clinical Laboratory and Standards Institute (CLSI) methods -- Antifungal susceptibility testing methods: non-CLSI methods for yeast and moulds -- Susceptibility testing of dermatophytes -- Usual susceptibility patterns of common yeasts -- Usual susceptibility patterns of common moulds and systemic fungi -- Usual susceptibility patterns for systemic dimorphic fungi -- Utility of antifungal susceptibility testing and clinical correlations.
  • Interferon methods and protocols 2005
    Springer Protocols
  • This book provides a readable introduction to modern toxicology with a particular focus on the mechanisms underlying the induction of toxicity by foreign substances. Since bioactivation is central to many toxic syndromes, special interest is devoted to chemicals that undergo conversion to toxic metabolites that induce toxic effects as diverse as cancer, birth defects and organ injury. The molecular consequences accompanying damage to cellular DNA and proteins is explored together with the relevance of toxicological paradigms to human diseases caused by alcohol and tobacco. The discipline of toxicology has developed rapidly since the thalidomide disaster in the 1960?s as scientists worldwide seek to understand the adverse health effects of human medicines, environmental pollutants, consumer chemicals and industrial reagents. An Introduction to Toxicology is intended to supplement the recommended reading list of undergraduate and graduate programs in toxicology and pharmacology as an enjoyable, accessible primer with illustrations that "unpack" the concepts being discussed in the text.
  • "This book bridges the gap between advances in basic biology and chemistry and technological applications in the field of toxicity assessments. 10 chapters describe major areas of progress in the laboratory and clinic. In the first section, the aspects of cellular organelles are discussed. In the second, the basic principles and applications of modern toxicological tools such as transcriptomic, proteomic, and metabolomic approaches are covered. In the third section, the recent developments on molecular modeling and systems biology are described with an eye on the future establishment of virtual cell technology. Finally the clinical implications for the understanding of acute and chronic renal toxicity are studied"--Provided by publisher.
  • Reverse pharmacognosy : a new concept for accelerating natural drug discovery / Quoc-Tuan Do and Philippe Bernard -- Effects of plant extracts on gene expression profiling : from macroarrays to microarray technology / Carlo Mischiati, Alessia Sereni, Mahmud Tareq Hassan Khan, Ilaria Lampronti and Roberto Gambari -- Effects of medicinal plant extracts on molecular interactions between DNA and transcription factors / Ilaria Lampronti, Mahmud Tareq Hassan Khan, Nicoletta Bianchi, Giordana Feriotto, Carlo Mischiati, Monica Borgatti and Roberto Gambari -- Plants with antitumor properties : from biologically active molecules to drugs / Ilaria Lampronti, Mahmud Tareq Hassan Khan, Nicoletta Bianchi, Elisabetta Lambertini, Roberta Piva, Monica Borgatti and Roberto Gambari -- Herbal extracts and compounds active against herpes simplex virus / Kenneth D. Thompson -- Pharmacological modulation of cough reflex / Gabriela Nosalova, Juraj Mokry and Sona Franova -- Phytotherapy of cough / Sona Franova, Gabriela Nosalova and Juraj Mokry -- The medicinal potential of black seed (Nigella sativa) and its components / Hala Gali-Muhtasib, Nahed El-Najjar and Regine Schneider-Stock -- Cyclin-dependent kinase inhibitors from natural sources : recent advances and future prospects for cancer treatment / Hala Gali-Muhtasib -- Anticancer and medicinal properties of essential oil and extracts of East Mediterranean sage (salvia triloba) / Hala Gali-Muhtasib -- Marine organisms from Brazil as source of potential anticancer agents / Letícia Veras Costa-Lotufo, Cláudia Pessoa, Maria Elisabete A. Moraes, Adaíla Marta Paixão Almeida, Manoel Odorico de Moraes and Tito Monteiro da Cruz Lotufo -- Anticancer potential of Northeast Brazilian plants / Cláudia Pessoa, Letícia Veras Costa-Lotufo, Albert Leyva, Maria Elisabete Amaral de Moraes and Manoel Odorico de Moraes -- Safety and efficacy of phytomedicines / Manoel Odorico de Moraes, Fernando Antônio Frota Bezerra, Letícia Veras Costa-Lotufo, Cláudia Pessoa and Maria Elisabete Amaral de Moraes -- Pharmacological and biochemical profiling of lead compounds from traditional remedies : the case of Croton cajucara / Maria Aparecida M. Maciel, Tereza Neuma C. Dantas, Janaína Keila P. Câmara, Angelo C. Pinto, Valdir F. Veiga Jr., Carlos R. Kaiser, Nuno A. Pereira, Cristina M.T.S. Carneiro, Frederico A. Vanderlinde, Antônio J. Lapa, Aniele R. Agner, Ilce M.S. Cólus, Juliana Echevarria-Lima, Noema F. Grynberg, Andressa Esteves-Souza, Kenia Pissinate and Aurea Echevarria -- Antihypertensive peptides from natural resources / Toshiro Matsui and Kiyoshi Matsumoto -- Xanthones as therapeutic agents : chemistry and pharmacology / Noungoue Tchamo Diderot, Ngouela Silvere and Tsamo Etienne -- Inhibition of immunodeficiency type-1 virus (HIV-1) life cycle by medicinal plant extracts and plant-derived compounds / Roberto Gambari and Ilaria Lampronti -- Anticancer properties of saffron, Crocus sativus Linn. / José-Antonio Fernández -- Lead compounds and drug candidates from some Turkish plants for human health / İlkay Orhan and Bilge Şener -- Molecular design of multifunctional anti-Salmonella agents based on natural products / Isao Kubo, Ken-ichi Fujita, Ken-ichi Nihei and Aya Kubo -- Plant growth inhibitory activities by secondary metabolites isolated from Latin American flora / Carlos L Céspedes, Juan C Marín, Mariana Domínguez, J Guillermo Avila and Blanca Serrato -- Metabolomics : systematic studies of the metabolic profiling / Mahmud Tareq Hassan Khan and Arjumand Ather.
  • 1. Chemical and genetic diversity of Wolfberry -- 2. Immunoregulation and Lycium Barbarum -- 3. The antioxidant, anti-inflammatory, and antiapoptotic effects of Wolfberry in fatty liver disease -- 4. Effectts of Lycium barbarum on modulation of blood vessel and hemodynamics -- 5. Dermatologic uses and effects of Lycium barbarum -- 6. Lycium Barbarum and tumors in the gastrointestinal tract -- 7. Prevention of neurodegeneration for Alzheimer's disease by Lycium barbarum -- 8. Prosexual effects of Lycium Barbarum -- 9. Lycium Barbarum: neuroprotective effects in ischemic stroke -- 10. Secondary degeneration after partial optic nerve injury and possible neuroprotective effects of Lycium Barbarum (Wolfberry) -- 11. Role of Lycium Barbarum extracts in retinal diseases -- 12. Allergenic sensitisation mediated by Wolfberry.
  • Part 1. Classification, Opportunities and Challenges -- Classification of Anticancer Drugs Based on Therapeutic Targets -- Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy -- Part 2. Polymer-Based Anticancer Prodrugs -- HPMA-Anticancer Drug Conjugates -- Poly-l-Glutamic Acid Anti-cancer Drug Conjugates -- Polysaccharide-Based Anticancer Prodrugs -- PEG-Anticancer Drugs -- Poly(ethylene glycol)-Protein, Peptide, and Enzyme Conjugates -- Part 3. Lipid-Based -- Anticancer Prodrugs -- Lipid-Based Anticancer Prodrugs -- Part 4. Antibody-Directed Cancer Therapy -- Antibody-Cytotoxic Compound Conjugates for Oncology -- Immunoconjugate Anticancer Therapeutics -- Antibody-Directed Enzyme Prodrug Therapy (ADEPT) for Cancer -- EGFR-Directed Monoclonal Antibodies -- The Biology of the HER Family and Her2/neu Directed-Antibody Therapy -- Anti-Vascular Endothelial Growth Factor Monoclonal Antibodies -- Monoclonal Antibody Therapy for Hematologic Malignancies -- Part 5. Anticancer Oligonucleotide Therapeutics -- Anticancer Oligonucleotides -- Part 6. Miscellaneous -- New Molecular Therapeutic Interventions: The Case of Breast Cancers.
  • v. 2 Springer
    v. 1. TRPs: truly remarkable proteins -- The TRCP subfamily -- TRPC1 -- TRPC2 -- TRPC3: a multifunctional signaling molecule -- TRPC4 and TRPC4-containing channels -- TRPC5 -- TRPC6: physiological function and pathophysiological relevance -- Transient receptor potential canonical 7 (TRPC7) -- The TRPV subfamily -- TRPV1 -- TRPV2 -- TRPV3 -- The TRPV4 channel -- TRPV5, a Ca2+ channel for the fine tuning of Ca2+ reabsorption -- TRPV6 channels -- The TRPM subfamily -- TRPM1 -- TRPM2 -- TRPM3 -- TRPM4 -- TRPM5 -- TRPM6 -- TRPM7 -- TRPM8 -- The TRPA1, TRPML and TRPP subfamily -- TRPA1 -- TRPML1: an ion channel in the lysosome -- TRPML2 and mucolipin evolution -- TRPML3 -- TRPP subfamily and polycystin-1 proteins -- v. 2. TRPs as special cell sensors -- Temperature sensing with TRPs -- TRPs in mechano-sensing and volume regulation -- TRPs as chemosensors (ROS, RNS, RCS, gasotransmitters) -- Photosensitive TRPs -- TRPs in taste and chemesthesis -- TRPs and Pain -- TRPs in hearing -- TRPs in olfaction -- General topics -- Evolutionary conserved, multitasking TRP channels-lessons from worms and flies -- Structural biology of TRP channels -- High-resolution views of TRPV1 and their implications for the TRP channel superfamily -- Physiological functions and regulation of TRPC channels -- The TRPCs-STIM1-orai interaction -- The TRPC family of TRP channels: roles inferred (mostly) from knockout mice and relationship to ORAI proteins -- TRPs: modulation by drug-like compounds -- TRP channels in reproductive (neuro)endocrinology -- Modulation of TRP ion channels by venomous toxins -- Phosphoinositide regulation of TRP channels -- TRP modulation by natural compounds -- What do we really know and what do we need to know: some controversies, perspectives, and surprises.
  • Cannabis and natural cannabis medicines / Robert C. Clarke and David P. Watson -- Chemistry and analysis of phytocannabinoids and other cannabis constituents / Rudolf Brenneisen -- Chemical fingerprinting of cannabis as a means of source identification / Mahmoud A. ElSohly, Donald F. Stanford, and Timothy P. Murphy -- Marijuana smoke condensate: chemistry and pharmacology / Hala N. ElSohly and Mahmoud A. ElSohly -- Pharmacology of cannabinoids / Lionel P. Raymon and H. Chip Walls -- The endocannabinoid system and the therapeutic potential of cannabinoids / Billy R. Martin -- Immunoassays for the detection of cannabis abuse: technologies, development strategies, and multilevel applications / Jane S-C. Tsai -- Mass spectrometric methods for determination of cannabinoid physiological specimens / Rodger L. Foltz -- Human cannabinoid pharmacokinetics and interpretation of cannabinoid concentrations in biological fluids and tissues / Marilyn A. Huestis and Michael L. Smith -- Medical and health consequences of marijuana / Jag H. Khalsa -- Effects of marijuana on the lung and immune defenses / Donald P. Tashkin and Michael D. Roth -- Marijuana and driving impairment / Barry K. Logan -- Postmortem considerations / Steven B. Karch -- Cannabinoid effects on biopsychological, neuropsychiatric and neurological processes / Richard E. Musty.
  • Insulin and IGF-I receptor structure and binding mechanism / Pierre de Meyts ... [et al.] -- Subcellular compartmentalization of insulin signaling processes and GLUT4 trafficking events / Robert T. Watson ... [et al.] -- Regulation of insulin action and insulin secretion by snare-mediated vesicle exocytosis / Debbie C. Thurmond -- Control of protein synthesis by insulin / Joseph F. Christian and John C. Lawrence -- Hepatic regulation of fuel metabolism / Catherine Clark and Christopher B. Newgard -- Insulin action gene regulation / Calum D. Sutherland, Richard M. O'Brien, and Daryl K. Granner -- Insulin action in the islet B-cell / Rohit N. KulkarnI -- Central regulation of insulin sensitivity / Silvana Obici and Luciano Rossetti -- Transgenic models of impaired insulin signaling / Francesco Oriente and Domenico Accili -- Insulin resistance / C. Hamish Courtney and Jerrold M. Olefsky.
  • Principles of pharmacology and mechanisms of drug action -- Principles of pharmacology and mechanisms of drug action -- Drug discovery, safety and efficacy -- Neurotransmission and the peripheral autonomic nervous system -- Ischaemic heart disease -- Systemic and pulmonary hypertension -- Heart failure -- Cardiac arrhythmias -- Cerebrovascular disease and dementia -- Peripheral vascular disease -- Haemostasis -- Asthma and chronic obstructive pulmonary disease -- Respiratory disorders : cough, respiratory stimulants, cystic fibrosis and neonatal respiratory distress syndrome -- Diuretics -- Disorders of micturition -- Erectile dysfunction -- General anaesthetics -- Local anaesthetics -- Opioid analgesics and the management of pain -- Anxiolytics, sedatives and hypnotics -- The major psychotic disorders : schizophrenia and mania -- Depression, attention deficit hyperactivity disorder and narcolepsy -- Epilepsy -- Extrapyramidal movement disorders and spasticity -- Other neurological disorders : multiple sclerosis, motor neuron disease and Guillain - Barre syndrome -- Migraine and other headaches -- The neuromuscular junction and neuromuscular blockade -- Myasthenia gravis -- Non-steroidal anti-inflammatory drugs -- Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis -- Hyperuricaemia and gout -- Nausea and vomiting -- Dyspepsia and peptic ulcer disease -- Inflammatory bowel disease -- Constipation, diarrhoea and irritable bowel syndrome -- Liver disease -- Obesity -- The immune response and immunosuppressant drugs -- Antihistamines and allergic disease -- Diabetes mellitus -- The thyroid and control of metabolic rate -- Calcium metabolism and metabolic bone disease -- Pituitary and hypothalamic hormones -- Corticosteroids (glucocorticoids and mineralocorticoids) -- Female reproduction -- Androgens, anti-androgens and anabolic steroids -- Anaemia and haematopoietic colony-stimulating factors -- Lipid disorders -- Skin disorders -- The eye -- Chemotherapy of infections -- Chemotherapy of malignancy -- Drug toxicity and overdose -- Substance abuse and dependence -- Prescribing, adherence and information about medicines -- Drug therapy in special situations.
  • Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs. This textbook provides detailed, up-to-date information on all aspects of medication-related osteonecrosis of the jaws, including clinical features, pathogenesis, treatment options, and preventive measures. It also explains safe prevention and treatment strategies for patients receiving antiresorptive drugs who require extractions, implant insertions, and other dento-alveolar surgeries. This book will be of major interest for medical and dental students, dentists, and oral and maxillofacial surgeons as well as osteologists and oncologists.
  • A unified and single-source reference book providing significant data on a wide spectrum of medicinal herbs practiced worldwide and their chemical ingredients. 350 plants are dealt with in detail dovetailing their distinguishing botanical characters, chemical components and biomarkers of all the useful parts, authentic medicinal properties and the pharmacological actions they elicit. Constituent compounds have been grouped according to their natural product classification. This book is intended to oncompass an in-depth coverage of the chemistry of "Plant Products" such as alkaloids, terponoids, phenolics, etc. Emerging trends like aromatherapy and antioxidant therapy are discussed and a user's guide is appended at the end.--excerpted from book jacket.
  • Medicinal plants classified in the family Annonaceae -- Medicinal plants classified in the family Myristicaceae -- Medicinal plants classified in the family Lauraceae -- Medicinal plants classified in the family Piperaceae -- Medicinal plants classified in the family Aristolochiaceae -- Medicinal plants classified in the family Nympheaceae -- Medicinal plants classified in the family Menispermaceae -- Medicinal plants classified in the family Polygonaceae -- Medicinal plants classified in the family Myrsinaceae -- Medicinal plants classified in the family Ebenaceae -- Medicinal plants classified in the family Bombacaceae -- Medicinal plants classified in the family Elaeocarpaceae -- Medicinal plants classified in the family Capparaceae -- Medicinal plants classified in the family Flacourtiaceae -- Medicinal plants classified in the family Passifloraceae -- Medicinal plants classified in the family Cucurbitaceae -- Medicinal plants classified in the family Connaraceae -- Medicinal plants classified in the family Anisophylleaceae -- Medicinal plants classified in the family Rosaceae -- Medicinal plants classified in the family Thymeleaceae -- Medicinal plants classified in the family Melastomataceae -- Medicinal plants classified in the family Rhizophoraceae -- Medicinal plants classified in the family Olacaceae -- Medicinal plants classified in the family Icacinaceae -- Medicinal plants classified in the family Euphorbiaceae -- Medicinal plants classified in the family Sapindaceae -- Medicinal plants classified in the family Anacardiaceae -- Medicinal plants classified in the family Simaroubaceae -- Medicinal plants classified in the family Meliaceae -- Medicinal plants classified in the family Rutaceae -- Medicinal plants classified in the family Loganiaceae -- Medicinal plants classified in the family Gentianaceae -- Medicinal plants classified in the family Apocynaceae -- Medicinal plants classified in the family Asclepiadaceae -- Medicinal plants classified in the family Solanaceae -- Medicinal plants classified in the family Verbenaceae.
  • New strategies for traditional medicine -- Developing better herbal medicines in the post-genomic era -- Revitalization of the knowledge of herbs: a way forward to discovery of new drugs -- Ethnobotanical uses of the native flora from Brazilian north-eastern region -- Diversity and uses of the genus croton (euphorbiaceae) in Northeastern Brazil -- Ethnomedical knowledge among the "Quilombolas" from the Amazon region of Brazil with a special focus on plants used as nervous system tonics -- Advances in the knowledge of medicinal plants in Eastern Andalusia, Spain -- Tropical propolis: recent advances in chemical components and Botanical origin -- Anti-malarial plants used in folk medicine in Bangladesh -- Usnea sulcata motyka: an ethnomycological review of its use in traditional medicine -- Sirukurinjan: An ancient remedy for a modern incurable disease, diabetes -- Herbal drugs used for domestic animals -- Endophytes from medicinal plants as novel sources of bioactive compounds -- Advances in medicinal plants with antitumoral activity -- Medicinal plants: how are they used to treat neurological diseases? -- Inflammatory diseases: mechanisms and natural remedies -- Recent advances to evaluate anti-diabetic medicinal plants -- Botanical origin and Biological activity of propolis -- Bioactivity of plant essential oils -- Antibacterial and antiviral effects of aromatic plant-derived essential oils: a scientific and medicinal approach -- Strategies of solvent system selection for the isolation of natural products by countercurrent chromatography.
  • Medicines for women 2015
    In this definitive new text, the major medicines, devices and vaccines used by women worldwide are brought together for the first time in a single volume. Written and edited by international experts with an evidence-based approach, Medicines for Women offers a comprehensive summary of all key areas. In the first part, issues relating to female drug exposure and prescribing to subgroups of women ℓ́ℓ for example during pregnancy and lactation, and to adolescent women ℓ́ℓ are presented in the context of contemporary clinical practice. In the second part, specific groups of medicines are reviewed, including oral contraceptives (with an additional chapter on venous thromboembolism), emergency contraception, contraceptive devices, treatment of chronic pelvic pain, hormone replacement therapy, bisphosphonates, herbal medicines for women, and human papilloma virus vaccines. Every chapter reviews and summarizes the efficacy and safety of each group of products and concludes with a useful set of clinical ℓ́ℓtake-homeℓ́ℓ messages. In the third part of the book, broader perspectives are presented ℓ́ℓ from a primary-care overview of prescribing for women, through to regulatory, political and religious aspects, including issues in developing countries. The two final chapters focus on communicating the benefits and risks of medicines for women. This book is aimed at prescribers, other healthcare professionals and students of womenℓ́ℓs health throughout the world. It is an extremely valuable resource for all in clinical practice, for students of medicine, nursing, pharmacy and related sciences, and also for those in medicines regulation, pharmacovigilance and the pharmaceutical industry.
  • This inclusive text describes hot melt extrusion for pharmaceutical applications, focusing on the materials used for the preparation of solid dispersions, fundamentals for preparing such systems and novel applications using extrusion technology. Highlighting viewpoints from the academic, excipient, equipment, product development and regulatory communities, this comprehensive text compiles input from industry thought leaders to illustrate strategies and technologies for applying hot melt extrusion for drug product development while also providing insight into the path forward for the technology in years to come.
  • Metabolic syndrome is a common syndrome affecting about 20% of the adult population in Europe, and the prevalence is likely similar in other industrialised countries worldwide. It is mainly caused by the western lifestyle, which tends to produce abdominal obesity, but a genetic predisposition also plays a part. This syndrome, which is linked to leisure lifestyles and overeating/obesity, can develop into type 2 diabetes, cardiovascular disease and cancer. Therefore, proper treatment and prevention are essential. This book discusses lifestyle intervention and treatment, specifically with pharmacological compounds, in order to formulate a strategy for treating the metabolic syndrome in daily practice.
  • Chapter 1. ₃Li Lithium Metallotherapeutics / Robin S.B. Williams and Adrian J. Harwood, p. 1-17 -- Chapter 2. ₅B Boron Compounds as Therapeutic Drugs / Geeta Rana, Kamesh Vyakaranam, John A. Maguire and Narayan S. Hosmane, p. 19-49 -- Chapter 3. ₁₂Mg The Role of Magnesium As a Metallotherapeutic Drug / Pietro Delva, p. 51-64 -- Chapter 4. ₁₃Al Aluminum Metallotherapeutics / Thanos Salifoglou, p. 65-82 -- Chapter 5. ₁₄Si Biological Activity of Organosilicon Compounds / Edmunds Lukevics and Luba Ignatovich, p. 83-107 -- Chapter 6. ₂₀Ca The Role of Calcium As a Metallotherapeutic Drug / Mario Barbagallo and Ligia J. Dominguez, p. 109-124 -- Chapter 7. ₂₂Ti Anti-Tumor Titanium Drugs / Erich Dubler, p. 125-142 -- Chapter 8. ₂₃V Insulin-Mimetic Vanadium-Containing Compounds / Tamás Kiss and Tamás Jakusch, p. 143-158 -- Chapter 9. ₂₅Mn Manganese Metallotherapeutics / Jeanne H. Freeland-Graves, Tanushree Bose and Abbass Karbassian, p. 159-178 -- Chapter 10. ₂₆Fe The Use of Iron-Based Drugs in Medicine / Xiang Wu and Mei Lin Go, p. 179-200 -- Chapter 11. ₂₇Co Cobalt Complexes As Potential Pharmaceutical Agents / Hui Chao and Liang-Nian Ji, p. 201-218 -- Chapter 12. ₂₉Cu Chemotherapeutic Copper Compounds / Francisco González-Vílchez and Rosario Vilaplana, p. 219-236 -- Chapter 13. ₃₀Zn The Role of Zinc As a Metallotherapeutic Agent / Jane V. Higdon and Emily Ho, p. 237-257 -- Chapter 14. ₃₁Ga Therapeutic Gallium Compounds / Lawrence R. Bernstein, p. 259-277 -- Chapter 15. ₃₂Ge Biological Activity of Organogermanium Compounds / Edmunds Lukevics and Luba Ignatovich, p. 279-295 -- Chapter 16. ₃₃As Metallotherapeutic Arsenic Compounds / Paul C. Ho, p. 297-311 -- Chapter 17. ₃₄Se The Use of Selenium-Based Drugs in Medicine / Michael Carland and Tahli Fenner, p. 313-332 -- Chapter 18. ₄₃Tc Technetium in Medicine / Oyebola O. Sogbein and John F. Valliant, p. 333-358 -- Chapter 19. ₄₄Ru Perspectives of Ruthenium Complexes in Cancer Therapy / Olivier Lentzen, Cécile Moucheron and Andrée Kirsch-De Mesmaeker, p. 359-378 -- Chapter 20. ₄₅Rh Rhodium in Medicine / Florian P. Pruchnik, p. 379-397 -- Chapter 21. ₄₆Pd The Use of Palladium Complexes in Medicine / Achilleas Garoufis, Sotiris K. Hadjikakou and Nick Hadjiliadis, p. 399-419 -- Chapter 22. ₅₀Sn Tin Compounds and Their Therapeutic Potential / Marcel Gielen and Edward R.T. Tiekink, p. 421-439 -- Chapter 23. ₅₁Sb Antimony in Medicine / Siucheong Yan, Lan Jin and Hongzhe Sun, p. 441-461 -- Chapter 24. ₇₅Re Therapeutic Rhenium Radiopharmaceuticals / Jonathan R. Dilworth and Paul S. Donnelly, p. 463-487 -- Chapter 25. ₇₈Pt Platinum-Based Drugs / Viktor Brabec and Jana Kasparkova, p. 489-506 -- Chapter 26. ₇₉Au Gold-Based Metallotherapeutics: Use and Potential / Soo Yei Ho and Edward R.T. Tiekink, p. 507-527 -- Chapter 27. ₈₃Bi Bismuth-Based Pharmaceuticals / Neil Burford and Melanie D. Eelman, p. 529-540 -- Chapter 28. Paramagnetic Metal Complexes As Contrast Agents for Magnetic Resonance Imaging / Silvio Aime, Alessandro Barge, Eliana Gianolio, Simonetta Geninatti Crich, Walter Dastrú and Fulvio Uggeri, p. 541-560.
  • Annotation Mercury (Hg) is a global pollutant that knows no environmental boundaries. Even the most stringent control of anthropogenic Hg sources will not eliminate exposure given its ubiquitous presence. Exposure to Hg occurs primarily via the food chain due to MeHgs accumulation in fish. Latest US statistics indicate that 46 States have fish consumption advisories. In addition, Hg is a common pollutant in hazardous waste sites, with an estimated 3-4 million children living within one mile of at least one of the 1,300+ active hazardous waste sites in the US. The effects on intellectual function in children prenatally exposed to MeHg via maternal fish consumption have been the subject of two on-going major, prospective, longitudinal studies in the Seychelles and the Faroe Islands. It is important to recognize that the risk for MeHg exposure is not limited only to islanders with high fish consumption. This bookwill provide state-of-the-art information to the graduate student training in toxicology, risk assessors, researchers and medical providers at large. It is aimed to bring the reader up to date on contemporary issues associated with exposure to methylmercury, from its effects on stem cells and neurons to population studies.
  • Methylxanthines 2011
    Notes on the History of Caffeine Use / Bertil B. Fredholm -- Distribution, Biosynthesis and Catabolism of Methylxanthines in Plants / Hiroshi Ashihara, Misako Kato and Alan Crozier -- Pharmacokinetics and Metabolism of Natural Methylxanthines in Animal and Man / Maurice J. Arnaud -- Inhibition of Cyclic Nucleotide Phosphodiesterases by Methylxanthines and Related Compounds / Sharron H. Francis, Konjeti R. Sekhar, Hengming Ke and Jackie D. Corbin -- Methylxanthines and Ryanodine Receptor Channels / Serge Guerreiro, Marc Marien and Patrick P. Michel -- Xanthines as Adenosine Receptor Antagonists / Christa E. Müller and Kenneth A. Jacobson -- Theobromine and the Pharmacology of Cocoa / Hendrik Jan Smit -- Propentofylline: Glial Modulation, Neuroprotection, and Alleviation of Chronic Pain / Sarah Sweitzer and Joyce De Leo -- Methylxanthines, Seizures, and Excitotoxicity / Detlev Boison -- Impacts of Methylxanthines and Adenosine Receptors on Neurodegeneration: Human and Experimental Studies / Jiang-Fan Chen and Yijuang Chern -- Methylxanthines and Pain / Jana Sawynok -- Methylxanthines and Sleep / Tarja Porkka-Heiskanen -- Methylxanthines and Reproduction / Alba Minelli and Ilaria Bellezza -- Methylxanthines During Pregnancy and Early Postnatal Life / Ulrika Ådén -- Methylxanthines and the Kidney / Hartmut Osswald and Jürgen Schnermann -- The Cardiovascular Effects of Methylxanthines / Niels P. Riksen, Paul Smits and Gerard A. Rongen -- Methylxanthines in Asthma / Stephen L. Tilley -- Methylxanthines and Inflammatory Cells / György Haskó and Bruce Cronstein -- Methylxanthines, Inflammation, and Cancer: Fundamental Mechanisms / Akio Ohta and Michail Sitkovsky -- Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse / Micaela Morelli and Nicola Simola -- Methylxanthines and Human Health: Epidemiological and Experimental Evidence / Marie-Soleil Beaudoin and Terry E. Graham.
  • Elsevier now offers a series of derivative works based on the acclaimed Meyler's Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician and/or clinician. Many of the drugs currently available to physicians have a long history of use as herbal remedies, including opium, aspirin, digitalis, and quinine. This volume will be a reference to health professionals and homeopathic practitioners in understanding the effects of herbal drugs. Surpasses the Physician's Desk Reference © by including clinical case studies and independent exper.
  • In vivo target site concentrations are probably the most important determinant of drug effects. Traditionally, linking drug concentrations to drug effects has been accomplished by modelling blood-derived data, mostly because a direct quantification of tissue concentrations has been beyond technical reach. Today, a direct measurement of target site concentrations is possible by employing microdialysis or complementary approaches such as imaging technologies. Microdialysis, initially conceived in the 1970s, has become a standard tool in drug development. This comprehensive overview of current microdialysis technology covers general and disease-specific aspects of microdialysis by international experts in the field. It provides useful information for colleagues in academia and industry who are interested PK-PD aspects of drug development.
  • Modern anesthetics 2008
  • Currently, there are tremendous advances being made in understanding the basic science of both the structure and function of botulinum neurotoxins. This knowledge is opening up opportunities in regard to both therapeutic uses and treatment and protection options for civil and bio-defense applications. This volume fully evaluates the status of neurotoxin research and exploitation. The book is a multi-authored collection of chapters written by the leading authorities responsible for the current scientific and clinical research that is advancing the understanding and exploitation of the neurotoxins, and is both up to date and authoritative.
  • "Preface Over the past few decades, molecular modeling (MM) has become an important tool in many academic institutions and industrial laboratories. While the role of MM in biological fields--especially in the design and development of novel drug molecules or formulations--is well established and acknowledged, its direct role in the design and development of performance chemicals and novel materials is still not well known. Questions such as, which new products have resulted from an MM-based approach? are still often asked. Although MM may be playing an important role in product development, quite often it becomes difficult to predict its direct impact because most of the time the problem being addressed involves a multidisciplinary approach. Further, the assumption that fundamental phenomena being modeled though MM will have a direct impact on the macroscopic and functional properties of a product make the situation more complicated. In most of the cases, MM actually works as an enabler toward novel product and material development (e.g., novel drug molecules in biological application) rather than directly coming up with new products and materials. This precisely is the reason that despite seeing value in MM tools, most engineers and practitioners are often focus on the question, how do I leverage these tools to design and develop novel materials or chemicals for the industry I am working with? Unfortunately, there is no simple answer to this question. Excellent books and very good research publications highlight the most intricate, fundamental, and theoretical details about MM techniques and tools"-- Provided by publisher.
  • "This book reviews the latest developments in pharmacognosy, introduces a series of new views and insights, presents the hotspots and focus of the field of study on molecular pharmacognosy, and predicts a new direction of study on the resource science of TCM. Furthermore, the book also provides an open communications platform for the development of molecular pharmacognosy."--Publisher.
  • Chemical Hazards in the Organisation / Chris Winder -- Toxicology of Water / Xiaowei Zhang, Steve Wiseman and John Giesy -- Perfluorinated Compounds / Christopher Lau -- Toxicologically Relevant Phthalates in Food / Oliver Kappenstein, Bärbel Vieth, Andreas Luch and Karla Pfaff -- Exposure to Polycyclic Aromatic Hydrocarbons: Bulky DNA Adducts and Cellular Responses / Frank Henkler, Kristin Stolpmann and Andreas Luch -- Heavy Metal Toxicity and the Environment / Paul B. Tchounwou, Clement G. Yedjou, Anita K. Patlolla and Dwayne J. Sutton -- Toxicology of Ambient Particulate Matter / Damiën van Berlo, Maja Hullmann and Roel P. F. Schins -- Nanomaterials: A Challenge for Toxicological Risk Assessment? / Andrea Haase, Jutta Tentschert and Andreas Luch -- Immunotoxicology and Its Application in Risk Assessment /; Andrew A. Rooney, Robert W. Luebke, MaryJane K. Selgrade and Dori R. Germolec.; Chemical Sensitization and Allergotoxicology / Rosette L. Van Den Heuvel, Nathalie Lambrechts, Sandra Verstraelen, Inge C. Nelissen and Greet E. R. Schoeters -- Male Reprotoxicity and Endocrine Disruption / Sarah Campion, Natasha Catlin, Nicholas Heger, Elizabeth V. McDonnell and Sara E. Pacheco, et al. -- Interspecies Uncertainty in Molecular Responses and Toxicity of Mixtures / Moiz M. Mumtaz and Hana R. Pohl -- Recent Trends in Statistical QSAR Modeling of Environmental Chemical Toxicity / Alexander Tropsha -- Chirality and Its Role in Environmental Toxicology / Imran Ali, Hassan Y. Aboul-Enein, Mohd Marsin Sanagi and Wan Aini Wan Ibrahim -- Genetic Variability in Molecular Responses to Chemical Exposure / Chirag J. Patel and Mark R. Cullen -- Biomarkers in Toxicology and Risk Assessment / Bruce A. Fowler -- A Personalized Life: Biomarker Monitoring from Cradle to Grave / Harald Jungnickel and Andreas Luch -- On the Role of Low-Dose Effects and Epigenetics in Toxicology / Lena Smirnova, Alexandra Sittka and Andreas Luch -- Hormesis: Improving Predictions in the Low-Dose Zone / E. J. Calabrese.
  • This book would combine chapters written by the most qualified authors around the world whose research encompasses the effect of morphine or other opioids on tumor growth and metastasis. This includes clinicians involved in trials determining which type of post surgical pain management can minimize the risk of recurrence or metastasis, researchers working on animal models and studying the effect of morphine on tumors, and most importantly the mechanism for this effect, and lastly cell biologists. There is currently a lot of research going on trying to reconcile the pro- and anti-cancer aspects of opioids actions.
  • Muscarinic receptor pharmacology and signaling -- Overview of muscarinic receptor subtypes -- Structure-function studies of muscarinic acetylcholine receptors -- Polymorphisms in human muscarinic receptor subtype genes -- Muscarinic receptor trafficking -- Physiological role of G-protein coupled receptor phosphorylation -- Novel muscarinic receptor mutant mouse models -- Muscarinic receptors in the CNS -- Muscarinic receptor pharmacology and circuitry for the modulation of cognition -- Muscarinic agonists and antagonists in schizophrenia -- Muscarinic pain pharmacology: realizing the promise of novel anagesics by overcoming old challenges -- Muscarinic modulation of striatal function and circuitry -- Muscarinic receptors in brain stem and mesopontine cholinergic arousal functions -- Muscarinic receptors in autonomic effector organs -- Muscarinic receptor agonists and antagonists: effects on ocular function -- Muscarinic receptor agonists and antagonists: effects on cardiovascular function -- Muscarinic receptor antagonists: effects on pulmonary function -- Muscarinic agonists and antagonists: effects on gastrointestinal function -- Muscarinic agonists and antagonists: effets on the urinary bladder -- Muscarinic receptors and mediation of hormonal effects of acetylcholine -- Muscarinic receptor agonists and antagonists: effects on inflammation and immunity -- Muscarinic receptor agonists and antagonists: effects on keratinocyte functions -- Muscarinic receptor agonists and antagonists: effects on cancer -- Activation of muscarinic receptors by non-neuronal acetylcholine.
  • Part 1. Natural Product Drugs and Cancer Therapeutics -- The Impact of Natural Products Upon Cancer Chemotherapy / A. Ganesan -- Identification and Development of Vascular Disrupting Agents: Natural Products That Interfere with Tumor Growth / Andrea T. Hooper, Frank Loganzo, Chad May and Hans-Peter Gerber -- Discodermolide: Past, Present, and Future / Ross E. Longley -- HDAC Inhibitors and Other Histone Modifying Natural Products as Emerging Anticancer Agents / Lilibeth A. Salvador and Hendrik Luesch -- Natural Product Cytotoxins as Payloads for Antibody Drug Conjugates / Frank E. Koehn -- Part 2. Advances in Natural Product Cancer Drug Discovery -- Natural Product Scaffolds in Cancer Therapy / Christian P. Mang and Lars Ole Haustedt -- The Role of Genetic Engineering in Natural Product-Based Anticancer Drug Discovery / Claudia Eva-Maria Unsin, Scott R. Rajski and Ben Shen -- Accessing Anti-cancer Natural Products by Plant Cell Culture / Lisa M. Leone and Susan C. Roberts -- Natural Products as Tools for Discovering New Cancer Targets / John A. Beutler.
  • Natural products and drug discovery / Arnold L. Demain and Lixin Zhang -- Integrated approaches for discovering novel drugs from microbial natural products / Lixin Zhang -- Automated analyses of HPLC profiles of microbial extracts: a new tool for drug discovery screening / Jose R. Tormo and Juan B. Garcia -- Manipulating microbial metabolites for drug discovery and production / C. Richard Hutchinson -- Improving drug discovery from microorganisms / Chris M. Farnet and Emmanuel Zazopoulos -- Developments in strain improvement technology: evolutionary engineering of industrial microorganisms through gene, pathway, and genome shuffling / Stephen B. del Cardayr -- The discovery of anticancer drugs from natural sources / David J. Newman and Gordon M. Cragg -- Case studies in natural product optimization: novel antitumor agents derived from Taxus brevifolia and Catharanthus roseus / Jian Hong and Shu-Hui Chen -- Terpenoids as therapeutic drugs and pharmaceutical agents / Guangyi Wang, Weiping Tang and Robert R. Bidigare -- Challenges and opportunities in the Chinese herbal drug industry / Wei Jia and Lixin Zhang -- Arsenic trioxide and leukemia: from bedside to bench / Guo-Qiang Chen ... [et al.] -- New methods to access microbial diversity for small molecule discovery / Karsten Zengler, Ashish Paradkar, and Martin Keller -- Accessing the genomes of uncultivated microbes for novel natural products / Asuncion Martinez ... [et al.] -- New natural product diversity from marine actinomycetes / Paul R. Jensen and William Fenical -- Novel natural products from rainforest endophytes / Gary Strobel, Bryn Daisy, and Uvidelio Castillo -- Biological, economic, ecological, and legal aspects of harvesting traditional medicine in Ecuador / Alexandra Guevara-Aguirre and Ximena Chiriboga.
  • This updated edition of Netter's Illustrated Pharmacology allows you to take a distinct visual approach to understanding both the basic science and clinical applications of pharmacology. Designed to be compatible and used in conjunction with other pharmacology resources, this medical reference book offers a vivid, uniquely effective visual presentation of the pharmacodynamic relationship between drugs and the human body. And with the new addition of Student Consult online access, Netter's Illustrated Pharmacology is even more convenient than ever before! Available online for the first time! Search the full contents of Netter's Illustrated Pharmacology no matter what your location with convenient access to Student Consult.Visually grasp the most important principles in pharmacology with succinct, easy-to-understand presentations of introductory pharmacologic principles based on classic images by Frank Netter, as well as dynamic new illustrations from other talented medical artists.Learn how drugs are used to treat specific disorders in the body, as well as their effects on a particular site, with a format divided by organ system and full-color illustrations of the systems themselves.Access in-depth guidance on the must-know elements of each pharmacologic principle with clear, concise notes located beneath the corresponding image.
  • This book reviews the imaging features associated with selected classes of pharmaceuticals and drugs on brain, head and neck, and spine and explains the implications of the imaging findings for the neuroradiologist and the clinician. Some agents produce characteristic abnormalities with distinctive imaging features, while others have a spectrum of manifestations on imaging. Still further agents produce rather nonspecific changes on imaging, requiring a differential diagnosis. In this book, informative cases are depicted by rich images, with concise accompanying explanatory text that reviews the class of agent and the mechanism of action and discusses image interpretation and its significance.
  • Imaging Tobacco Smoking with PET and SPECT -- Behavioral Mechanisms Underlying Nicotine Reinforcement -- The Role of Mesoaccumbens Dopamine in Nicotine Dependence -- Nicotine Withdrawal -- Neurobiologal bases of cue- and nicotine-induced reinstatement of nicotine seeking -- Psychiatric disorders as vulnerability factors for nicotine addiction: What have we learned from animal models?.
  • This book provides critical reviews of the role of neurotrophins and their receptors in a wide variety of diseases including neurodegenerative diseases like Huntington's syndrome, cognitive function, psychiatric disorders such as clinical depression, Rett syndrome, motoneurone disease, spinal cord injury, pain, metabolic disease and cardiovascular disease. It also contains contributions from leaders in the field dealing with the basic biology, transcriptional and post-translational regulation of the neurotrophins and their receptors. The present book will review all recent areas of progress in the study of neurotrophins and their biological roles.
  • This book provides an up-to-date review of recently identified natural anti-tumor compounds from various natural origins including plants, fungi, endophytic fungi and marine organisms. It also℗ℓincludes discussion of℗ℓnew areas℗ℓsuch as℗ℓbiotechnology and nanoparticles. Chapters explain the challenges and developments in anti-cancer drug discovery approaches, traditional remedies for prevention and treatment of cancer, marine-derived anti-cancer compounds, and antibiotics used as anti-cancer agents, as well as different classes of terpenoids and carbohydrates, which have℗ℓbeen the subject of discussion℗ℓin this field as efficient anti-cancer candidates. This book will be a concise guide for researchers in the field of pharmaceutical sciences, students and residents in pharmacy and medicine as well as those researching phytochemistry and natural products.
  • New drug development -- The regulatory environment -- Drug discovery -- Nonclinical research -- Designing clinical trials -- Conducting clinical trials I: Experimental methodology -- Conducting clinical trials II: Operational execution -- Statistical analysis -- Statistical significance -- Clinical significance -- Sample size estimation -- General safety assessments -- Efficacy assessment -- Cardiac and cardiovascular safety assessments -- Manufacturing small molecule drugs and biologicals -- Postmarketing surveillance -- Main themes and concluding comments -- References -- Index.
  • Global patterns of nicotine and tobacco consumption / S.K. Hammond -- Nicotine chemistry, metabolism, kinetics and biomarkers / N.L. Benowitz, J. Hukkanen and P. Jacob, 3rd -- Nicotine content and delivery across tobacco products / M.V. Djordjevic and K.A. Doran -- The road to discovery of neuronal nicotinic cholinergic receptor subtypes / A.C. Collins ... [et al.] -- Magnetic resonance imaging studies of cigarette smoking / A. Azizian ... [et al.] -- In vivo brain imaging of human exposure to nicotine and tobacco / A. Sharma and A.L. Brody -- Molecular and cellular mechanisms of action of nicotine in the CNS / J. Barik and S. Wonnacott -- The neuronal pathways mediating the behavioral and addictive properties of nicotine / D.J. Balfour -- Molecular genetics of nicotine metabolism / J.C. Mwenifumbo and R.F. Tyndale -- Sex differences in nicotine action / S. Pogun and G. Yararbas -- Recognising nicotine: the neurobiological basis of nicotine discrimination / J.W. Smith and I.P. Stolerman -- Effects of nicotine in experimental animals and humans: an update on addictive properties / B. Le Foll and S.R. Goldberg -- Discriminative stimulus effects of nicotine in humans / K.A. Perkins -- Rodent models of nicotine withdrawal syndrome / D.H. Malin and P. Goyarzu -- Approaches, challenges, and experience in assessing free nicotine / D.L. Ashley ... [et al.] -- Tobacco industry manipulation of nicotine dosing / G.F. Wayne and C.M. Carpenter -- Pharmacotherapy for tobacco dependence / R.V. Fant ... [et al.] -- Nicotine psychopharmacology: policy and regulatory / J.E. Henningfield and M. Zeller.
  • Introduction: defining the position of non-biological complex drugs -- Polymeric micelles -- Liposomes: the science and the regulatory landscape -- Glatiramoids -- Iron carbohydrate complexes: characteristics and regulatory challenges -- Drug nanocrystals -- Analytical methods for determining the size (distribution) in parenteral dispersions -- NBCD pharmacokinetics and bioanalytical methods to meaure drug release -- Low molecular weight heparins, biological drugs close to non-biological complex drugs -- Nanoparticle albumin-bound anticancer agents -- The EU regulatory landscape of non-biological complex drugs -- Epilogue: What did we learn? What can we expect in the future? Concluding remarks and outstanding issues -- Index.
  • Machine generated contents note: I.Development of Biophar-Maceuticals Defined as Novel Biologics -- 1.Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development / Thomas R. Gelzleichter -- Introduction -- History and Evolution of Biopharmaceuticals -- Development of Diverse Biopharmaceutical Modalities -- Comparison of Small-Molecule Drugs to Biopharmaceuticals -- Summary -- References -- 2.Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological Medicines / Maggie Dempster -- Introduction -- Species Selection -- Study Design Considerations for Repeat-Dose Studies -- Immunogenicity -- Reproductive and Developmental Toxicity -- Genotoxicity and Carcinogenicity -- Special Considerations for Anticancer Drugs -- First-in-Human (Fih) Clinical Trial -- Summary -- References -- 3.Early De-risking Strategy for Novel Biotherapeutics / Beth Hinkle -- Introduction -- Establishing A Safety Profile for Biotherapeutics -- General Safety Considerations Related to Biotherapeutics -- Progress in Evaluation of Immunotoxicity -- Can We Better Address Potential Off-Target Toxicity? -- Summary -- References -- 4.Novel Biopharmaceuticals: Pharmacokinetics, Pharmacodynamics, and Bioanalytics / Wolfgang Seghezzi -- Introduction -- Absorption, Distribution and Elimination of Biopharmaceuticals -- Disposition of Modified Molecules -- "Metabolism" and Biodistribution for Biopharmaceuticals -- Immunogenicity and impacts on PK and biodistribution -- Pharmacokinetics and Pharmacodynamics -- Preclinical to Clinical Translation -- Bioanalytics -- Drug Assays -- Biomarkers: Target Engagement Assays -- Immunogenicity Assessment: ADA Assays -- Summary -- References -- II.Development of Biosimilars -- 5.Overview of Biosimilar Therapeutics / Danuta J. Herzyk -- Introduction -- The Concept of Biosimilars -- General Considerations for Development of Biosimilars -- Biosimilar Candidates Based on Modality and Therapeutic Class -- Summary -- References -- 6.Regulatory Standards for the Approval of Biosimilar Products: A Global Review / Barbara Mounho-Zamora -- Introduction -- European Union -- Pioneer for the First Regulatory Pathway for Biosimilar Products -- The World Health Organization Guidance on Biosimilars -- Regulatory Pathway for Biosimilar Products in the United States -- Biosimilar Pathways in Other Regions -- Summary -- References -- 7.Early Characterization of Biosimilar Therapeutics / Thomas R. Gelzleichter -- Introduction -- Recombinant Insulins -- Recombinant Human Growth Hormone -- Recombinant Erythropoietins -- Recombinant Granulocyte Colony-Stimulating Factor -- Recombinant Interferons -- Low Molecular Weight Heparins -- Monoclonal Antibodies -- Other Classes -- Summary -- References -- III.Vaccines -- 8.Introduction to Vaccines and Adjuvants / Deborah L. Novicki -- Introduction -- The History of Vaccines -- The Impact of Vaccines on Human Health -- Advancements in Vaccines Technologies -- Advancements in Adjuvant Technologies -- Approved Infectious Disease Vaccines and Diseases for Which Preventive Vaccines are Still Needed -- Therapeutic Vaccines -- Product Complexity From a Quality Perspective -- Nonclinical Testing -- Clinical Testing -- Vaccine Development Using the Animal Rule -- The Anti-Vaccines Movement and Misperceptions About Vaccines and Their Safety -- Summary -- References -- 9.Global Regulatory Guidelines for Vaccines / Lisa M. Plitnick -- Introduction -- Toxicity Assessment -- Additional Toxicity Assessments -- Special Considerations -- Formulation/Delivery Devices -- Alternate Routes of Administration -- Special Considerations for Particular Types of Vaccines -- Summary -- References -- 10.Special Considerations for the Nonclinical Safety Assessment of Vaccines / Jayanthi J. Wolf -- Introduction -- De-risking Strategies for Vaccines -- Pharmacokinetics and Pharmacodynamics Assessments -- Differences in the Nonclinical Safety Assessment of Vaccines and Biopharmaceutical Drugs -- Summary -- References -- IV.Specialty Biologics and Indications -- 11.Turning the Corner with Viral-based Gene Therapy -- Development of the Rogue Biopharmaceutical / Timothy K. Maclachlan -- Introduction -- A History and Primer of Gene Therapy -- The Process of Getting Genes into Cells -- Health Authority Regulation of Gene Therapy Products -- Nonclinical Safety Studies and Regulatory Guidance -- Summary -- References -- 12.Blood Products / Vikram Arora -- Introduction -- Plasma-Derived Blood Products -- Blood Products Derived from Recombinant Technologies -- Summary -- References -- 13.Biological Therapies for Cancer / Gautham K. Rao -- Introduction -- Global Regulatory Guidances -- General Principles of Toxicology Assessments -- Nonclinical Studies and Principles of Study Design -- Specialty Toxicology Assessments -- Pharmacokinetics, Immunogenicity, and Pharmacodynamics -- Nonclinical Development of Marketed Biologies -- Recombinant Analogs of Endogeneous Human Proteins (Interferons, Cytokines, Enzymes) -- Summary -- References -- 14.Nonclinical Development of Multi-targeting Biopharmaceuticals / Anu V. Connor -- Introduction -- Scientific Rationale for Multi-Targeting Biopharmaceuticals (MTBs) -- Evolution of Technology Platforms -- General Challenges and Considerations -- Summary of Challenges -- T Cell-Dependent Bispecific Antibody (TDB) Biotherapeutics -- Dual-Targeting Antibodies -- Summary -- References -- 15.Considerations in the Development of Pluripotent Stem Cell-based Therapies / Joy A. Cavagnaro -- Introduction -- Early Decisions -- Nonclinical Development -- Translating Preclinical Data to Clinical Application -- Global Regulatory Guidance -- Summary -- References.
  • A survey of novel molecular targets for anticancer drug discovery -- Microarrays: small spots produce major advances in pharmacogenomics -- Strategies to target chemotherapeutics to tumors -- QSAR and pharmacophore mapping strategies in novel anticancer drug discovery -- Applications of nuclear magnetic resonance and mass spectrometry to anticancer drug discovery -- Antisense strategies for the development of novel cancer therapeutics -- Antibodies and vaccines as novel cancer therapeutics -- Inhibitors as targets for cancer therapy -- Preclinical testing and validation of novel anticancer agents -- Surrogate end points and biomarkers for early trials of novel anticancer agents -- Regulatory considerations in clinical trials of novel anticancer drugs -- Improving the efficacy and safety of anticancer agents: the role of pharmacogenetics -- Imaging of pharmacodynamic end points in clinical trials -- Devising proof-of-concept strategies in oncology clinical trials -- Clinical trial designs for cytostatic agents and agents directed at novel molecular targets -- Cancer gene therapy clinical trials: from the bench to the clinic -- Molecular targets for radiosensitization -- Patient accrual to clinical trials.
  • This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
  • Preface -- Steroid Receptor Coactivators (SRCs) as Integrators of Multiple Signaling Pathways in Cancer Progression -- Role of Alteration/Deficiency in Activation (ADA) Complex in the Cell Cycle, Genomic Instability and Cancer -- RUNX2 Transcriptional Regulation in Development and Disease -- Epigenetic Mechanisms of Cancer Metastasis -- Regulatory Effects of Arsenic on Cellular Signaling Pathways: Biological Effects and Therapeutic Implications -- Nuclear Factors Linking Cancer and Inflammation -- Regulation of the Jak/STATs Pathways by Histone Deacetylases -- Receptor Tyrosine Kinases in the Nucleus: Nuclear Functions and Therapeutic Implications in Cancers -- Nucleolar Signaling Determines Cell Fate The RP-Mdm2-p53 Axis Fine-Tunes Cellular Homeostasis -- Transcriptional Regulation of Lipogenesis as a Therapeutic Target for Cancer Treatment -- Selective Inhibition of Acetyl-Lysine Effector Domains of the Bromodomain Family in Oncology -- Domain Specific Targeting of Cancer -- The Potential of Targeting Splicing for Cancer Therapy -- Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies -- Histone Demethylases in Prostate Cancer -- Therapeutic Significance of Chromatin Remodeling Complexes in Cancer -- Index.
  • Ocular pharmacology and toxicology 2014
    Springer Protocols
    Challenges in ocular pharmacokinetics, pharmacodynamics, and toxicology / Brian C. Gilger -- Selection of appropriate animal models in ocular research : ocular anatomy and physiology of common animal models / Brian C. Gilger, Eva Abarca, and Jacklyn H. Salmon -- Challenges and strategies in drug residue measurement (bioanalysis) of ocular tissues / Poonam R. Velagaleti and Michael H. Buonarati -- Chemistry, manufacturing, and control of ophthalmic formulations / Malay Ghosh and Imran Ahmed -- ADME and ocular therapeutics : retina / Cornelis J. Van der Schyf, Samuel D. Crish, Christine Crish, Denise Inman, and Werner J. Geldenhuys -- Compositions, formulation, pharmacology, pharmacokinetics, and toxicity of topical, periocular, and intravitreal ophthalmic drugs / Kishore Cholkar, Aswani Dutt Vadlapudi, Hoang M. Trinh, and Ashim K. Mitra -- Sustained-release ocular drug delivery systems : bench to bedside development / Susan S. Lee, Michael R. Robinson, and Scott M. Whitcup -- Ophthalmic examination as it pertains to general ocular toxicology : basic and advanced techniques and species-associated findings / David A. Wilkie -- Study design and methodologies for evaluation of anti-glaucoma drugs / Paul E. Miller -- Study design and methodologies for study of ocular medical devices / Joseph W. Carraway and Elaine M. Daniel -- Methodologies for microscopic characterization of ocular toxicity / Leandro B.C. Teixeira and James A. Render -- Nanoparticles for drug and gene delivery in treating diseases of the eye / Shreya S. Kulkarni and Uday B. Kompella.
  • 1 Antibacterial agents -- 2 Antifungal agents -- 3 Antiviral agents -- 4 Antiparasitic agents -- 5 Antiglaucoma agents -- 6 Neuro-ophthalmology -- 7 Anti-inflammatory agents -- 8 Mydriates, cycloplegics, and reversal agents -- 9 Lubricants and viscoelastics -- 10 Miscellaneous conditions -- 11 Anti-angiogenesis agents -- 12 Contact lens.
  • Thoroughly revised and updated, Optimization in Drug Discovery: In Vitro Methods, Second Edition presents a wide spectrum of in vitro assays including formulation, plasma binding, absorption and permeability, cytochrome P450 (CYP) and UDP-glucuronosyltransferases (UGT) metabolism, CYP inhibition and induction, drug transporters, drug-drug interactions via assessment of reactive metabolites, genotoxicity, and chemical and photo-mutagenicity assays. Written for the Methods in Pharmacology and Toxicology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and tips on troubleshooting and avoiding known pitfalls. Expert authors have developed and utilized these in vitro assays to achieve drug-like characteristics in addition to efficacy properties and good safety profiles of drug candidates. Comprehensive and up-to-date, Optimization in Drug Discovery: In Vitro Methods, Second Edition aims to guide researchers down the difficult path to successful drug discovery and development.
  • Oral mucositis 2012
    Treatment tolerance is a challenge for most cancer patients, and it is therefore essential that healthcare professionals (HCP) are quick to recognize adverse events and implement management strategies to address them. This pocket book provides an in-depth guide to the epidemiology, diagnosis and management of oral mucositis, a common adverse event of chemotherapy.
  • Pain control 2015
    Emerging concepts of pain therapy based on neuronal mechanisms -- The pharmacology of nociceptor priming -- Sodium channels and pain -- Role of nerve growth factor in pain -- Central sensitization in humans: assessment and pharmacology -- Nitric oxide-mediated pain processing in the spinal cord -- The role of the endocannabinoid system in pain -- The role of glia in the spinal cord in neuropathic and inflammatory pain -- Plasticity of inhibition in the spinal cord -- Modulation of peripheral inflammation by the spinal cord -- The relationship between opiods and immune signalling in the spinal cord -- The role of proteases in pain -- Amygdala pain mechanisms -- Itch and pain differences and commonalities -- Index.
  • Pasteurella multocida: Diseases and Pathogenesis / I. W. Wilkie, M. Harper, J. D. Boyce and B. Adler -- Pathogenomics of Pasteurella multocida / J. D. Boyce, T. Seemann, B. Adler and M. Harper -- The Key Surface Components of Pasteurella multocida: Capsule and Lipopolysaccharide / Marina Harper, John D. Boyce and Ben Adler -- Pasteurella multocida and Immune Cells / Katharina F. Kubatzky -- Molecular Biology of Pasteurella multocida Toxin / Joachim H. C. Orth and Klaus Aktories -- Pasteurella multocida Toxin Interaction with Host Cells: Entry and Cellular Effects / Brenda A. Wilson and Mengfei Ho -- Swine Atrophic Rhinitis Caused by Pasteurella multocida Toxin and Bordetella Dermonecrotic Toxin / Yasuhiko Horiguchi -- The Pasteurella multocida Toxin: A New Paradigm for the Link Between Bacterial Infection and Cancer / Alistair Lax.
  • The Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book-it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science. Contains a collection of experiences of different groups taking different types of biomarkers to different levels of qualification and provides insightful case studies of an important area of regulatory science Focuses on practical advice, concepts, strategies and overall outcomes to support those working toward biomarker qualification for clinical use Offers a valuable resource for members of the regulatory, pharmaceutical and biomarker development communities.
  • Calcium ions represent Mother Nature's "ion-of-choice" for regulating fundamental physiological functions, as they initiate a new life at the time of fertilization and guide subsequent developmental and physiological functions of the human body. Calcium channels, which act as gated pathways for the movement of calcium ions across the membranes, play a central part in the initiation of calcium signals, and defects in calcium channel function have been found to result in a plethora of human diseases, referred to as the calcium channelopathies. Pathologies of Calcium Channels brings together leading international experts to discuss our current understanding of human diseases associated with the various calcium channels, from their molecular basis to potential future therapeutic targeting of calcium channels.
  • Peptide-based drug design 2008
    Springer Protocols
    Peptide-based drug design : here and now / Laszlo Otvos, Jr. -- Strategies for the discovery, isolation, and characterization of natural bioactive peptides from the immune system of invertebrates / Philippe Bulet -- Sequence analysis of antimicrobial peptides by tandem mass spectrometry / Christin Stegemann and Ralf Hoffmann -- The spot technique : synthesis and screening of peptide macroarrays on cellulose membranes / Dirk F.H. Winkler and William D. Campbell -- Analysis of A[beta] interactions using ProteinChip technology / Eleni Giannakis ... [et al.] -- NMR in peptide drug development / Jan-Christoph Westermann and David J. Craik -- Molecular dynamics simulations of peptides / Jeffrey Copps, Richard F. Murphy and Sandor Lovas -- Short linear cationic antimicrobial peptides : screening, optimizing, and prediction / Kai Hilpert, Christopher D. Fjell and Artem Cherkasov -- Investigating the mode of action of proline-rich antimicrobial peptides using a genetic approach : a tool to identify new bacterial targets amenable to the design of novel antibiotics / Marco Scocchi ... [et al.] -- Serum stability of peptides / Håvard Jenssen and Stein Ivar Aspmo -- Preparation of glycosylated amino acids suitable for Fmoc solid-phase assembly / Mare Cudic and Gayle D. Burstein -- Synthesis of O-phosphopeptides on solid phase / David Singer and Ralf Hoffmann -- Peptidomimetics : Fmoc solid-phase pseudopeptide synthesis / Predrag Cudic and Maciej Stawikowski -- Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines / Brandon Y. Chua, Weiguang Zeng and David C. Jackson -- Synthesis of a multivalent, multiepitope vaccine construct / Laszlo Otvos, Jr. -- Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins / Marina V. Backer ... [et al.].
  • This volume examines the effects of natural products and functional/medical foods (nutritional programming) on disease management. It specifically focuses on diseases related to inflammation and immunity, cancer and cachexia, allergies, and brain and neuro/immune. As both pharmacologists and nutritionists are recognizing that the one disease/one target/one drug (or nutrient) concept will be less successful than in the past, this book aims to stress the importance of a multi-target approach versus a single-target approach. It also presents aspects of molecular characteristics of food ingredients toward clinical effectiveness and relevance. The interest in food in health and disease has exploded in the past few years, and publications on the microbiome can be found in all major scientific journals and newspapers. A new concept uses functional foods hand in hand with standard pharmacological therapies, which can be conceptualized in the term 'pharma-nutrition.' With the complementary values of pharma and nutrition, scientists might be able to overcome the increased incidence worldwide of complex multi-factorial disorders, chronic and degenerative diseases in particular.
  • Translational medicine: a paradigm shift in modern drug discovery and development: the role of biomarkers / Mark Day, J. Lynn Rutkowski, and Giora Z. Feuerstein -- Natural products in drug discovery: present status and perspectives / Gabriella Molinari -- Protein pharmaceuticals: discovery and preclinical development / Davinder S. Gill -- The role of nanobiotechnology in drug discovery / Kewal K. Jain -- Conotoxin venom peptide therapeutics / Richard J. Lewis -- Shark novel antigen receptors: the next generation of biologic therapeutics? / Caroline Barelle, Davinder Gill, and Keith Charlton -- Immune interventions of human diseases through toll-like receptors / Cevayir Coban, Ken J. Ishii, and Shizuo Akira -- Genome-based vaccine development: a short cut for the future / Danilo Gomes Moriel ... [et al.] -- The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections? / Carmen Giefing, Eszter Nagy, and Alexander von Gabain -- HSV as a vector in vaccine development and gene therapy / Peggy Marconi ... [et al.] -- Virus-like particles as a vaccine delivery system: myths and facts / Polly Roy and Rob Noad -- Applications of bacterial ghosts in biomedicine / Petra Lubitz, Ulrike Beate Mayr, and Werner Lubitz -- Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design / Thomas Ebensen and Carlos A. Guzmøn -- Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS / Aurelio Cafaro ... [et al.] -- New strategies to overcome the drawbacks of currently available flu vaccines / Epifanio Fichera ... [et al.].
  • 1. Overview of Medicines Regulatory Systems in the Gulf Region -- 2. The Regulatory Review Process in the Gulf Region -- 3. Regulatory Review Times in the Gulf Region -- 4. Quality Measures in the Gulf Regulatory Practices -- 5. The Current Status of the Common Technical Document -- 6. The Current Status of Drug Safety and Pharmacovigilance -- 7. The Centralized Regulatory Review in the Gulf Region -- 8. The Gulf States Assessment and Experience With the Centralised Procedure -- 9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure -- 10. Proposal For an Improved Centralized Regulatory System -- 11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions -- 12. The Regulatory Dilemma in the Gulf Region: The Way Forward.
  • Contains proceedings of the AAPS Stability Workshop.
  • Challenges, opportunities, and evolving landscapes in pharmacogenomics and personalized medicine : an industry perspective / Nadine Cohen and Theresa Frangiosa -- Implementation of pharmacogenomic sample collection in clinical trials / Deborah Sokol Ricci and Monique Franc -- Pharmacogenomics : the regulatory environment and labeling implications / Myong-Jin Kim ... [et al.] -- Applications of pharmacogenomics in drug discovery / Duncan McHale -- Applications of pharmacogenomics in clinical trials / Monique Franc -- Pharmacogenomics applications in drug metabolism : from genotyping to drug label-challenges? / Ann K. Daly -- The genetics of adverse drug reactions : promises and problems / Martin Armstrong -- Strategies and resources for marker selection and genotyping in genetic association studies / Nicole Soranzo, Dong-Jing Fu, and Qingqin S. Li -- Study design and statistical issues in pharmacogenetics research : from candidate genes to genome-wide screens / Nicholas J. Schork, Nathalie Malo, and Eric J. Topol -- Holy SNP, Batman! / Reyna Favis -- Predictive biomarker classifiers in the design of pivotal clinical trials / Richard Simon -- Translation of biomarkers into clinical utility / William L. Trepicchio and George Mulligan -- Pharmacogenomic study feasibility assessment and pharmaceutical business decision-making / Monique Franc and Theresa Frangiosa -- Co-development of drugs and pharmacogenomics-based diagnostics in oncology / Jeffrey S. Ross -- Pharmacogenomics applications in epilepsy / Chantal Depondt -- Pharmacogenomics in Alzheimer's disease / Ramón Cacabelos -- Pharmacogenomics applications in psychiatric disorders / Todd Lencz and Anil K. Malhotra -- Pharmacogenomics in HIV disease / Amalio Telenti -- Pharmacogenomics and cardiovascular drugs / Gérard Siest ... [et al.] -- Pharmacogenomic applications in children / Susan F.A. Grant and Hakon Hakonarson -- Pharmacogenomics of rare and monogenic disorders / Paul D. Maher.
  • Pharmacogenomics principles : introduction to personalized medicine / Parvaz Madadi, and Gideon Koren -- Traditional therapeutic drug monitoring and pharmacogenomics : are they complementary? / Christine Snozek, Loralie J. Langman, and Amitava Dasgupta -- Pharmacogenomics aspect of warfarin therapy / Matthew D. Krasowski -- Pharmacogenetics and cancer chemotherapy / Christine L.H. Snozek -- Pharmacogenomic considerations in anesthesia and pain management / Christine Formea, Wayne T. Nicholson -- Pharmacogenomics of immunosuppressants / Nicolas Picard and Pierre Marquet -- Pharmacogenomics of cardiovascular drugs / Linnea M. Baudhuin -- Pharmacogenomics aspect of antiretroviral therapy / Natella Y. Rakhmanina and John N. van den Anker -- Pharmacogenetics of psychoactive drugs / Jorge L. Sepulveda -- Pharmacogenomic aspects of adverse drug-drug interactions / Loralie J. Langman and Christine Snozek -- Microarray technology and other methods in pharmacogenomics testing / Jorge L. Sepulveda -- Pharmacogenetic testing in the clinical laboratory environment / Mark P. Borgman and Mark W. Linder.
  • Pharmacogenomics : historical perspective and current status / Rosane Charlab and Lei Zhang -- Denaturing high-performance liquid chromatography for mutation detection and genotyping / Donna Lee Fackenthal [and others] -- Clinical SNP detection by the smartAmp method / Toshihisa Ishikawa and Yoshihide Hayashizaki -- MALDI-TOF mass spectrometry / Dirk van den Boom, Matthias Wjst, and Robin E. Everts -- TaqMan® drug metabolism genotyping assays for the detection of human polymorphisms involved in drug metabolism / Toinette Hartshorne -- Pyrosequencing of clinically relevant polymorphisms / Cristi R. King and Sharon Marsh -- Pharmacogenetics using Luminex® xMAP® technology : a method for developing a custom multiplex single nucleotide polymorphism mutation assay / Gonnie Spierings and Sherry A. Dunbar -- Use of linkage analysis, genome-eide association studies, and next-generation sequencing in the identification of disease-causing mutations / Eric Londin [and others] -- GoldenGate genotyping assay : custom design, processing, and data analysis / Anna González-Neira -- Genome-wide gene expression profiling, genotyping, and copy number analyses of acute myeloid leukemia using affymetrix geneChips. / Mathijs A. Sanders and Peter J.M. Valk -- Epigenetic techniques in pharmacogenetics / Sandra G. Heil -- Plasmid derived external quality controls for genetic testing / Tahar van der Straaten and Henk-Jan Guchelaar -- Allelic imbalance assays to quantify allele-specific gene expression and transcription factor binding / Francesca Luca and Anna Di Rienzo -- SCAN : a systems biology approach to pharmacogenomic discovery / Eric R. Gamazon, R. Stephanie Huang, and Nancy J. Cox -- Methods to examine the impact of nonsynonymous SNPs on protein degradation and function of human ABC transporter / Toshihisa Ishikawa, Kanako Wakabayashi-Nakao, and Hiroshi Nakagawa -- In vitro identification of cytochrome P450 enzymes responsible for drug metabolism / Zhengyin Yan and Gary W. Caldwell -- In vitro and in vivo mouse models for pharmacogenetic studies / Amber Frick [and others] -- Hydrodynamic tail vein assay as a tool for the study of liver promoters and enhancers / Mee J. Kim and Nadav Ahituv -- Guide to the current web-based resources in pharmacogenomics / Dylan M. Glubb [and others] -- PharmGKB : the pharmacogenomics knowledge base / Caroline F. Thorn, Teri E. Klein, and Russ B. Altman -- Genetic databases in pharmacogenomics : the frequency of inherited disorders database (FINDbase) / Marianthi Georgitsi and George P. Patrinos -- Development of predictive models for estimating warfarin maintenance dose based on genetic and clinical factors / Lu Yang and Mark W. Linder -- Evidence based drug dosing and pharmacotherapeutic recommendations per genotype / Vera H.M. Deneer and Ron H.N. van Schaik.
  • Ch. 1. Pharmacogenomics principles of alcohol and DOA / Christine L.H. Snozek and Loralie J. Langman -- ch. 2. Alcohol : use and abuse / Amitava Dasgupta -- ch. 3. Slate and trait makers of alcohol abuse / Joshua Bornhorst ... [et al.] -- ch. 4. Introduction to drugs of abuse / Larry Broussard and Catherine Hammett-Stabler -- ch. 5. Pharmacogenomics of amphetamine and related drugs / Steven C. Kazmierczak -- ch. 6. Pharmacogenomics of cocaine / Loralie J. Langman and Christine L.H. Snozek -- ch. 7. Genetic aspect of marijuana metabolism and abuse / Pradip Datta -- ch. 8. Genetic aspect of opiate metabolism and addiction / Jorge L. Sepulveda -- ch. 9. Pharmacogenomics aspects of addiction treatment / F. Gerard Moeller -- ch. 10. Methodologies in pharmacogenetics testing / Jorge L. Sepulveda.
  • ch. 1. Physicochemistry -- ch. 2. Pharmacokinetics -- ch. 3. Absorption -- ch. 4. Distribution -- ch. 5. Clearance -- ch. 6 Renal clearance -- ch. 7. Metabolic (hepatic) clearance -- ch. 8. Toxicity -- ch. 9. Inter-species -- ch. 10. High(er) throughput ADME studies.
  • SECTION I. Basic Principles -- Chapter 1. Basic Principles / Ronald D. Schoenwald -- SECTION II. Industrial and Regulatory Applications -- Chapter 2. PK/PD Approach / Honghui Zhou -- Chapter 3. Pharmacokinetics and Metabolism in Drug Discovery and Preclinical Development / Nishit B. Modi -- Chapter 4. Phase I, II, and III FDA Submissions / Mark G. Eller -- Chapter 5. Bioavailability and Bioequivalence / Veneeta Tandon -- SECTION III. Clinical Applications -- Chapter 6. General Approaches to Clinical Pharmacokinetic Monitoring / Ronald A. Herman -- Chapter 7. Aminoglycosides and Other Antibiotics / Michael E. Klepser and Erika J. Ernst -- Chapter 8. Cardiovascular Agents / John M. Dopp and Bradley G. Phillips -- Chapter 9. Psychotropic Agents / Paul J. Perry -- Chapter 10. Theophylline / Bernd Meibohm -- Chapter 11. Anticonvulsant Agents / Gail D. Anderson -- SECTION IV. Research Applications -- Chapter 12. Classical Modeling / David W A. Bourne -- Chapter 13. Noncompartmental Modeling: An Overview / Ronald A. Herman -- Chapter 14. Physiologically Based Pharmacokinetic Models / James M. Gallo -- Chapter 15. Population Pharmacokinetics / Jeffrey S. Barrett -- Chapter 16. The Linear Systems Approach / Peter Veng-Pedersen -- Index.
  • This book is the 4th in a series of Acute Care books written with the aim to address the NEEDS of health care providers when handling the acutely ill patients. Globally it has become apparent that the study of pharmacology and subsequent clinical training has not always adequately equipped young doctors with the ability to administer drugs to their patients safely and confidently, particularly in the critically ill patient. Compounding this issue is the lack of resource material related to these pharmacological concepts contained in one book that can help health care providers to understand and manage drug therapy in the acute situation. In spite of progressively newer and more developed protocols, guidelines, algorithms and many other books addressing the technical aspects of what needs to be done, most health care providers still find it difficult to grasp the basic pharmacological knowledge and rationally deliver the CARE that is required in the acute phase of patient management. The editors/authors have therefore aimed for a book that highlights topics and pharmacological issues pertinent to management of patients in their hour of need. This is a multi-author book but the style has been guided by 3 editors. The editors have used a different perspective? that of normalizing abnormal physiological processes with pharmacological agents? to address the GAPS in a bedside to bench approach. The details are pared down but important principles/concepts are emphasized.
  • The natural world with a large number of terrestrial and marine plants and lower organisms is a great source of bioactive compounds historically used as remedies in various diseases. Within the last decade, such compounds became more attractive targets for pharmacologists and the pharmaceutical industry in drug development projects. This volume presents the pharmacological potential of chemically defined natural compounds obtained from plants, fungi, algae and cyanobacteria with antiparasitic activity, that have been tested against various endo-parasitic protozoan and helminth species. --Source other than Library of Congress.
  • Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs.
  • This book describes the clinical challenge currently posed by stable angina pectoris and provides guidance for those making clinical decisions regarding its pharmacological treatment. The importance of providing effective treatment is beyond dispute and this book deals with the most relevant aspects related to its pharmacological treatment. The pathogenesis of myocardial ischemia as the basis for rational treatment of angina is discussed thoroughly together with all major management goals including optimal symptom control and the secondary prevention of serious cardiovascular events. Pharmacological Treatment of Chronic Stable Angina Pectoris provides a clear description of the mechanisms of action and clinical indications of available anti-angina drugs and strategies for the use of novel pharmacological agents. It also includes a critical appraisal of the major management guidelines, which will assist the reader to interpret current evidence and provide the most appropriate forms of treatment. The ongoing controversy regarding medical therapy versus myocardial revascularization for the management of stable angina pectoris is also addressed. This eminently practical book will help guiding the reader through the complexities of the field and will be highly appreciated by clinicians, clinical cardiologists and cardiology trainees alike.
  • Pharmacology -- Pharmacokinetic Principles -- Introduction to Specialist Therapeutics.
  • 2013 ClinicalKey
    "Better understand the complexities of pharmacology and physiology relevant to your practice with the brand-new medical reference book, Anesthetic Pharmacology and Physiology. Drs. Hugh Hemmings and Talmage Egan provide the clinical insights you need to effectively administer anesthesia, ensuring patient safety and the most optimal outcomes. Access comprehensive, continually updated research on the physiology of organ systems and clinical topics in the pharmacology of anesthetic drugs. Quickly and easily reference the information you need through user-friendly tables, figures, and algorithms, all presented in lavish full color throughout. Understand the molecular mechanism of drug actions and identify key drug interactions that may complicate anesthesia with dedicated sections on these key areas"--Provided by publisher.
  • Everything you need to know about all of today's drugs in a coherent, easy-to-use format - from the underlying science through innovation, translation, regulation, and clinical implementation. This multimedia resource fills a critical need for a more clinically focused, user-friendly pharmacology reference. Evidence-based therapeutic guidelines facilitate decision making; and coverage of pharmacogenetics and pharmacogenomics, regenerative pharmacology, stem cell therapies, and the emerging field of individualized medicine keeps you at the forefront of the latest developments.
  • The double page spreads in this book each cover a discrete topic and broadly correspond to the chapters of the main textbook 'Pharmacology' by Rang et al. Each spread includes at least one summary diagram and a small amount of text plus a 'clinical use' box.
  • Chapter 1. Pharmacology: The Chemical Control of Physiology -- Chapter 2. Drug Affinity and Efficacy -- Chapter 3. Predicting Agonist Effect -- Chapter 4. Drug Antagonism: Orthosteric Drug Effects -- Chapter 5. Allosteric Drug Effects -- Chapter 6. Enzymes as Drug Targets -- Chapter 7. Pharmacokinetics I: Permeation and Metabolism -- Chapter 8. Pharmacokinetics II: Distribution and Multiple Dosing -- Chapter 9. In Vivo Pharmacology -- Chapter 10. Safety Pharmacology -- Chapter 11. Answers to Chapter Questions -- Chapter 12. Derivations and Proofs.
  • "This work is the first monograph devoted solely to Bombax ceiba, popularly known as the Red Silk Cotton Tree. Consisting of seven chapters, it covers all relevant aspects of this plant, from its historical and spiritual importance, to its botanical characterization, pharmacognostical details and ethnobiological uses, to its scientific validation in various animal and human studies. Each part of the tree is of medicinal value and possesses many novel chemical constituents such as shamimicin, bombasin, bombamalone, bombamaloside etc. along with other bioactive secondary metabolites. The book presents the chemical structures of the most important constituents and highlights various pharmacological activities, predominantly antioxidant, anti-inflammatory, anti-mutagenic, hypoglycemic, hypotensive, hepatoprotective and fibrinolytic, which may prove to be a source for the development of a novel phyto-pharmaceutical agent to treat diabetes, heart disease and cancer. In addition, separate chapters deal with the commercial and ecological significance of B. ceiba, as well as a case study on its conservation. Numerous color illustrations are included to identify the plant and to justify its nickname, the “Little Bird's Cafeteria”."--Publisher's website.
  • What is pharmacology? -- How different tissues process drug response -- Drug-receptor theory -- Pharmacological assay formats : binding -- Agonists : the measurement of affinity and efficacy in functional assays -- Orthosteric drug antagonism -- Allosteric drug antagonism -- The process of drug discovery -- Pharmacokinetics -- Target- and system-based strategies for drug discovery -- "Hit" to drug : lead optimization -- Statistics and experimental design -- Selected pharmacological methods -- Exercises in pharmacodynamics and pharmacokinetics.
  • "Pharmacology: An Illustrated Review covers the facts and concepts you must master for classroom and USMLE success--as well as key knowledge for daily clinical practice. Thieme's new illustrated Review Series serves an important dual purpose for medical students--both concise course review and high-yield USMLE test preparation. Covering all the basic science subjects that you will take in medical school and that will be found on the USMLE Step 1, the series features unparalleled color illustrations, a streamlined format, and hundreds of print and online study questions and answers--all designed to increase your mastery of the topic, promote classroom success, and boost your confidence for the exam! Combining targeted reviews of the basic sciences with a multitude of exam questions for easy reinforcement and retention, these efficient-to-study books put success at your fingertips"--Provided by publisher.
  • Pharmacology. 4th ed. 2013
    Pharmacology, 4th Edition helps you master the "must-know" concepts in this subject and how they apply to everyday clinical problem solving and decision making. This concise yet comprehensive text clearly explains and illustrates challenging concepts and helps you retain the material - from course exams and the USMLE Step 1 right through to clinical practice. Quickly reference essential information thanks to abundant tables throughout, and drug classification boxes at the beginning of each chapter. See how pharmacology applies to practice with real-world case studies. Prepare for exams with self-assessment questions at the end of each chapter. Understand complex concepts visually with the aid of superb full-color illustrations. Access the complete contents online at, along with an additional glossary, chapter-by-chapter summaries and case studies, a full list of featured drugs, 150 USMLE-style questions, animations, and more.
  • Although more than 10 new antiepileptic drugs have been developed in the past decade, epilepsy remains resistant to drug therapy in about one-third of patients, many of whom struggle with the disease their entire lives. Managing these patients is a challenge and requires a structured multidisciplinary approach. The book includes chapters on all issues related to pharmacoresistance in epilepsy, and describes recent developments in the pathogenesis and treatment of this disorder. It addresses abnormalities in inhibitory mechanisms, epilepsy-related changes to the immune system, development of pharmacoresistance caused by chronic exposure to antiepileptic drugs, and novel therapeutic strategies for preventing or slowing down the progression of the disease. Clinicians and basic scientists alike will find up-to-date information on the development of pharmacoresistance, as well as reviews of mechanisms associated with epilepsy that may help them consider novel strategies for preventing the development of pharmacoresistance in the first place. The book also features information on new therapeutic strategies for control of epilepsy, such as transcutaneous electrical stimulation and virtual screening of new antiepileptic drugs. Pharmacoresistance in Epilepsy: From Genes and Molecules to Promising Therapies is useful to anyone working in the field, whether they're studying epilepsy in the lab or treating it in a doctor's office.
  • This book is driven by the considerable progress made by novel imaging techniques in understanding the pathophysiology and evolution of aortic disease and its diagnosis. Despite the lack of symptoms in stable conditions, most aortic diseases have a high morbidity and mortality. New therapeutic strategies such as endovascular treatment and surgical techniques have appeared to improve conventional surgery in advanced phases of the disease, but until recently, medical treatment has focused on the control of cardiovascular risk factors using beta-blockers to reduce aortic wall stress by reducing blood pressure and heart rate. Pharmacotherapy in Aortic Disease updates the reader on the new medical treatment that are changing the natural history of these diseases. Leading experts have created a critical in-depth, yet concise, analysis of the available medical treatments for different aortic disease entities. Both basic research studies and clinical trials discussed in this book serve as a base for improving therapeutic management, delaying the need for surgery, and prolonging survival in these patients.
  • Definition and classification of pulmonary hypertension / Marc Humbert, David Montani, Oleg V. Evgenov, and Gérald Simonneau -- Pulmonary hypertension: pathophysiology and signaling pathways / Bradley A. Maron and Joseph Loscalzo -- Pulmonary hypertension: pathology / Peter Dorfmüller -- Pulmonary hypertension: biomarkers / Christopher J. Rhodes, John Wharton, and Martin R. Wilkins -- Rodent models of group 1 pulmonary hypertension / John J. Ryan, Glenn Marsboom, and Stephen L. Archer -- General supportive care / Ioana R. Preston -- Calcium-channel blockers in pulmonary arterial hypertension / Marie-Camille Chaumais, Elise Artaud Macari, and Olivier Sitbon -- Prostacyclins / Horst Olschewski -- Endothelin Receptor Antagonists / Martine Clozel, Alessandro Maresta, and Marc Humbert -- Phosphodiesterase-5 inhibitors / Barbara A. Cockrill and Aaron B. Waxman -- Inhaled nitric oxide for the treatment of pulmonary arterial hypertension / Steven H. Abman -- Soluble guanylate cyclase stimulators in pulmonary hypertension / Johannes-Peter Stasch and Oleg V. Evgenov -- Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction / Michael G. Risbano and Mark T. Gladwin -- Rho-kinase inhibitors / Yoshihiro Fukumoto and Hiroaki Shimokawa -- Serotonin transporter and serotonin receptors / Serge Adnot, Amal Houssaini, Shariq Abid, Elisabeth Marcos, and Valérie Amsellem -- Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension / Eva Berghausen, Henrik ten Freyhaus, and Stephan Rosenkranz -- Emerging molecular targets for anti-proliferative strategies in pulmonary arterial hypertension / Ly Tu and Christophe Guignabert -- Anti-inflammatory and immunosuppressive agents in PAH / Jolyane Meloche, Sébastien Renard, Steeve Provencher, and Sébastien Bonnet -- Vasoactive peptides and the pathogenesis of pulmonary hypertension: role and potential therapeutic application / Reshma S. Baliga, Raymond J. MacAllister, and Adrian J. Hobbs -- Pulmonary hypertension: novel pathways and emerging therapies inhibitors of cGMP and cAMP metabolism / Yassine Sassi and Jean-Sébastien Hulot -- Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers) / Geoffrey Watson, Eduardo Oliver, Lan Zhao, and Martin R. Wilkins -- Pulmonary hypertension: current management and future directions / Lewis J. Rubin.
  • v. 2, 2011 Springer
    Vol. 1 / (ix, 306 p.) -- v. 2. / (x, 301 p.).
  • Placebo 2014
    Due to the recent explosion of placebo research at many levels the Editors believe that a volume on Placebo would be a good addition to the Handbook of Experimental Pharmacology series. In particular, this volume will be built up on a meeting on Placebo which will be held in Tuebingen (Germany) in January 2013, and where the most prominent researchers in this field will present and exchange their ideas. The authors who will be invited to write chapters for this volume will be the very same speakers at this meeting, thus guaranteeing high standard and excellence in the topic that will be treated. The approach of the book is mainly pharmacological, including basic research and clinical trials, and the contents range from different medical conditions and systems, such as pain and the immune system, to different experimental approaches, like in vivo receptor binding and pharmacological/behavioral conditioning. Overall, the volume will give an idea of modern placebo research, of timely concepts in both experimental and clinical pharmacology, as well as of modern methods and tools in neuroscience.
  • Plant vaccines: an immunological perspective / D.C. Hooper -- Display of peptides on the surface of tobacco mosaic virus particles / M.L. Smith ... [et al.] -- Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality / S. Chebolu and H. Daniell -- Production of antibodies in plants: approaches and perspectives / K. Ko, R. Brodzik and Z. Steplewski -- Plant production of veterinary vaccines and therapeutics / R.W. Hammond and L.G. Nemchinov -- Plant-based oral vaccines: results of human trials / C.O. Tacket.
  • Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem.
  • Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed "too early" to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest.
  • Preface -- Introduction -- Prescription assessment -- Availability of medicines -- Oral solids -- Oral liquids -- Pulmonary -- Oropharynx -- Nose -- Ear -- Eye -- Rectal and vaginal -- Dermal -- Parenteral -- Irrigation and dialysis -- Product design -- Biopharmaceutics -- Quality risk management -- Physical chemistry -- Microbiology -- Statistics -- Radiopharmacy -- Stability -- Raw materials -- Containers -- Human resources -- Occupational health and safety -- Premises -- Equipment -- Basic operations -- Sterilisation methods -- Aseptic handling -- Quality requirements and analysis -- Documentation -- Production, Validation Quality Control -- Quality systems -- Logistics -- Instructions for the use of medicines -- Impact on Environment -- Information sources -- Index.
  • Introduction -- Preventive and predictive genetics: a perspective -- Roadmap to drug development enabled by pharmacogenetics -- Pharmacogenetics, statistical considerations -- Pharmacokinetics and pharmacogenetics: bringing the magic bullet closer to reality -- Pharmacogenetics of adverse drug reactions -- Pharmacogenomics for haemoglobinopathies therapeutics -- Pharmacogenetics of neurodegenerative disorders -- Pharmacogenetics of asthma -- Pharmacogenetics and antineoplastic therapies -- Pharmacogenetics of coumarin anticoagulant therapy -- Implementation of genomic medicine: tools and challenges -- Ethical considerations in the genomic era -- Index.
  • Preface -- Part 1. An Overview of Safety Pharmacology and its Role in Drug Discovery -- Part 2. The Safety Pharmacology Core Battery -- Part 3. Supplemental Safety Pharmacology -- Part 4. Safety Pharmacology of Biological and Anticancer Pharmaceuticals -- Part 5. Clinical Safety Pharmacology.
  • Progress in drug research v. 62-, 2005-
  • The misfolding and aggregation of specific proteins is an early and obligatory event in many of the age-related neurodegenerative diseases of humans, and appears to occur many years before the onset of clinical symptoms. The initial cause of this pathogenic cascade and the means whereby disease spreads through the nervous system, remain uncertain. A recent surge of research, first instigated by pathologic similarities between prion disease and Alzheimer's disease, has increasingly implicated corruptive protein templating, or seeding, as a prime factor in the neurodegenerative process. The prion-like corruption of proteins also characterizes such clinically and etiologically diverse neurological disorders as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Understanding the misfolding, aggregation, trafficking and pathogenicity of affected proteins thus could reveal universal principles and common therapeutic targets for some of the most devastating and intractable human brain disorders.
  • Establishment of adventitious root cultures of Echinacea purpurea for the production of caffeic acid derivatives / K.Y. Paek, H.N. Murthy and E.J. Hahn -- In vitro propagation of Rauwolfia serpentina using liquid medium, assessment of genetic fidelity of micropropagated plants, and simultaneous quantitation of reserpine, ajmaline, and ajmalicine / M.K. Goel ... [et al.] -- Medicinal properties, in vitro protocols and secondary metabolite analyses of Scots pine / H. Haggman ... [et al.] -- Saussurea medusa cell suspension cultures for flavonoid production / C.Z. Liu and P.K. Saxena -- Large-scale in vitro multiplication of Crataeva nurvala / S.B. Babbar, N. Walia and A. Kaur -- Bilberry in vitro protocols and analyses of phenolic compounds / L. Jaakola ... [et al.] -- In vitro propagation of two tuberous medicinal plants: Holostemma ada-kodien and Ipomoea mauritiana / S.P. Geetha ... [et al.] -- In vitro production of gymnemic acid from Gymnema sylvestre (Retz) R. Br. Ex Roemer and Schultes through callus culture under abiotic stress conditions / A.B. Ali Ahmed, A.S. Rao and M.V. Rao -- Establishment of plant regeneration and cryopreservation system from zygotic embryo-derived embryogenic cell suspension cultures of Ranunculus kazusensis / S.W. Kim and M.J. Oh -- In vitro culture and secondary metabolite isolation in bryophytes / A. Sabovljevic, M. Sabovljevic and N. Jockovic -- Micropropagation and in vitro conservation of vanilla (Vanilla planifolia Andrews) / M. Divakaran and K.N. Babu -- Protocol for in vitro regeneration and marker glycoside assessment in Swertia chirata Buch-Ham / S. Koul ... [et al.] -- Protocols for establishment of an in vitro collection of medicinal plants in the genus Scutellaria / I.B. Cole, F.T. Farooq and S.J. Murch -- Protocols for in vitro culture and phytochemical analysis of Phyllanthus species (Euphorbiaceae) / E. Catapan ... [et al.] -- In vitro clonal propagation of Asparagus racemosus, a high value medicinal plant / S. Saxena and N. Bopana -- Micropropagation of Penthorum chinense through axillary buds / J. Yang and Z.S. Peng -- Spontaneous plant regeneration and production of secondary metabolites from hairy root cultures of Centaurium erythraea Rafn / A. Subotic ... [et al.] -- Transgenic Hypericum perforatum / G. Franklin, M.M. Oliveira and A.C. Dias -- Agrobacterium-mediated transformation of Ruta graveolens L / K. Lievre ... [et al.] -- Gene expression profiling in Taxus baccata L. seedlings and cell cultures / K. Brun akova and J. Kosuth -- Catapol production in Chinese foxglove (Rehmannia glutinosa Libos.) hairy roots transformed with Agrobacterium rhizogenes ATCC15834 / S.J. Hwang -- Identification of medicinal plants and plant sequences: multiplexed MLPA assay / R.A. Barthelson -- Isolation of microsatellites from Catharanthus roseus (L.) G. Don using enriched libraries / S. Bhatia and B. Shokeen -- Production of cinnamyl glycosides in compact callus aggregate cultures of Rhodiola rosea through biotransformation of cinnamyl alcohol / Z. Gyorgy and A. Hohtola -- Spearmint plantlet culture system as a means to study secondary metabolism / B. Tisserat, M. Berhow and S.F. Vaughn -- Bioreactor production of secondary metabolites from cell cultures of periwinkle and sandalwood / J.V. Valluri -- Camptothecin production by in vitro cultures and plant regeneration in Ophiorrhiza species / T. Asano ... [et al.] -- Metabolomic analysis of Ocotea odorifera cell cultures: a model protocol for acquiring metabolite data / M. Maraschin ... [et al.] -- Production of 9-methoxycanthin-6-one from callus cultures of (Eurycoma longifolia Jack) Tongkat Ali / M. Maziah and N. Rosli -- Plant secondary metabolism in altered gravity / L.K. Tuominen, L.H. Levine and M.E. Musgrave -- The role of biotechnology in the production of the anticancer compound podophyllotoxin / H. Lata, C.S. Mizuno and R.M. Moraes.
  • 1 Challenges and Opportunities for Biotech Quality by Design -- 2 Lessons Learned From Monoclonal Antibody Applications to the Office of Biotechnology Products Quality by Design Pilot Program -- 3 Definitions and Scope of Key Elements of QbD -- 4 An Overview of Quality by Design for Drug Product -- 5 Development of Drug Product Formulations: Molecular Design and Early Candidates Screening -- 6 Approaches for Early Developability Assessment of Proteins to Guide Quality by Design of Liquid Formulations -- 7 Application of QbD Principles to Late-stage Formulation Development for Biological Liquid Products -- 8 Application of QbD Principles for Lyophilized Formulation Development -- 9 Drug Substance Frozen Storage and Thawing -- 10 Quality by Design as Applied to Drug Substance Formulation using Ultrafiltration and Diafiltration -- 11 A QbD Approach in the Development and Scale-up of Mixing Processes -- 12 Application of QbD Elements in the Development and Scale-up of a Commercial Filtration Process -- 13 Application of QbD Elements in the Development and Scale-up of Commercial Filling Process -- 14 Lyophilization Process Design and Development Using QbD Principles -- 15 Visible and Subvisible Protein Particle Inspection Within a QbD-based Strategy -- 16 Quality by Design for Distribution of Environmentally Sensitive Pharmaceutical Products -- 17 Quality by Design for Primary Container Components -- 18 Devices and Combination Products for Biopharmaceuticals -- 19 Applicability of QbD for Vaccine Drug Product Development -- 20 Automation and High Throughput Technologies in Biopharmaceutical Drug Product Development with QbD Approaches -- 21 Critical Quality Attributes, Specifications, and Control Strategy -- 22 Multivariate Analysis for Process Understanding, Monitoring, Control and Optimization in Lyophilization Processes -- 23 Using Mathematical Modeling and Prior Knowledge for QbD in Freeze-drying Processes -- 24 Application of Multivariate Statistical Process Monitoring to Lyophilization Process -- 25 Application of PAT in Real-time Monitoring and Controlling of Lyophilization Process -- 26 Product Homogeneity Assessment during Validation of Biopharmaceutical Drug Product Manufacturing Processes -- 27 Application of Quality by Design Principles to the Drug Product Technology Transfer Process -- 28 Regulatory Considerations For Implementation of the QbD Paradigm for Biologics: Laying the Foundation for Product and Process Lifecycle Management.
  • Overview of quantitative drug design -- Noncovalent interactions in biological systems -- Preparation of 3D structures of molecules for 3D QSAR -- Calculating physical properties of molecules -- Biological data -- Form of equations that relate potency and physical properties -- Statistical basis of regression and partial least-squares analysis -- Strategy for the statistical evaluation of a data set of related molecules -- Detailed examples of QSAR calculations on erythromycin esters -- Case studies -- Methods to approach other structure-activity problems.
  • "This comprehensive overview details the process of radiopharmaceutical development, from cellular studies to animal experiments to the design and implementation of clinical trials. It examines the relative benefits of various radiopharmaceuticals and provides guidance on dose estimation and agent selection. Utilizing figures of merit for quantitative assessment, it covers standard medical internal radiation dose (MIRD), absorbed dose method for imaging agents, vivo methods for obtaining activity data, errors of activity estimation techniques, phantom-based and patient-based dose estimates and their associated uncertainties, and options available to clinical physicists. Supported by numerous examples from clinical trials, it discusses two and three dimensional estimation processes, including modern hybrid scanners such as SPECT/CT and PET/CT"--Provided by publisher.
  • What is pharmacology? -- How drugs act : general principles -- How drugs act : molecular aspects -- How drugs act : cellular aspects, excitation, contraction and secretion -- Cell proliferation, apoptosis, repair and regeneration -- Cellular mechanisms : host defence -- Method and measurement in pharmacology -- Absorption and distribution of drugs -- Drug metabolism and elimination -- Pharmacokinetics -- Individual variation, pharmacogenomics and personalised medicine -- Chemical mediators and the autonomic nervous system -- Cholinergic transmission -- Noradrenergic transmission -- 5-Hydroxytryptamine and the pharmacology of migraine -- Purines -- Local hormones 1 : histamine and the biologically active lipids -- Local hormones 2 : peptides and proteins -- Cannabinoids -- Nitric oxide and related mediators -- The heart -- The vascular system -- Atherosclerosis and lipoprotein metabolism -- Haemostasis and thrombosis -- Haemopoietic system and treatment of anaemia -- Anti-inflammatory and immunosuppressant drugs -- Skin -- Respiratory system -- The kidney and urinary system -- The gastrointestinal tract -- The control of blood glucose and drug treatment of diabetes mellitus -- Obesity -- The pituitary and the adrenal cortex -- The thyroid -- The reproductive system -- Bone metabolism -- Chemical transmission and drug action in the central nervous system -- Amino acid transmitters -- Other transmitters and modulators -- Neurodegenerative diseases -- General anaesthetic agents -- Analgesic drugs -- Local anaesthetics and other drugs affecting sodium channels -- Anxiolytic and hypnotic drugs -- Antiepileptic drugs -- Antipsychotic drugs -- Antidepressant drugs -- CNS stimulants and psychotomimetic drugs -- Drug addiction, dependence and abuse -- Basic principles of antimicrobial chemotherapy -- Antibacterial drugs -- Antiviral drugs -- Antifungal drugs -- Antiprotozoal drugs -- Anthelmintic drugs -- Anticancer drugs -- Harmful effects of drugs -- Lifestyle drugs and drugs in sport -- Biopharmaceuticals and gene therapy -- Drug discovery and development.
  • 1. Pharmacokinetics -- 2. Pharmacodynamics -- 3. Introduction to Autonomic and Neuromuscular Pharmacology -- 4. Cholinergic Drugs -- 5. Adrenergic Drugs -- 6. Muscle Relaxants -- 7. CNS Introduction, and Sedative-Hypnotic and Anxiolytic Drugs -- 8. Anesthetics -- 9. Anticonvulsant Drugs -- 10. Psychotherapeutic Drugs -- 11. Drugs Used in the Treatment of Parkinson's Disease -- 12. Antiarrhythmic Drugs -- 13. Antihypertensive Drugs -- 14. Other Cardiovascular Drugs -- 15. Diuretics -- 16. Drugs Used in the Treatment of Coagulation Disorders -- 17. Hematopoietic Drugs -- 18. Nonsteroidal Anti-Inflammatory Drugs and other Nonopioid Analgesic-Antipyretic Drugs -- 19. Opioid Analgesics and Antagonists -- 20. Drugs Used in the Treatment of Asthma, Chronic Obstructive Pulmonary Disease and Allergies -- 21. Drugs Used in the Treatment of Gastrointestinal Disorders -- 22. Immunosuppressive Drugs and Drugs Used in the Treatment of Rheumatic Disorders and Gout -- 23. Drugs Used in the Treatment of Hypothalamic, Pituitary, Thyroid, and Adrenal Disorders -- 24. Drugs Used in the Treatment of Diabetes Mellitus and Errors of Glucose Metabolism -- 25. Drugs Used in the Treatment of Bone and Calcium Disorders -- 26. Drugs Used in Reproductive Endocrinology -- 27. Antimicrobial Drugs -- 28. Other Anti-Infective Drugs -- 29. Chemotherapeutic Drugs -- 30. Toxicology and Drugs of Abuse Common Laboratory Values.
  • "Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer's disease could be stabilized by one or both these drugs."--P. [4] of cover.
  • "Regenerative medicine is broadly defined as the repair or replacement of damaged cells, tissues, and organs. It is a multidisciplinary effort in which technologies derive from the fields of cell, developmental, and molecular biology; chemical and material sciences (i.e., nanotechnology); engineering; surgery; transplantation; immunology; molecular genetics; physiology; and pharmacology. As regenerative medicine technologies continue to evolve and expand across the boundaries of numerous scientific disciplines, they remain at the forefront of the translational research frontier with the potential to radically alter the treatment of a wide variety of disease and dysfunction. The goal of this book is to draw attention to the critical role that the pharmacological sciences will undeniably play in the advancement of these treatments. This book is invaluable for advanced students, postdoctoral fellows, researchers new to the field of regenerative medicine/tissue engineering, and experienced investigators looking for new research avenues. This is the first state-of-the-art book in this rapidly evolving field of research"--Provided by publisher.
  • This book is designed for advanced students and researchers in cell biology, biochemistry, molecular biology, medicine in general, and cancer in particular. It provides the latest data on the transcriptome of the mammary gland in order to establish the molecular and cellular biology of differentiation leading to cancer prevention. The authors have based their work on the epidemiological evidence that early first full term pregnancy is a protective factor in humans against breast cancer and using this knowledge have developed in vivo and in vitro experimental systems that have demonstrated mechanistically how the differentiation takes place. The transcriptoma analysis of the female breast shows that an early first full term pregnancy reprograms the organ by imprinting a genomic signature that differs according to reproductive history. This reprogramming takes place at the chromatin level by changing the transcriptional process. The modification of the transcriptional control is due to the expression of non-coding RNA sequences and post-transcriptional control driven by the spliceosome. The plasticity of the genome of the human breast makes possible this reprogramming that is not only induced by the physiological process of pregnancy but by the use of hormones mimicking pregnancy. The role of stem cells and their reprogramming during differentiation are presented as a new paradigm in breast cancer prevention.
  • "This book covers the regulatory required evaluation and study of the potentially adverse pharmacological effects of new drugs, from the general regulatory requirements to the specific studies that must be done and how they are performed and interpreted. Based on more than 30 years of direct experience, the author describes tricks and practical insights for making studies work and understanding why they don't. The second edition includes current regulations (US FDA and international especially Europe and Japan) and updated test methods, interpretation, and science"--Provided by publisher.
  • This is the very first book to deal with sex and gender differences in drug therapy - an increasingly recognized medical need. It starts with an overview on S/G in clinical syndromes and a documentation of the medical and socioeconomic damage caused by gender specific adverse drug effects. Part I covers S/G differences in pharmacokinetics. Researchers will be satisfied by the detailed discussion of the mechanisms of S/G differences in drug effects that represents cutting edge science and includes interaction of drugs with sex hormones, genomic and epigenetic mechanisms. It also covers S/G in drug development, in animal models and clinical development and S/G in drug prescriptions. Part II targets S/G differences in drug effects in cardiovascular, pulmonary, CNS, neuromuscular, neuropsychiatric and metabolic diseases, in cancer, inflammation, and rheumatic diseases, in bacterial and retroviral infections, thrombosis, embolism. New drugs will be discussed.
  • Sphingolipids are lipid components of the plasma membrane in eukaryotic cells. They have an important function in signaling mechanisms in the cell. This book on sphingolipids provides insights into the basics of sphingolipid biology and drug development, with a particular emphasis on the sphingolipid derivative ceramide. In the first part basic functions of sphingolipids are described, as well as the genetics of important enzymes, sphingolipid metabolism and synthesis. The second part of this first volume focuses on drug development and pharmacology. The book is intended for scientists in pharmacology, biochemistry and cell biology with a focus on biomedical research as well as for clinicians working in pharmacology, oncology, cardiology, neurology and infectious disease. Together with Volume 216 by the same editors, the collection represents a unique, comprehensive work on sphingolipids, providing information on both sphingolipids' basic biology (including synthesis, metabolism and cell biology) and their important function in a (patho-)physiological context.
  • Sphingolipids in Cancer. Sphingosine Kinase/Sphingosine 1-Phosphate Signaling in Cancer Therapeutics and Drug Resistance / Shanmugam Panneer Selvam, Besim Ogretmen -- Using ASMase Knockout Mice to Model Human Diseases / Guoqiang Hua, Richard Kolesnick -- New Perspectives on the Role of Sphingosine 1-Phosphate in Cancer / Susan Pyne, Nigel J. Pyne -- Sphingolipids and Response to Chemotherapy / Marie-Thérèse Dimanche-Boitrel, Amélie Rebillard -- Lung Cancer and Lung Injury: The Dual Role of Ceramide / Tzipora Goldkorn, Samuel Chung, Simone Filosto -- Sphingolipids' Role in Radiotherapy for Prostate Cancer / Carla Hajj, Adriana Haimovitz-Friedman -- Sphingolipids in Cardio-Reno-vascular Diseases. Sphingolipid Metabolism and Atherosclerosis / Xian-Cheng Jiang, Jing Liu -- Cardiovascular Effects of Sphingosine-1-Phosphate (S1P) / Bodo Levkau -- Cross Talk Between Ceramide and Redox Signaling: Implications for Endothelial Dysfunction and Renal Disease / Pin-Lan Li, Yang Zhang -- Sphingolipids in Inflammation, Infection and Lung Diseases. Sphingolipids in Lung Endothelial Biology and Regulation of Vascular Integrity / Taimur Abbasi, Joe G. N. Garcia -- Sphingolipids in Acute Lung Injury / Stefan Uhlig, Yang Yang -- The Involvement of Sphingolipids in Chronic Obstructive Pulmonary Diseases / Irina Petrache, Daniela N. Petrusca -- Ceramide in Cystic Fibrosis / Heike Grassmé, Joachim Riethmüller, Erich Gulbins -- Regulation of the Sphingosine Kinase/Sphingosine 1-Phosphate Pathway / K. Alexa Orr Gandy, Lina M. Obeid -- Bacterial Infections and Ceramide / Heike Grassmé, Katrin Anne Becker -- Viral Infections and Sphingolipids / Jürgen Schneider-Schaulies, Sibylle Schneider-Schaulies -- Ceramide in Plasma Membrane Repair / Annette Draeger, Eduard B. Babiychuk -- Sphingolipids and Inflammatory Diseases of the Skin / Burkhard Kleuser, Lukasz Japtok -- Sphingolipids in Obesity, Type 2 Diabetes, and Metabolic Disease / S. B. Russo, J. S. Ross, L. A. Cowart -- Sphingolipids in Neuro-psychiatry and Muscle Diseases. Neuronal Forms of Gaucher Disease / Einat B. Vitner, Anthony H. Futerman Sphingolipids in Neuroinflammation / Laura Davies, Klaus Fassbender, Silke Walter -- Sphingolipids in Psychiatric Disorders and Pain Syndromes / C. Mühle, M. Reichel, E. Gulbins, J. Kornhuber -- Role of Sphingosine 1-Phosphate in Skeletal Muscle Cell Biology / Paola Bruni, Chiara Donati.
  • "This volume focuses on the role of sphingosine-1-phosphate (S1P) and its analogs in the induced sequestration of lymphocytes in secondary lymphoid organs or in the microenvironment of tissues involved in infection or autoimmune disease. Initial chapters define the pathways to understand S1P signaling. They cover the organization of signaling systems, the structural biology of the S1P1 receptor, and the chemical and genetic tools that are available and useful to explore this area of research and therapeutics. The later chapters highlight S1P and endothelial integrity, lymphocyte migration in the spleen, and S1P agonist in controlling immunopathologic manifestations of acute respiratory influenza virus infection (in the lung), and its accompanying cytokine storm as well as immunopathologic disease of the central nervous system, including the beginning of treatments in multiple sclerosis. One chapter reveals the possible involvement of other lipid molecules, their use for better understanding lipid signaling, and their potential in the modulation of immune responses."--Publisher's website.
  • This comprehensive book encompasses various facets of sterile product development. Key concepts relevant to the successful development of sterile products are illustrated through case studies and are covered under three sections in this book: Formulation approaches that discuss a variety of dosage forms including protein therapeutics, lipid-based controlled delivery systems, PEGylated biotherapeutics, nasal dosage form, and vaccines, Process, container closure and delivery considerations including freeze-thaw process challenges, best practices for technology transfer to enable commercial product development, innovations and advancement in aseptic fill-finish operations, approaches to manufacturing lyophilized parenteral products, pen / auto-injector delivery devices, and associated container closure integrity testing hurdles for sterile product closures, Regulatory and quality aspects in the areas of particulate matter and appearance evaluation, sterile filtration, admixture compatibility considerations, sterilization process considerations, microbial contamination investigations and validation of rapid microbiological methods, and dry and moist heat sterilizers This book is a useful resource to scientists and researchers in both industry and academia, and it gives process and product development engineers insight into current industry practices and evolving regulatory expectations for sterile product development.
  • Stratified medicine : a new challenge for academia, industry, regulators and patients -- Stratified medicine : a new era in the therapeutic approach -- Challenges for academic medicine and clinicians -- Challenges for diagnostics industry -- Challenges for the pharmaceutical industry -- Separate or codevelopment of biomarker and drug : the scenarios -- Challenges for the regulatory agencies in establishing an environment favorable for stratified medicine -- Challenges for the patients facing stratified medicine & personal genomics -- Conclusions & outlook to the future health system -- Stratified medicine : a challenging social experiment.
  • Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a "failed morning after contraceptive" to become the "gold standard" for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
  • This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia.
  • Basics of Personalized Medicine -- Molecular Diagnostics as Basis of Personalized Medicine -- Role of Biomarkers in Personalized Medicine -- Pharmacogenetics -- Pharmacogenomics -- Role of Pharmacoproteomics -- Role of Metabolomics in Personalized Medicine -- Personalized Biological Therapies -- Development of Personalized Medicine -- Personalized Therapy for Cancer -- Personalized Management of Neurological Disorders -- Personalized Therapy of Cardiovascular Diseases -- Personalized Management of Miscellaneous Disorders -- Personalized Preventive Medicine -- Organization of Personalized Medicine -- Ethical and Regulatory Aspects of Personalized Medicine -- Economics of Personalized Medicine -- Future of Personalized Medicine.
  • Setting up a Kinase Discovery and Development Project / Gideon Bollag -- Drug Efficacy Testing in Mice / William Y. Kim, Norman E. Sharpless -- Gastrointestinal Stromal Tumors / Cristina Antonescu -- EGFR Mutant Lung Cancer / Yixuan Gong, William Pao -- Targeting Oncogenic BRAF in Human Cancer / Christine A. Pratilas, Feng Xing, David B. Solit -- Beyond BRAF in Melanoma / Adil Daud, Boris C. Bastian -- JAK-Mutant Myeloproliferative Neoplasms / Ross L. Levine -- Will Kinase Inhibitors Make it as Glioblastoma Drugs? / Ingo K. Mellinghoff, Nikolaus Schultz, Paul S. Mischel -- Predictive Genomic Biomarkers / Rakesh Kumar, Rafael G. Amado -- Epigenetic Biomarkers / Timothy A. Chan, Stephen B. Baylin -- Adjuvant Trials of Targeted Agents: The Newest Battleground in the War on Cancer / Robert L. Cohen.
  • Overview of drug development / James A. Popp and Jeffery A. Engelhardt -- Nonclinical safety evaluation of drugs / Thomas M. Monticello and Jeanine L. Bussiere -- Toxicokinetics and drug metabolism : relating toxicity to compound exposure and disposition / David D. Christ -- Introduction to toxicologic pathology / Judit E. Markovits ... [et al.] -- Routine and special techniques in toxicologic pathology / Daniel J. Patrick, Peter C. Mann -- Principles of clinical pathology / Robert L. Hall -- Toxicogenomics in toxicologic pathology / Mark J. Hoenerhoff and David E. Malarkey -- Spontaneous lesions in control animals used in toxicity studies / Robert C. Johnson, Robert H. Spaet, Daniel L. Potenta -- Gastrointestinal tract / Judit E. Markovits -- Liver, gall bladder, and exocrine pancreas / Russell C. Cattley, James A. Popp, Steven L. Vonderfecht -- Respiratory system / David J. Lewis and Tom P. McKevitt -- Urinary system / Kendall S. Frazier and John Curtis Seely -- Hematopoietic system / Kristin Henson, Glenn Elliott, Gregory S. Travlos -- The lymphoid system / Patrick J. Haley -- Bone, muscle, and tooth / John L. Vahle ... [et al.] -- The cardiovascular system / Calvert Louden, David Brott -- Endocrine glands / Sundeep Chandra, Mark Hoenerhoff, Richard Peterson -- Reproductive system and mammary gland / Justin D. Vidal ... [et al.] -- Skin / Zbigniew Wojcinski ... [et al.] -- Nervous system / Mark T. Butt, Robert Sills, Alys Bradley -- Special senses : eye and ear / James A. Render, Kenneth A. Schafer, Richard A. Altschuler.
  • "Circulation of blood is vital for the survival of vertebrates, including man. Mainly, it plays an important role in carrying food nutrients and oxygen to every tissue and organ and in removing all waste products and carbon dioxide. Any imbalance in the hemostatic and cardiovascular systems can lead to death and severe debility. A number of animals have developed mechanisms to target these systems and exploit the vulnerability. In some species (for example, snakes), such mechanisms are used to immobilize and kill the victim/prey, whereas in others (for example, insects, such as leaches, mosquitoes and ticks), they are used to provide a continuous supply of blood. These mechanisms include, but are not limited to, procoagulant and anticoagulant actions that affect the coagulation cascade and platelet aggregation, as well as altering vasodilatory responses. In all these various animals, these mechanisms have evolved to perfection over millions of years to support their survival. In last 3-4 decades, due to the efforts of scientists from various backgrounds including biology, protein chemistry, molecular biology, pharmacology, hematology, and structural biology, significant progress in understanding the structure-function relationships, as well as the mechanism of action have been made in a number of exogenous factors that affect blood coagulation, platelet aggregation and vasodilation from various animals. These exogenous factors have contributed significantly to the development of research tools as well as providing new therapeutic agents."
  • "Skin, once thought to be an impenetrable barrier, is an extremely active organ capable of interacting with its environment. Advancements in science combined with the need for diverse drug delivery modalities have introduced a variety of transdermal and intradermal products for existing drugs at a fraction of the cost of new drug development. Commercialization of transdermal drug delivery requires technology from many disciplines beyond pharmaceutical sciences, such as polymer chemistry, adhesion sciences, mass transport, web film coating, printing, and medical technology. A comprehensive discussion of these technologies and practices, Transdermal and Intradermal Delivery of Therapeutic Agents: Application of Physical Technologies, covers: Commercial development of devices and products based on transdermal physical enhancement technologies, Selecting optimal enhancement technology for a specific drug molecule using case studies that cover physicochemical properties as well as practical commercial considerations related to cost, unmet clinical needs, marketing, or intellectual property protection, Technologies such as microneedles, iontophoresis, electroporation, and sonophoresis with examples for delivery of small molecules, cosmeceuticals, proteins, and vaccines, Practical information on experimental procedures and challenges related to skin irritation and safety issues. Up-to-date and accessible to researchers and industry experts, this book provides a comprehensive discussion of the physical approaches and practical considerations for the laboratory and marketplace"--Provided by publisher.
  • This book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development. Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
  • Transporters in Drug Development is a corner stone in a high profile book series on advances in pharmaceutical sciences initiated by AAPS, Springer and Professor Daan Crommelin as series Editor. Transporters in Drug Development: Discovery, Optimization, Clinical Study and Regulation list chapters written by leading researchers in the transporter field from academia, pharmaceutical industry and medicines agencies. The book encompasses examples and advises on how membrane transporters can be dealt with in academic industrial drug discovery and pharmaceutical development as well as from a regulatory perspective. Methods and examples of in vitro characterization of single transporters in intestine, liver and kidney are described as well as characterization of substrate overlap between various transporters. Furthermore, probes and biomarkers are suggested for studies of the transporters impact on the pharmacokinetics of drug substrates/candidates interacting on transporters. The challenges of translating in vitro observed interaction of transporters into in vivo relevance are discussed as well as the perspectives of applying targeted proteomics and mechanistic modelling in this process.
  • TRP channels in drug discovery v.1-2=, 2012
    Springer Protocols
    2nd ed., 2014 Springer Protocols
    V. 1. Introduction to TRPs : a quest for novel drug targets / Bernd Nilius -- TRP-mediated cytoskeletal reorganization : implications for disease and drug development / Chandan Goswami -- TRPA1 in drug discovery / Jun Chen, Steve McGaraughty, and Philip R. Kym -- Canonical transient receptor potential channel expression, regulation, and function in vascular and airway diseases / Brij B. Singh, Christina M. Pabelick, and Y.S. Prakash -- TRPM2 function and potential as a drug target / Barbara A. Miller -- Ca2+-activated monovalent cation-selective channels TRPM4 and TRPM5 / Barbara Colsoul ... [et al.] -- Emerging role of TRPM7 in the regulation of magnesium homeostasis / Vladimir Chubanov ... [et al.] -- TRPM8 channels as potential therapeutic targets for pain, analgesia, and thermoregulation / David D. McKemy -- TRPML channels in function, disease, and prospective therapies / David A. Zeevi -- TRPP signaling module : TRPP2/polycystin-1 and TRPP2/PKD1L1 / Alexis Hofherr -- TRPV1 as a polymodal sensor : potential to discover TRPV1 antagonists selective for specific activating modalities / Olivier Radresa ... [et al.] -- Nociceptive and nonnociceptive roles of TRPV3 and its "druggability" / Sungjae Yoo and Sun Wook Hwang -- TRPV4 and drug discovery / Fabien Vincent and Matthew A.J. Duncton -- TRP expression and function in the lung airways / Alexander Dietrich and Thomas Gudermann -- Hypoxia-dependent TRP channel function in pulmonary arterial smooth muscle cells / Beate Fuchs ... [et al.] -- Endotoxin-induced airway inflammation and asthma models / Zsuzsanna Helyes and Zsofia Hajna -- Enhanced cough, animal models / Raffaele Gatti ... [et al.] -- Capsaicin inhalation test in man / Eva Millqvist -- TRP channels in the genitourinary tract / Ana Charrua and Francisco Cruz -- Animal models of cystitis / Celia D. Cruz and Antonio Avelino -- Overactive bladder models / Roberto Soler ... [et al.] V. 2. TRPs to cardiovascular disease / José C. González-Cobos, Xuexin Zhang, Rajender K. Motiani, Kelly E. Harmon, and Mohamed Trebak -- Anemic zebrafish models of cardiomyopathy / Xiaojing Sun and Xiaolei Xu -- Methods to study the effects of TRP channel drugs on vascular endothelial cell function / Yan Ma, Yung-Wui Tjong, and Xiaoqiang Yao -- Atherosclerosis models with cell-mediated calcification / Beili Zhu -- Models of hypertension and blood pressure recording / Luciana Aparecida Campos and Ovidiu Constantin Baltatu -- Balloon injury in rats as a model for studying TRP channel contribution to vascular smooth muscle remodeling / Wei Zhang and Mohamed Trebak -- TRP channels in the brain / Antonio Reboreda -- Investigation of the possible role of TRP channels in schizophrenia / Loris A. Chahl -- Investigating diseases of dopaminergic neurons and melanocytes using zebrafish / Amanda Decker and Robert Cornell -- A practical guide to evaluating anxiety-related behavior in rodents / Caitlin J. Riebe and Carsten T. Wotjak -- Rodent models of conditioned fear: behavioral measures of fear and memory / Jennifer L. McGuire, Jennifer L. Coyner, and Luke R. Johnson -- Chick anxiety-depression screening model / Stephen W. White and Kenneth J. Sufka -- A clinically relevant thromboembolic stroke model in the aged rat / Ryan C. Turner, Alisa S. Elliott, Jason D. Huber, and Charles L. Rosen -- Use of cell-stretch system to examine the characteristics of mechanosensor channels: axonal growth/neuroregeneration studies / Koji Shibasaki -- Methods in neuronal growth cone biology / Robert J. Gasperini and Lisa Foa -- Transient receptor potential channels and pruritus / Heike Benecke, Janine Wäring, Tobias Lotts, and Sonja Ständer -- Skin sensitivity studies / Laurent Misery -- Hair follicle culture / Michael P. Philpott -- Animal models for type 1 diabetes / Anish Suri and Matteo Levisetti -- Type 2 diabetes models / Dorte X. Gram -- Using diet to induce metabolic disease in rodents / Angela M. Gajda, Michael A. Pellizzon, and Matthew R. Ricci -- Rodent models to evaluate anti-obesity drugs / Sharon C. Cheetham and Helen C. Jackson -- Experimental colitis models / Patrick A. Hughes, Stuart M. Brierley, Joel Castro, Andrea M. Harrington, and L. Ashley Blackshaw -- Tumor xenograft models to study the role of TRP channels in Tumorigenesis / V'yacheslav Lehen'kyi, Sergii Khalimonchyk, Albin Pourtier, Maylis Raphaël, and Natalia Prevarskaya -- Methods to study thermonociception in rodents / Kata Bölcskei -- Methods for the assessment of heat perception in humans / Michael F. Crutchlow and Joel D. Greenspan -- Collagen antibody-induced arthritis: a disease-relevant model for studies of persistent joint pain / Katalin Sandor, Kutty Selva Nandakumar, Rikard Holmdahl, and Camilla I. Svensson -- Animal models of muscular dystrophy / Yuko Iwata and Shigeo Wakabayashi -- Concluding remarks.
  • Strategies and techniques for bioanalytical assays as part of new drug discovery / Walter A. Korfmacher -- The drug discovery process: from molecules to drugs / Mike S. Lee, Steven E. Klohr -- PK principles and PK/PD applications / Hong Mei, Richard A. Morrison -- Mass spectrometry for in vitro ADME screening / Inhou Chu -- Metabolite identification strategies and procedures / Ragu Ramanathan, S. Nilgün Çömezoǧlu, W. Griffith Humphreys -- Reactive metabolite screening and covalent-binding assays / Gérard Hopfgartner -- Fast metabolite screening in a discovery setting / Xiaoying Xu -- Fast chromatography with UPLC and other techniques / Sam Wainhaus -- Supercritical fluid chromatography-mass spectrometry / Yunsheng Hsieh -- Biomarkers of efficacy and toxicity: discovery and assay / Joanna R. Pols -- Imaging mass spectrometry for small molecules / Fangbiao Li -- MALDI IMS for proteins and biomarkers / Michelle L. Reyzer, Richard M. Caprioli -- Ambient ionization methods and their early applications in ADME studies / Jing-Tao Wu -- Pharmaceutical applications of accelerator mass spectrometry / Lan Gao, Swapan Chowdhury.
  • II Springer
  • A number of techniques to study ion channels have been developed since the electrical basis of excitability was first discovered. Ion channel biophysicists have at their disposal a rich and ever-growing array of instruments and reagents to explore the biophysical and structural basis of sodium channel behavior. Armed with these tools, researchers have made increasingly dramatic discoveries about sodium channels, culminating most recently in crystal structures of voltage-gated sodium channels from bacteria. These structures, along with those from other channels, give unprecedented insight into the structural basis of sodium channel function. This volume of the Handbook of Experimental Pharmacology will explore sodium channels from the perspectives of their biophysical behavior, their structure, the drugs and toxins with which they are known to interact, acquired and inherited diseases that affect sodium channels and the techniques with which their biophysical and structural properties are studied.
all 403 titles

Access restricted to Stanford community

Shortcut to Licensed Content

Lane Gateway to Licensed Content

TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.

What is it?

Lane Gateway to Licensed Content

Bookmark on Other Websites

Bookmark on Lane

  • TO INSTALL, RIGHT CLICK this button.
  • Select "Add to Favorites" (click “Continue” if you see a security alert)
  • From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
  • Once installed it will look like this
  • Click "Bookmark on Lane" to bookmark any webpage
  • Your saved bookmark will appear on this page

What is it?

A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more. Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed is a clinical information resource used by physicians to answer clinical questions quickly and easily at the point of care. Topics are updated daily as new evidence becomes available. Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialtiesProvides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences. Includes cited reference searching, citation maps, and an analyze tool.Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not. Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities. In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines. Over 10,000 notes outline the status of specific infections within each country.
Large number of high quality software and database programming titles from O'Reilly. Other software titles are also available from Sams and Prentice Hall. Limited to 7 concurrent users.Vast collection of software and database programming titles from multiple publishers, including Microsoft Press.Largest provider of engineering-related eBooks; includes titles in computer science and biomedical engineering.Over 4,000 full-text e-books covering scientific and technical information from CRC Press and others. Many handbooks and single volume reference sources.Includes peer-reviewed life science and biomedical research protocols compiled from Methods in Molecular Biology, Methods in Molecular Medicine, Methods in Biotechnology, Methods in Pharmacology and Toxicology, Neuromethods, the Biomethods Handbook, the Proteomics Handbook, and Springer Laboratory Manuals.Contains full text access to selected biomedical and nursing books.Provides online, full-text access to Springer's journal titles as well as journals from other publishers. Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.